{"outcome_uid": "163e6883", "clinical_question": "Should patients with RA initiating MTX receive MTX at 15mg or more per week (includes up-titrating to 15mg over the first month) or less than 15mg per week as the initial dose?", "population": "Patients with RA initiating MTX", "intervention": "MTX < 15mg per week", "comparator": "MTX 15mg per week", "outcome": "Disease Activity (follow up: 3 months; assessed with: DAS 28-ESR)", "importance": "CRITICAL", "related_paper_list": ["8113db3a"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"MTX 15 mg/week": "53", "<MTX 15mg/week as initial dose": "47"}, "Annotation": {"data": "1. 7.5mg/week MTX\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.08 lower (0.41 lower to 0.25 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "10", "Database": "2021 ACR RA"}
{"outcome_uid": "36189ed9", "clinical_question": "Should patients with RA initiating MTX receive MTX at 15mg or more per week (includes up-titrating to 15mg over the first month) or less than 15mg per week as the initial dose?", "population": "Patients with RA initiating MTX", "intervention": "MTX < 15mg per week", "comparator": "MTX 15mg per week", "outcome": "Disability (follow up: 3 months; assessed with: HAQ-DI)", "importance": "IMPORTANT", "related_paper_list": ["8113db3a"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval including both values suggesting benefit and values suggesting no effect. Very small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"MTX 15 mg/week": "53", "<MTX 15mg/week as initial dose": "47"}, "Annotation": {"data": "1. 7.5mg/week MTX\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.11 lower (0.29 lower to 0.07 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "10", "Database": "2021 ACR RA"}
{"outcome_uid": "32b5a40f", "clinical_question": "Should patients with RA initiating MTX receive MTX at 15mg or more per week (includes up-titrating to 15mg over the first month) or less than 15mg per week as the initial dose?", "population": "Patients with RA initiating MTX", "intervention": "MTX < 15mg per week", "comparator": "MTX 15mg per week", "outcome": "Withdrawal due to lack of efficacy (follow up: 3 months)", "importance": "IMPORTANT", "related_paper_list": ["8113db3a"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval including both values suggesting benefit and values suggesting harm. Very small sample size and low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"MTX 15 mg/week": "0/53 (0.0%) ", "<MTX 15mg/week as initial dose": "2/47 (4.3%)"}, "Annotation": {"data": "1. 7.5mg/week MTX\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.18 (0.01 to 3.61)", "Absolute Effect (95% CI)": "35 fewer per 1,000 (from 42 fewer to 111 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "10", "Database": "2021 ACR RA"}
{"outcome_uid": "e8d43408", "clinical_question": "Should patients with RA initiating MTX receive MTX at 15mg or more per week (includes up-titrating to 15mg over the first month) or less than 15mg per week as the initial dose?", "population": "Patients with RA initiating MTX", "intervention": "MTX < 15mg per week", "comparator": "MTX 15mg per week", "outcome": "Withdrawal due to adverse events (follow up: 3 months)", "importance": "IMPORTANT", "related_paper_list": ["8113db3a"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval including both values suggesting benefit and values suggesting harm. Very small sample size and low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"MTX 15 mg/week": "2/53 (3.8%) ", "<MTX 15mg/week as initial dose": "2/47 (4.3%)"}, "Annotation": {"data": "1. 7.5mg/week MTX\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.89 (0.13 to 6.05)", "Absolute Effect (95% CI)": "5 fewer per 1,000 (from 37 fewer to 215 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "10", "Database": "2021 ACR RA"}
{"outcome_uid": "31e12e05", "clinical_question": " Should patients with RA who have not been previously treated with boDMARD and tsDAMRD receive T2T strategies or usual care?", "population": "Patients with RA who have not been previously treated with boDMARD and tsDAMRD", "intervention": "T2T strategy", "comparator": "usual care", "outcome": "Remission (follow up: range 6 months to 1.5 years; assessed with: DAS 44 <1.4 and DAS28 ESR <2.6)", "importance": "CRITICAL", "related_paper_list": ["6e1cd0bc", "2671be0a", "06522c73"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and lack of blinding."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"T2T": "88/176 (50.0%)", "Usual care": "32/186 (17.2%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 2.89 (2.04 to 4.09)", "Absolute Effect (95% CI)": "325 more per 1,000 (from 179 more to 532 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "12a", "Database": "2021 ACR RA"}
{"outcome_uid": "3b70985b", "clinical_question": " Should patients with RA who have not been previously treated with boDMARD and tsDAMRD receive T2T strategies or usual care?", "population": "Patients with RA who have not been previously treated with boDMARD and tsDAMRD", "intervention": "T2T strategy", "comparator": "usual care", "outcome": "Disease activity (follow up: range 6 months to 1.5 years; assessed with: ACR 20)", "importance": "CRITICAL", "related_paper_list": ["6e1cd0bc", "2671be0a"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and lack of blinding."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"T2T": "69/76 (90.8%)", "Usual care": "48/77 (62.3%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.46 (1.21 to 1.76)", "Absolute Effect (95% CI)": "287 more per 1,000 (from 131 more to 474 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "12a", "Database": "2021 ACR RA"}
{"outcome_uid": "f28700d3", "clinical_question": " Should patients with RA who have not been previously treated with boDMARD and tsDAMRD receive T2T strategies or usual care?", "population": "Patients with RA who have not been previously treated with boDMARD and tsDAMRD", "intervention": "T2T strategy", "comparator": "usual care", "outcome": "Disease activity (follow up: range 6 months to 1.5 years; assessed with: ACR 50)", "importance": "CRITICAL", "related_paper_list": ["6e1cd0bc", "2671be0a"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and lack of blinding."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"T2T": "62/76 (81.6%)", "Usual care": "30/77 (39.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 2.09 (1.55 to 2.82)", "Absolute Effect (95% CI)": "425 more per 1,000 (from 214 more to 709 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "12a", "Database": "2021 ACR RA"}
{"outcome_uid": "b0d2db83", "clinical_question": " Should patients with RA who have not been previously treated with boDMARD and tsDAMRD receive T2T strategies or usual care?", "population": "Patients with RA who have not been previously treated with boDMARD and tsDAMRD", "intervention": "T2T strategy", "comparator": "usual care", "outcome": "Disease activity (follow up: range 6 months to 1.5 years; assessed with: ACR 70)", "importance": "CRITICAL", "related_paper_list": ["6e1cd0bc", "2671be0a"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and lack of blinding."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"T2T": "54/76 (71.1%)", "Usual care": "16/77 (20.8%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 3.43 (2.16 to 5.43)", "Absolute Effect (95% CI)": "505 more per 1,000 (from 241 more to 921 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "12a", "Database": "2021 ACR RA"}
{"outcome_uid": "f530e27f", "clinical_question": " Should patients with RA who have not been previously treated with boDMARD and tsDAMRD receive T2T strategies or usual care?", "population": "Patients with RA who have not been previously treated with boDMARD and tsDAMRD", "intervention": "T2T strategy", "comparator": "usual care", "outcome": "Disease activity (follow up: range 6 months to 1.5 years; assessed with: DAS 44/DAS28 ESR)", "importance": "CRITICAL", "related_paper_list": ["6e1cd0bc", "2671be0a", "06522c73"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and lack of blinding."}, "Inconsistency": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious inconsistency. I2= 96%."}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"T2T": "174", "Usual care": "181"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "SMD 0.43 lower (0.65 lower to 0.21 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "12a", "Database": "2021 ACR RA"}
{"outcome_uid": "8d864500", "clinical_question": " Should patients with RA who have not been previously treated with boDMARD and tsDAMRD receive T2T strategies or usual care?", "population": "Patients with RA who have not been previously treated with boDMARD and tsDAMRD", "intervention": "T2T strategy", "comparator": "usual care", "outcome": "Radiographic progression (follow up: range 1 years to 1.5 years; assessed with: modified Sharp score)", "importance": "IMPORTANT", "related_paper_list": ["2671be0a", "41ed8200"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious risk of bias. Lack of allocation concealment, lack of blinding, and attrition bias."}, "Inconsistency": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious inconsistency. I2= 78%."}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"T2T": "143", "Usual care": "159"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.6 lower (1.68 lower to 0.47 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "12a", "Database": "2021 ACR RA"}
{"outcome_uid": "669bdeca", "clinical_question": " Should patients with RA who have not been previously treated with boDMARD and tsDAMRD receive T2T strategies or usual care?", "population": "Patients with RA who have not been previously treated with boDMARD and tsDAMRD", "intervention": "T2T strategy", "comparator": "usual care", "outcome": "Disability (follow up: range 1.5 years to 2 years; assessed with: HAQ-DI)", "importance": "IMPORTANT", "related_paper_list": ["6e1cd0bc", "2671be0a", "41ed8200"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious risk of bias. Lack of allocation concealment, lack of blinding, and attrition bias."}, "Inconsistency": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious inconsistency. I2= 71%."}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting no effect."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"T2T": "323", "Usual care": "328"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.13 lower (0.3 lower to 0.05 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "12a", "Database": "2021 ACR RA"}
{"outcome_uid": "f12d7ed1", "clinical_question": " Should patients with RA who have not been previously treated with boDMARD and tsDAMRD receive T2T strategies or usual care?", "population": "Patients with RA who have not been previously treated with boDMARD and tsDAMRD", "intervention": "T2T strategy", "comparator": "usual care", "outcome": "Quality of life (follow up: 1.5 years; assessed with: SF-12 PCS)", "importance": "IMPORTANT", "related_paper_list": ["2671be0a"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and lack of blinding."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting no effect. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"T2T": "53", "Usual care": "50"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 5.3 higher (0.86 higher to 9.74 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "12a", "Database": "2021 ACR RA"}
{"outcome_uid": "551d3958", "clinical_question": " Should patients with RA who have not been previously treated with boDMARD and tsDAMRD receive T2T strategies or usual care?", "population": "Patients with RA who have not been previously treated with boDMARD and tsDAMRD", "intervention": "T2T strategy", "comparator": "usual care", "outcome": "Quality of life (follow up: 1.5 years; assessed with: SF-12 MCS)", "importance": "IMPORTANT", "related_paper_list": ["2671be0a"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and lack of blinding."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting no effect. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"T2T": "53", "Usual care": "50"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 4.9 higher (1.69 lower to 11.49 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "12a", "Database": "2021 ACR RA"}
{"outcome_uid": "24570424", "clinical_question": " Should patients with RA who have not been previously treated with boDMARD and tsDAMRD receive T2T strategies or usual care?", "population": "Patients with RA who have not been previously treated with boDMARD and tsDAMRD", "intervention": "T2T strategy", "comparator": "usual care", "outcome": "Pain (follow up: range 1.5 years to 2 years; assessed with: VAS 0-100)", "importance": "IMPORTANT", "related_paper_list": ["6e1cd0bc", "2671be0a", "41ed8200"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious risk of bias. Lack of allocation concealment, lack of blinding, and attrition bias."}, "Inconsistency": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious inconsistency. I2= 74%."}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting no effect."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"T2T": "225", "Usual care": "220"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 12.15 lower (17.76 lower to 6.54 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "12a", "Database": "2021 ACR RA"}
{"outcome_uid": "5103ab51", "clinical_question": " Should patients with RA who have not been previously treated with boDMARD and tsDAMRD receive T2T strategies or usual care?", "population": "Patients with RA who have not been previously treated with boDMARD and tsDAMRD", "intervention": "T2T strategy", "comparator": "usual care", "outcome": "Withdrawal due to lack of efficacy (follow up: range 1.5 years to 2 years)", "importance": "IMPORTANT", "related_paper_list": ["6e1cd0bc", "06522c73", "41ed8200"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious risk of bias. Lack of allocation concealment, lack of blinding, and attrition bias."}, "Inconsistency": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious inconsistency. I2= 75%."}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"T2T": "17/272 (6.3%)", "Usual care": "25/279 (9.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.71 (0.39 to 1.29)", "Absolute Effect (95% CI)": "26 fewer per 1,000 (from 55 fewer to 26 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "12a", "Database": "2021 ACR RA"}
{"outcome_uid": "835807a2", "clinical_question": " Should patients with RA who have not been previously treated with boDMARD and tsDAMRD receive T2T strategies or usual care?", "population": "Patients with RA who have not been previously treated with boDMARD and tsDAMRD", "intervention": "T2T strategy", "comparator": "usual care", "outcome": "Withdrawal due to adverse events (follow up: range 6 months to 1.5 years)", "importance": "IMPORTANT", "related_paper_list": ["6e1cd0bc", "06522c73", "c1d5b421"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious risk of bias. Two studies consisting of 97% of the weight have high risk of bias due to lack of allocation concealment, lack of blinding of outcome assessors, and reporting incomplete outcome data."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": "I2=55%"}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"T2T": "16/326 (4.9%)", "Usual care": "19/310 (6.1%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.86 (0.46 to 1.59)", "Absolute Effect (95% CI)": "9 fewer per 1,000 (from 33 fewer to 36 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "12a", "Database": "2021 ACR RA"}
{"outcome_uid": "7ca16a69", "clinical_question": " Should patients with RA who have not been previously treated with boDMARD and tsDAMRD receive T2T strategies or usual care?", "population": "Patients with RA who have not been previously treated with boDMARD and tsDAMRD", "intervention": "T2T strategy", "comparator": "usual care", "outcome": "Serious adverse events (follow up: 6 months)", "importance": "IMPORTANT", "related_paper_list": ["6e1cd0bc"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"T2T": "2/21 (9.5%)", "Usual care": "1/22 (4.5%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 2.10 (0.20 to 21.42)", "Absolute Effect (95% CI)": "50 more per 1,000 (from 36 fewer to 928 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "12a", "Database": "2021 ACR RA"}
{"outcome_uid": "a90d73a8", "clinical_question": " Should patients with RA who have not been previously treated with boDMARD and tsDAMRD receive T2T strategies or usual care?", "population": "Patients with RA who have not been previously treated with boDMARD and tsDAMRD", "intervention": "T2T strategy", "comparator": "usual care", "outcome": "Cardiovascular disease (follow up: 2 years)", "importance": "IMPORTANT", "related_paper_list": ["4b539132"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious risk of bias. Lack of allocation concealment, lack of blinding, and attrition bias."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Very small number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"T2T": "4/149 (2.7%)", "Usual care": "0/140 (0.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 8.46 (0.46 to 155.72)", "Absolute Effect (95% CI)": "0 fewer per 1,000 (from 0 fewer to 0 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "12a", "Database": "2021 ACR RA"}
{"outcome_uid": "ef58beaf", "clinical_question": " Should patients with RA who have not been previously treated with boDMARD and tsDAMRD receive T2T strategies or usual care?", "population": "Patients with RA who have not been previously treated with boDMARD and tsDAMRD", "intervention": "T2T strategy", "comparator": "usual care", "outcome": "Death (follow up: mean 1.5 years)", "importance": "IMPORTANT", "related_paper_list": ["2671be0a"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and lack of blinding."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"T2T": "1/55 (1.8%)", "Usual care": "3/55 (5.5%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.33 (0.04 to 3.11)", "Absolute Effect (95% CI)": "37 fewer per 1,000 (from 52 fewer to 115 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "12a", "Database": "2021 ACR RA"}
{"outcome_uid": "00de1082", "clinical_question": "In patients with RA receiving T2T, should the treatment goal be low disease activity or remission?", "population": "Patients with RA", "intervention": "Treat to low disease activity", "comparator": "treat to remission", "outcome": "DAS remission (follow up: 1 year; assessed with DAS44 ≤ 1.6)", "importance": "CRITICAL", "related_paper_list": ["79161999"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": "Unclear risk of bias related to missing data as rate of those data not reported\nIn the remission goal group (DAS <1.6), baseline DAS was lower than in the low disease activity goal group (DAS ≤2.4) targeted group; symptom duration was shorter and baseline radiological damage was less often present. The investigators adjusted for these differences in their analyses, but this could have still favored the remission goal group"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Observational Study", "Certainty": "LOW", "No of participants": {"a treatment goal of low disease activity": "40/133 (30.1%)", "a treatment goal of remission": "89/175 (50.9%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.59 (0.44 to 0.80)", "Absolute Effect (95% CI)": "209 fewer per 1,000 (from 285 fewer to 102 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "13", "Database": "2021 ACR RA"}
{"outcome_uid": "c1045730", "clinical_question": "In patients with RA receiving T2T, should the treatment goal be low disease activity or remission?", "population": "Patients with RA", "intervention": "Treat to low disease activity", "comparator": "treat to remission", "outcome": "Disease activity (follow up: 1 year; assessed with DAS-44 (Lower values – > benefit) (MCID -1.2)", "importance": "CRITICAL", "related_paper_list": ["79161999"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": "Unclear risk of bias related to missing data as rate of those data not reported"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Observational Study", "Certainty": "LOW", "No of participants": {"a treatment goal of low disease activity": "133", "a treatment goal of remission": "175"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.1 lower (0.35 lower to 0.15 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "13", "Database": "2021 ACR RA"}
{"outcome_uid": "f80bcf7a", "clinical_question": "Should patients with RA not tolerating MTX, on folic acid 1 mg/day, increase the dose of folic acid?", "population": "Patients with RA not tolerating MTX on 1mg of folic acid", "intervention": "Increase dose of folic acid to > 1mg per day", "comparator": "Remain on folic acid 1 mg per day", "outcome": "Disease activity (follow up: 6 months; assessed with: DAS28-ESR (Lower values – > benefit) (MCID -1.17)", "importance": "CRITICAL", "related_paper_list": ["a6672bfe"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": "Concern about risk of bias associated with handling of incomplete outcome data."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population who are starting MTX treatment (MTX-naive and not on folic acid) with different folic acid doses (10 mg/week vs 30 mg/week)."}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Remain on folic acid 1 mg per day": "51", "Increase dose of folic acid to > 1mg per day": "49"}, "Annotation": {"data": "1. Folic acid dose is 5-10 mg/week.\n2. Folic acid dose is 27.5-30mg/week.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.28 higher (0.1 higher to 0.46 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "15", "Database": "2021 ACR RA"}
{"outcome_uid": "fbc80f3f", "clinical_question": "Should patients with RA not tolerating MTX, on folic acid 1 mg/day, increase the dose of folic acid?", "population": "Patients with RA not tolerating MTX on 1mg of folic acid", "intervention": "Increase dose of folic acid to > 1mg per day", "comparator": "Remain on folic acid 1 mg per day", "outcome": "Disability (follow up: range 6 months to 12 months; assessed with: HAQ-DI or modified HAQ (Lower values – > benefit) (values>0.2 are considered clinically significant)", "importance": "IMPORTANT", "related_paper_list": ["a6672bfe", "bdf72d22"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": "Concern about risk of bias associated with handling of incomplete outcome data."}, "Inconsistency": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious inconsistency. I2=79%."}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population who are starting MTX treatment (MTX-naive and not on folic acid) with different folic acid doses (5-10 mg/week vs 27.5-30 mg/week)."}, "Imprecision": {"result": "SERIOUS", "rationales": "According to the Cochrane's handbook, Cohen suggested that SMD=0.2 be considered a 'small' effect size, 0.5 represents a 'medium' effect size and 0.8 a 'large' effect size. This means that if two groups' means do not differ by 0.2 standard deviations or more, the difference is trivial, even if it is statistically significant.\nDowngraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Remain on folic acid 1 mg per day": "76", "Increase dose of folic acid to > 1mg per day": "75"}, "Annotation": {"data": "1. Folic acid dose is 5-10 mg/week.\n2. Folic acid dose is 27.5-30mg/week.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "SMD 0.49 SD higher (0.16 higher to 0.82 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "15", "Database": "2021 ACR RA"}
{"outcome_uid": "8334a345", "clinical_question": "Should patients with RA not tolerating MTX, on folic acid 1 mg/day, increase the dose of folic acid?", "population": "Patients with RA not tolerating MTX on 1mg of folic acid", "intervention": "Increase dose of folic acid to > 1mg per day", "comparator": "Remain on folic acid 1 mg per day", "outcome": "Withdrawal due to adverse events (follow up: range 6 months to 12 months)", "importance": "IMPORTANT", "related_paper_list": ["a6672bfe", "bdf72d22"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": "Concern about risk of bias associated with handling of incomplete outcome data."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population who are starting MTX treatment (MTX-naive and not on folic acid) with different folic acid doses (5-10 mg/week vs 27.5-30 mg/week)."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm. Very low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Remain on folic acid 1 mg per day": "3/76 (3.9%)", "Increase dose of folic acid to > 1mg per day": "2/75 (2.7%)"}, "Annotation": {"data": "1. Folic acid dose is 5-10 mg/week.\n2. Folic acid dose is 27.5-30mg/week.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.42 (0.29 to 6.92)", "Absolute Effect (95% CI)": "11 more per 1,000 (from 19 fewer to 158 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "15", "Database": "2021 ACR RA"}
{"outcome_uid": "ec153cb0", "clinical_question": "Should patients with RA on oral MTX monotherapy 15 mg per week who are NOT at target increase the dose of oral MTX or switch to SC MTX?", "population": "Patients with RA on oral MTX monotherapy 15 mg per week who are not at target", "intervention": "Increase the dose of oral MTX", "comparator": "Switch to SC MTX", "outcome": "Disease activity (follow up: 6 months; assessed with: ACR 20)", "importance": "CRITICAL", "related_paper_list": ["dd941abe"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious risk of bias. Lack of blinding and lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Very small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to SC MTX": "43/46 (93.5%)", "Increase dose of oral MTX": "36/46 (78.3%)"}, "Annotation": {"data": "1. SC 20mg MTX for 4 weeks, then 25mg MTX for 8 weeks.\n2. PO 20mg MTX for 4 weeks, then 25mg MTX for 8 weeks.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.19 (1.01 to 1.42)", "Absolute Effect (95% CI)": "149 more per 1,000 (from 8 more to 329 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "18", "Database": "2021 ACR RA"}
{"outcome_uid": "213390a6", "clinical_question": "Should patients with RA on oral MTX monotherapy 15 mg per week who are NOT at target increase the dose of oral MTX or switch to SC MTX?", "population": "Patients with RA on oral MTX monotherapy 15 mg per week who are not at target", "intervention": "Increase the dose of oral MTX", "comparator": "Switch to SC MTX", "outcome": "Disease activity (follow up: 6 months; assessed with: ACR 50)", "importance": "CRITICAL", "related_paper_list": ["dd941abe"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious risk of bias. Lack of blinding and lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Very small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to SC MTX": "41/46 (89.1%)", "Increase dose of oral MTX": "33/46 (71.7%)"}, "Annotation": {"data": "1. SC 20mg MTX for 4 weeks, then 25mg MTX for 8 weeks.\n2. PO 20mg MTX for 4 weeks, then 25mg MTX for 8 weeks.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.24 (1.01 to 1.53)", "Absolute Effect (95% CI)": "172 more per 1,000 (from 7 more to 380 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "18", "Database": "2021 ACR RA"}
{"outcome_uid": "6758372e", "clinical_question": "Should patients with RA on oral MTX monotherapy 15 mg per week who are NOT at target increase the dose of oral MTX or switch to SC MTX?", "population": "Patients with RA on oral MTX monotherapy 15 mg per week who are not at target", "intervention": "Increase the dose of oral MTX", "comparator": "Switch to SC MTX", "outcome": "Disease activity (follow up: 6 months; assessed with: ACR 70)", "importance": "CRITICAL", "related_paper_list": ["dd941abe"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious risk of bias. Lack of blinding and lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to SC MTX": "5/46 (10.9%)", "Increase dose of oral MTX": "4/46 (8.7%)"}, "Annotation": {"data": "1. SC 20mg MTX for 4 weeks, then 25mg MTX for 8 weeks.\n2. PO 20mg MTX for 4 weeks, then 25mg MTX for 8 weeks.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.25 (0.36 to 4.36)", "Absolute Effect (95% CI)": "22 more per 1,000 (from 56 fewer to 292 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "18", "Database": "2021 ACR RA"}
{"outcome_uid": "166c79bb", "clinical_question": "Should patients with RA on oral MTX monotherapy 15 mg per week who are NOT at target increase the dose of oral MTX or switch to SC MTX?", "population": "Patients with RA on oral MTX monotherapy 15 mg per week who are not at target", "intervention": "Increase the dose of oral MTX", "comparator": "Switch to SC MTX", "outcome": "Disability (follow up: 6 months; assessed with: HAQ)", "importance": "IMPORTANT", "related_paper_list": ["dd941abe"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious risk of bias. Lack of blinding and lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Very small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to SC MTX": "46", "Increase dose of oral MTX": "46"}, "Annotation": {"data": "1. SC 20mg MTX for 4 weeks, then 25mg MTX for 8 weeks.\n2. PO 20mg MTX for 4 weeks, then 25mg MTX for 8 weeks.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 2.3 lower (4.06 lower to 0.54 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "18", "Database": "2021 ACR RA"}
{"outcome_uid": "3379c301", "clinical_question": "Should patients with RA on oral MTX monotherapy 15 mg per week who are NOT at target increase the dose of oral MTX or switch to SC MTX?", "population": "Patients with RA on oral MTX monotherapy 15 mg per week who are not at target", "intervention": "Increase the dose of oral MTX", "comparator": "Switch to SC MTX", "outcome": "Pain (follow up: 6 months; assessed with: VAS 0-10)", "importance": "IMPORTANT", "related_paper_list": ["dd941abe"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious risk of bias. Lack of blinding and lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Very small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to SC MTX": "46", "Increase dose of oral MTX": "46"}, "Annotation": {"data": "1. SC 20mg MTX for 4 weeks, then 25mg MTX for 8 weeks.\n2. PO 20mg MTX for 4 weeks, then 25mg MTX for 8 weeks.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 1.43 lower (2.05 lower to 0.81 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "18", "Database": "2021 ACR RA"}
{"outcome_uid": "842cff39", "clinical_question": "this is a question?", "population": "Patients with RA on maximally tolerated dose of MTX monotherapy (either oral or SC) who are not at target", "intervention": "Add SSZ and HCQ", "comparator": "add TNF Inhibitor", "outcome": "Disease activity (follow up: 6 months; assessed with: ACR20)", "importance": "CRITICAL", "related_paper_list": ["a55c0534"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence intervals includes both values suggesting benefit and values suggesting harm. Concern about risk of bias associated with lack of allocation concealment taken into account when rating down for imprecision."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Add SSZ+HCQ": "89/159 (56.0%)", "Add TNFi": "90/163 (55.2%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.01 (0.83 to 1.23)", "Absolute Effect (95% CI)": "6 more per 1,000 (from 94 fewer to 127 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "19", "Database": "2021 ACR RA"}
{"outcome_uid": "a437b9f2", "clinical_question": "this is a question?", "population": "Patients with RA on maximally tolerated dose of MTX monotherapy (either oral or SC) who are not at target", "intervention": "Add SSZ and HCQ", "comparator": "add TNF Inhibitor", "outcome": "Disease activity (follow up: 6 months; assessed with: ACR50)", "importance": "CRITICAL", "related_paper_list": ["a55c0534"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting harm and values suggesting no effect."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Add SSZ+HCQ": "41/159 (25.8%)", "Add TNFi": "58/163 (35.6%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.72 (0.52 to 1.01)", "Absolute Effect (95% CI)": "100 fewer per 1,000 (from 171 fewer to 4 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "19", "Database": "2021 ACR RA"}
{"outcome_uid": "011da7dd", "clinical_question": "this is a question?", "population": "Patients with RA on maximally tolerated dose of MTX monotherapy (either oral or SC) who are not at target", "intervention": "Add SSZ and HCQ", "comparator": "add TNF Inhibitor", "outcome": "Disease activity (follow up: 6 months; assessed with: ACR70)", "importance": "CRITICAL", "related_paper_list": ["a55c0534"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"Add SSZ+HCQ": "8/159 (5.0%)", "Add TNFi": "26/163 (16.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.32 (0.15 to 0.68)", "Absolute Effect (95% CI)": "108 fewer per 1,000 (from 136 fewer to 51 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "19", "Database": "2021 ACR RA"}
{"outcome_uid": "ddacc37b", "clinical_question": "this is a question?", "population": "Patients with RA on maximally tolerated dose of MTX monotherapy (either oral or SC) who are not at target", "intervention": "Add SSZ and HCQ", "comparator": "add TNF Inhibitor", "outcome": "Disease activity (follow up: 6 months; assessed with: DAS28-ESR (Lower values – > benefit) (MCID -1.17)", "importance": "CRITICAL", "related_paper_list": ["a55c0534"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"Add SSZ+HCQ": "157", "Add TNFi": "161"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.27 higher (0.01 lower to 0.55 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "19", "Database": "2021 ACR RA"}
{"outcome_uid": "ac948257", "clinical_question": "this is a question?", "population": "Patients with RA on maximally tolerated dose of MTX monotherapy (either oral or SC) who are not at target", "intervention": "Add SSZ and HCQ", "comparator": "add TNF Inhibitor", "outcome": "Remission (follow up: 6 months; assessed with: DAS28-CRP < 2.6)", "importance": "CRITICAL", "related_paper_list": ["a55c0534"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting harm and values suggesting no effect."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Add SSZ+HCQ": "20/157 (12.7%)", "Add TNFi": "35/161 (21.7%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.59 (0.35 to 0.97)", "Absolute Effect (95% CI)": "89 fewer per 1,000 (from 141 fewer to 7 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "19", "Database": "2021 ACR RA"}
{"outcome_uid": "955a4f9e", "clinical_question": "this is a question?", "population": "Patients with RA on maximally tolerated dose of MTX monotherapy (either oral or SC) who are not at target", "intervention": "Add SSZ and HCQ", "comparator": "add TNF Inhibitor", "outcome": "Radiographic progression (follow up: 6 months; assessed with: mTSS (Lower values – > benefit) (MCID 4.6)", "importance": "IMPORTANT", "related_paper_list": ["a55c0534"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"Add SSZ+HCQ": "158", "Add TNFi": "160"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.42 higher (0.22 lower to 1.05 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "19", "Database": "2021 ACR RA"}
{"outcome_uid": "b6666bb8", "clinical_question": "this is a question?", "population": "Patients with RA on maximally tolerated dose of MTX monotherapy (either oral or SC) who are not at target", "intervention": "Add SSZ and HCQ", "comparator": "add TNF Inhibitor", "outcome": "Disability (follow up: 6 months; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22)", "importance": "IMPORTANT", "related_paper_list": ["a55c0534"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting harm and values suggesting no effect."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Add SSZ+HCQ": "155", "Add TNFi": "160"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.07 higher (0.11 lower to 0.25 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "19", "Database": "2021 ACR RA"}
{"outcome_uid": "13a1b2c3", "clinical_question": "this is a question?", "population": "Patients with RA on maximally tolerated dose of MTX monotherapy (either oral or SC) who are not at target", "intervention": "Add SSZ and HCQ", "comparator": "add TNF Inhibitor", "outcome": "Malignancy (from SRs of harms)", "related_paper_list": ["45b0286b"], "assessment_results": {"GRADE": {"result_interpretation": "The Systematic Review RefID=4638, 2012 (RCTs=9, n=3712) comparing csDMARD + placebo vs infliximab + MTX among RA showed that for cancer, the result was RR=0.83 (0.22-3.13) at 2 years and RR=0.56(0.22-1.47) at all time points (6 months, 1 year and 2 years combined)", "Study design": "Systematic Review"}}, "PICO_IDX": "19", "Database": "2021 ACR RA"}
{"outcome_uid": "cc5bbf8a", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and low disease activity receive MTX monotherapy or an alternative csDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and low disease activity", "intervention": "MTX monotherapy", "comparator": "SSZ", "outcome": "Disease activity (follow up: 1 year; assessed with: DAS28-ESR (Lower values – > benefit) (MCID -1.17)", "importance": "CRITICAL", "related_paper_list": ["fd4777bd", "d7a31839"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation and lack of blinding of outcome assessors of non-radiographic outcomes in the study with the higher weight,"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": "I2= 41%"}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population with moderate to high disease activity. "}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Small sample size. "}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"MTX monotherapy": "104", "SSZ": "102"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.14 higher (0.18 lower to 0.47 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "1a", "Database": "2021 ACR RA"}
{"outcome_uid": "3ba0bc1b", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and low disease activity receive MTX monotherapy or an alternative csDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and low disease activity", "intervention": "MTX monotherapy", "comparator": "SSZ", "outcome": "Disability (follow up: 1 year; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22)", "importance": "IMPORTANT", "related_paper_list": ["fd4777bd", "d7a31839"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation and lack of blinding of outcome assessors of non-radiographic outcomes in the study with the higher weight,"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population with moderate to high disease activity. "}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Small sample size. "}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"MTX monotherapy": "104", "SSZ": "102"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.04 lower (0.2 lower to 0.13 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "1a", "Database": "2021 ACR RA"}
{"outcome_uid": "3d02c5c4", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and low disease activity receive MTX monotherapy or an alternative csDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and low disease activity", "intervention": "MTX monotherapy", "comparator": "SSZ", "outcome": "Pain (follow up: 1 year; assessed with: VAS 0-100 (Lower values – > benefit) (MCID -11.9)", "importance": "IMPORTANT", "related_paper_list": ["d7a31839"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population with moderate to high disease activity. "}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size. "}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"MTX monotherapy": "35", "SSZ": "34"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.1 higher (13.46 lower to 13.66 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "1a", "Database": "2021 ACR RA"}
{"outcome_uid": "01b3af42", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and low disease activity receive MTX monotherapy or an alternative csDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and low disease activity", "intervention": "MTX monotherapy", "comparator": "SSZ", "outcome": "Serious adverse events (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["d7a31839"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population with moderate to high disease activity. "}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size. "}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"MTX monotherapy": "0/35 (0.0%)", "SSZ": "3/34 (8.8%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.14 (0.01 to 2.59)", "Absolute Effect (95% CI)": "76 fewer per 1,000 (from 87 fewer to 140 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "1a", "Database": "2021 ACR RA"}
{"outcome_uid": "47cb6548", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and low disease activity receive MTX monotherapy or an alternative csDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and low disease activity", "intervention": "MTX monotherapy", "comparator": "SSZ", "outcome": "Withdrawal due to lack of efficacy (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["fd4777bd", "d7a31839"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation and lack of blinding of outcome assessors of non-radiographic outcomes in the study with the higher weight,"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population with moderate to high disease activity. "}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Small sample size and low number of events. "}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"MTX monotherapy": "5/104 (4.8%)", "SSZ": "10/102 (9.8%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.51 (0.19 to 1.39)", "Absolute Effect (95% CI)": "48 fewer per 1,000 (from 79 fewer to 38 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "1a", "Database": "2021 ACR RA"}
{"outcome_uid": "f21524f0", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and low disease activity receive MTX monotherapy or an alternative csDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and low disease activity", "intervention": "MTX monotherapy", "comparator": "SSZ", "outcome": "Withdrawal due to adverse events (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["fd4777bd", "d7a31839"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation and lack of blinding of outcome assessors of non-radiographic outcomes in the study with the higher weight,"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": "I2= 44%"}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population with moderate to high disease activity. "}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting no effect. Small sample size. "}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"MTX monotherapy": "9/104 (8.7%)", "SSZ": "19/102 (18.6%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.46 (0.22 to 0.98)", "Absolute Effect (95% CI)": "101 fewer per 1,000 (from 145 fewer to 4 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "1a", "Database": "2021 ACR RA"}
{"outcome_uid": "cd979f9b", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and low disease activity receive MTX monotherapy or an alternative csDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and low disease activity", "intervention": "MTX monotherapy", "comparator": "LEF", "outcome": "Disease activity (follow up: 6 months; assessed with: DAS28-ESR (Lower values – > benefit) (MCID -1.17)", "importance": "CRITICAL", "related_paper_list": ["fa180e46"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "VERY_SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and lack of blinding of patients, personnel, and outcome assessors."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population with moderate to high disease activity."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"MTX monotherapy": "147", "LEF": "147"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.1 lower (0.27 lower to 0.07 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "1a", "Database": "2021 ACR RA"}
{"outcome_uid": "a7a382d5", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed and low disease activity receive MTX monotherapy or an alternative csDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and low disease activity", "intervention": "MTX monotherapy", "comparator": "LEF", "outcome": "Disease activity (follow up: 4 months; assessed with: ACR 20)", "importance": "CRITICAL", "related_paper_list": ["ade90865"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population with moderate to high disease activity."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"MTX monotherapy": "88/180 (48.9%)", "LEF": "95/182 (52.2%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.94 (0.76 to 1.15)", "Absolute Effect (95% CI)": "31 fewer per 1,000 (from 125 fewer to 78 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "1b", "Database": "2021 ACR RA"}
{"outcome_uid": "e1285d51", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed and low disease activity receive MTX monotherapy or an alternative csDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and low disease activity", "intervention": "MTX monotherapy", "comparator": "LEF", "outcome": "Disease activity (follow up: 4 months; assessed with: DAS28-ESR (Lower values – > benefit) (MCID -1.17)", "importance": "CRITICAL", "related_paper_list": ["ad9d3d6b"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding of patients, personnel, and outcome assessors."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population with moderate to high disease activity."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting no effect. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"MTX monotherapy": "21", "LEF": "19"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.67 lower (1.5 lower to 0.16 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "1b", "Database": "2021 ACR RA"}
{"outcome_uid": "3e078508", "clinical_question": "Should patients with RA on maximally tolerated dose of LEF monotherapy who are NOT at target, and have previously failed MTX (due to an inadequate response or adverse events), add SSZ and HCQ, or add a boDMARD, or add tsDMARD?", "population": "Patients with RA on maximally tolerated dose of LEF monotherapy who are not at target, and have previously failed MTX (due to an inadequate response or adverse events)", "intervention": "Add SSZ and HCQ", "comparator": "add TNF Inhibitor", "outcome": "Disease activity (follow up: 6 months; assessed with: ACR20)", "importance": "CRITICAL", "related_paper_list": ["a55c0534"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population on maximally tolerated dose of MTX monotherapy and not LEF."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence intervals include both values suggesting benefit and values suggesting harm. Concern about risk of bias associated with lack of allocation concealment taken into account when rating down for imprecision."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Add SSZ+HCQ": "89/159 (56.0%)", "Add TNFi": "90/163 (55.2%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.01 (0.83 to 1.23)", "Absolute Effect (95% CI)": "6 more per 1,000 (from 94 fewer to 127 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "20", "Database": "2021 ACR RA"}
{"outcome_uid": "92c2bfe2", "clinical_question": "Should patients with RA on maximally tolerated dose of LEF monotherapy who are NOT at target, and have previously failed MTX (due to an inadequate response or adverse events), add SSZ and HCQ, or add a boDMARD, or add tsDMARD?", "population": "Patients with RA on maximally tolerated dose of LEF monotherapy who are not at target, and have previously failed MTX (due to an inadequate response or adverse events)", "intervention": "Add SSZ and HCQ", "comparator": "add TNF Inhibitor", "outcome": "Disease activity (follow up: 6 months; assessed with: ACR50)", "importance": "CRITICAL", "related_paper_list": ["a55c0534"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population on maximally tolerated dose of MTX monotherapy and not LEF."}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting harm and values suggesting no effect."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Add SSZ+HCQ": "41/159 (25.8%)", "Add TNFi": "58/163 (35.6%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.72 (0.52 to 1.01)", "Absolute Effect (95% CI)": "100 fewer per 1,000 (from 171 fewer to 4 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "20", "Database": "2021 ACR RA"}
{"outcome_uid": "132f8219", "clinical_question": "Should patients with RA on maximally tolerated dose of LEF monotherapy who are NOT at target, and have previously failed MTX (due to an inadequate response or adverse events), add SSZ and HCQ, or add a boDMARD, or add tsDMARD?", "population": "Patients with RA on maximally tolerated dose of LEF monotherapy who are not at target, and have previously failed MTX (due to an inadequate response or adverse events)", "intervention": "Add SSZ and HCQ", "comparator": "add TNF Inhibitor", "outcome": "Disease activity (follow up: 6 months; assessed with: ACR70)", "importance": "CRITICAL", "related_paper_list": ["a55c0534"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population on maximally tolerated dose of MTX monotherapy and not LEF."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Add SSZ+HCQ": "8/159 (5.0%)", "Add TNFi": "26/163 (16.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.32 (0.15 to 0.68)", "Absolute Effect (95% CI)": "108 fewer per 1,000 (from 136 fewer to 51 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "20", "Database": "2021 ACR RA"}
{"outcome_uid": "7e904940", "clinical_question": "Should patients with RA on maximally tolerated dose of LEF monotherapy who are NOT at target, and have previously failed MTX (due to an inadequate response or adverse events), add SSZ and HCQ, or add a boDMARD, or add tsDMARD?", "population": "Patients with RA on maximally tolerated dose of LEF monotherapy who are not at target, and have previously failed MTX (due to an inadequate response or adverse events)", "intervention": "Add SSZ and HCQ", "comparator": "add TNF Inhibitor", "outcome": "Disease activity (follow up: 6 months; assessed with: DAS28-ESR)", "importance": "CRITICAL", "related_paper_list": ["a55c0534"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population on maximally tolerated dose of MTX monotherapy and not LEF."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Add SSZ+HCQ": "157", "Add TNFi": "161"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.27 higher (0.01 lower to 0.55 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "20", "Database": "2021 ACR RA"}
{"outcome_uid": "68036fd2", "clinical_question": "Should patients with RA on maximally tolerated dose of LEF monotherapy who are NOT at target, and have previously failed MTX (due to an inadequate response or adverse events), add SSZ and HCQ, or add a boDMARD, or add tsDMARD?", "population": "Patients with RA on maximally tolerated dose of LEF monotherapy who are not at target, and have previously failed MTX (due to an inadequate response or adverse events)", "intervention": "Add SSZ and HCQ", "comparator": "add TNF Inhibitor", "outcome": "Remission (follow up: 6 months; assessed with: DAS28-CRP < 2.6)", "importance": "CRITICAL", "related_paper_list": ["a55c0534"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population on maximally tolerated dose of MTX monotherapy and not LEF."}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting harm and values suggesting no effect."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Add SSZ+HCQ": "20/157 (12.7%)", "Add TNFi": "35/161 (21.7%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.59 (0.35 to 0.97)", "Absolute Effect (95% CI)": "89 fewer per 1,000 (from 141 fewer to 7 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "20", "Database": "2021 ACR RA"}
{"outcome_uid": "9dc7571c", "clinical_question": "Should patients with RA on maximally tolerated dose of LEF monotherapy who are NOT at target, and have previously failed MTX (due to an inadequate response or adverse events), add SSZ and HCQ, or add a boDMARD, or add tsDMARD?", "population": "Patients with RA on maximally tolerated dose of LEF monotherapy who are not at target, and have previously failed MTX (due to an inadequate response or adverse events)", "intervention": "Add SSZ and HCQ", "comparator": "add TNF Inhibitor", "outcome": "Radiographic progression (follow up: 6 months; assessed with: mTSS)", "importance": "IMPORTANT", "related_paper_list": ["a55c0534"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population on maximally tolerated dose of MTX monotherapy and not LEF."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Add SSZ+HCQ": "158", "Add TNFi": "160"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.42 higher (0.22 lower to 1.05 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "20", "Database": "2021 ACR RA"}
{"outcome_uid": "0383bc2d", "clinical_question": "Should patients with RA on maximally tolerated dose of LEF monotherapy who are NOT at target, and have previously failed MTX (due to an inadequate response or adverse events), add SSZ and HCQ, or add a boDMARD, or add tsDMARD?", "population": "Patients with RA on maximally tolerated dose of LEF monotherapy who are not at target, and have previously failed MTX (due to an inadequate response or adverse events)", "intervention": "Add SSZ and HCQ", "comparator": "add TNF Inhibitor", "outcome": "Disability (follow up: 6 months; assessed with: HAQ-DI)", "importance": "IMPORTANT", "related_paper_list": ["a55c0534"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population on maximally tolerated dose of MTX monotherapy and not LEF."}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting harm and values suggesting no effect."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Add SSZ+HCQ": "155", "Add TNFi": "160"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.07 higher (0.11 lower to 0.25 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "20", "Database": "2021 ACR RA"}
{"outcome_uid": "16c55d4a", "clinical_question": "Should patients with RA on maximally tolerated dose of LEF monotherapy who are NOT at target, and have previously failed MTX (due to an inadequate response or adverse events), add SSZ and HCQ, or add a boDMARD, or add tsDMARD?", "population": "Patients with RA on maximally tolerated dose of LEF monotherapy who are not at target, and have previously failed MTX (due to an inadequate response or adverse events)", "intervention": "Add SSZ and HCQ", "comparator": "add TNF Inhibitor", "outcome": "Malignancy (from SRs of harms)", "related_paper_list": ["45b0286b"], "assessment_results": {"GRADE": {"result_interpretation": "The Systematic Review RefID=4638, 2012 (RCTs=9, n=3712) comparing csDMARD + placebo vs infliximab + MTX among RA showed that for cancer, the result was RR=0.83 (0.22-3.13) at 2 years and RR=0.56(0.22-1.47) at all time points (6 months, 1 year and 2 years combined)", "Study design": "Systematic Review"}}, "PICO_IDX": "20", "Database": "2021 ACR RA"}
{"outcome_uid": "b51b8cf7", "clinical_question": "Should patients with RA on DMARD(s) who are NOT at target switch to another DMARD versus add a 2nd DMARD?", "population": "Patients with RA on non-biologic DMARD(s) who are not at target", "intervention": "Switch to another DMARD", "comparator": "Add another DMARD", "outcome": "Disease activity (follow up: range 4 months to 2 years; assessed with: ACR 20)", "importance": "CRITICAL", "related_paper_list": ["f8f1a82c", "323b4f71", "d76da5a9", "39e9c906", "8f68ef49", "d40d9e70", "bcdcb109", "49208898", "71272a3e"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": "Three studies at low risk of bias represent 60% of the weight."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"Switch DMARDs": "795/1279 (62.2%)", "Add DMARDs": "1112/1658 (67.1%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.93 (0.86 to 1.02)", "Absolute Effect (95% CI)": "47 fewer per 1,000 (from 94 fewer to 13 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "21a", "Database": "2021 ACR RA"}
{"outcome_uid": "e2526179", "clinical_question": "Should patients with RA on DMARD(s) who are NOT at target switch to another DMARD versus add a 2nd DMARD?", "population": "Patients with RA on non-biologic DMARD(s) who are not at target", "intervention": "Switch to another DMARD", "comparator": "Add another DMARD", "outcome": "Disease activity (follow up: range 4 months to 2 years; assessed with: ACR 50)", "importance": "CRITICAL", "related_paper_list": ["f8f1a82c", "323b4f71", "d76da5a9", "39e9c906", "8f68ef49", "d40d9e70", "bcdcb109", "49208898", "71272a3e"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": "Three studies at low risk of bias represent 60% of the weight."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"Switch DMARDs": "491/1279 (38.4%)", "Add DMARDs": "744/1658 (44.9%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.87 (0.79 to 0.97)", "Absolute Effect (95% CI)": "58 fewer per 1,000 (from 94 fewer to 13 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "21a", "Database": "2021 ACR RA"}
{"outcome_uid": "6d83d7da", "clinical_question": "Should patients with RA on DMARD(s) who are NOT at target switch to another DMARD versus add a 2nd DMARD?", "population": "Patients with RA on non-biologic DMARD(s) who are not at target", "intervention": "Switch to another DMARD", "comparator": "Add another DMARD", "outcome": "Disease activity (follow up: range 4 months to 2 years; assessed with: ACR 70)", "importance": "CRITICAL", "related_paper_list": ["f8f1a82c", "323b4f71", "d76da5a9", "39e9c906", "8f68ef49", "d40d9e70", "bcdcb109", "49208898", "71272a3e"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": "Three studies at low risk of bias represent 60% of the weight."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"Switch DMARDs": "266/1263 (21.1%)", "Add DMARDs": "422/1658 (25.5%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.84 (0.73 to 0.97)", "Absolute Effect (95% CI)": "41 fewer per 1,000 (from 69 fewer to 8 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "21a", "Database": "2021 ACR RA"}
{"outcome_uid": "ba54348b", "clinical_question": "Should patients with RA on DMARD(s) who are NOT at target switch to another DMARD versus add a 2nd DMARD?", "population": "Patients with RA on non-biologic DMARD(s) who are not at target", "intervention": "Switch to another DMARD", "comparator": "Add another DMARD", "outcome": "Disease activity (follow up: range 4 months to 2 years; assessed with: DAS28 or DAS44 (lower values --> benefit) (values>0.2 are considered clinically important)", "importance": "CRITICAL", "related_paper_list": ["323b4f71", "d76da5a9", "39e9c906", "8f68ef49", "bcdcb109", "49208898", "71272a3e"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": "Three studies at low risk of bias represent 60% of the weight."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm. According to the Cochrane's handbook, Cohen suggested that SMD=0.2 be considered a 'small' effect size, 0.5 represents a 'medium' effect size and 0.8 a 'large' effect size. This means that if two groups' means do not differ by 0.2 standard deviations or more, the difference is trivial, even if it is statistically significant."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"Switch DMARDs": "0", "Add DMARDs": "0"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "SMD 0.24 SD higher (0.1 higher to 0.38 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "21a", "Database": "2021 ACR RA"}
{"outcome_uid": "8ce7c79b", "clinical_question": "Should patients with RA on DMARD(s) who are NOT at target switch to another DMARD versus add a 2nd DMARD?", "population": "Patients with RA on non-biologic DMARD(s) who are not at target", "intervention": "Switch to another DMARD", "comparator": "Add another DMARD", "outcome": "Remission (follow up: range 4 months to 1 year; assessed with: DAS remission < 2.6 )", "importance": "CRITICAL", "related_paper_list": ["f8f1a82c", "323b4f71", "d76da5a9", "8f68ef49", "d40d9e70", "bcdcb109"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"Switch DMARDs": "250/998 (25.1%)", "Add DMARDs": "356/1367 (26.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.85 (0.70 to 1.02)", "Absolute Effect (95% CI)": "39 fewer per 1,000 (from 78 fewer to 5 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "21a", "Database": "2021 ACR RA"}
{"outcome_uid": "aacf817a", "clinical_question": "Should patients with RA on DMARD(s) who are NOT at target switch to another DMARD versus add a 2nd DMARD?", "population": "Patients with RA on non-biologic DMARD(s) who are not at target", "intervention": "Switch to another DMARD", "comparator": "Add another DMARD", "outcome": "Flare (follow up: 1 months)", "importance": "IMPORTANT", "related_paper_list": ["bcdcb109"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and blinding."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Switch DMARDs": "0/155 (0.0%)", "Add DMARDs": "1/152 (0.7%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.33 (0.01 to 7.96)", "Absolute Effect (95% CI)": "4 fewer per 1,000 (from 7 fewer to 46 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "21a", "Database": "2021 ACR RA"}
{"outcome_uid": "d1319106", "clinical_question": "Should patients with RA on DMARD(s) who are NOT at target switch to another DMARD versus add a 2nd DMARD?", "population": "Patients with RA on non-biologic DMARD(s) who are not at target", "intervention": "Switch to another DMARD", "comparator": "Add another DMARD", "outcome": "Radiographic progression (follow up: 6 months; assessed with: mTSS (Lower values – > benefit) (MCID 4.6)", "importance": "IMPORTANT", "related_paper_list": ["d76da5a9"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"Switch DMARDs": "276", "Add DMARDs": "277"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.17 higher (0.14 higher to 0.2 higher)(The studies ACT-RAY and SURPRISE found that the RR of developing no radiographic progression (change in mTSS ≤0.5) was 0.96 (95%CI 0.91 to 1.02), absolute risk reduction 34 fewer per 1000 (95%CI 76 fewer to 17 more).)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "21a", "Database": "2021 ACR RA"}
{"outcome_uid": "189f71e4", "clinical_question": "Should patients with RA on DMARD(s) who are NOT at target switch to another DMARD versus add a 2nd DMARD?", "population": "Patients with RA on non-biologic DMARD(s) who are not at target", "intervention": "Switch to another DMARD", "comparator": "Add another DMARD", "outcome": "Pain (follow up: range 4 months to 12 months; assessed with: VAS pain (0-100) (Lower values – > benefit) (MCID -11.9)", "importance": "IMPORTANT", "related_paper_list": ["323b4f71", "d76da5a9", "8f68ef49", "cdb4d7a1", "83353996"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"Switch DMARDs": "949", "Add DMARDs": "1328"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 1.9 higher (0.3 lower to 4.1 higher)(The study ORAL Strategy found that the RR of improvement in pain VAS (0-100) ≥ 10 was 0.99 (95% CI 0.92 to 1.07), absolute risk reduction 8 fewer per 1000 (95%CI 62 fewer to 54 more).)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "21a", "Database": "2021 ACR RA"}
{"outcome_uid": "0b2199e2", "clinical_question": "Should patients with RA on DMARD(s) who are NOT at target switch to another DMARD versus add a 2nd DMARD?", "population": "Patients with RA on non-biologic DMARD(s) who are not at target", "intervention": "Switch to another DMARD", "comparator": "Add another DMARD", "outcome": "Disability (follow up: range 4 months to 2 years; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22)", "importance": "IMPORTANT", "related_paper_list": ["323b4f71", "d76da5a9", "39e9c906", "8f68ef49", "cdb4d7a1"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias in three studies representing 55% of the weight."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"Switch DMARDs": "670", "Add DMARDs": "673"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0 (0.06 lower to 0.07 higher)(The studies ADORE, ORAL strategy and Strand 2006, found that the RR of improvement in HAQ-DI (≥0.22 or ≥0.25 change from baseline) was 0.94 (95%CI 0.83 to 1.07), absolute risk reduction 39 fewer per 1000 (95%CI 112 fewer to 46 more).)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "21a", "Database": "2021 ACR RA"}
{"outcome_uid": "1427b701", "clinical_question": "Should patients with RA on DMARD(s) who are NOT at target switch to another DMARD versus add a 2nd DMARD?", "population": "Patients with RA on non-biologic DMARD(s) who are not at target", "intervention": "Switch to another DMARD", "comparator": "Add another DMARD", "outcome": "Fatigue (follow up: 1 year; assessed with: FACIT-F (Higher values – > benefit) (MCID 15.9)", "importance": "IMPORTANT", "related_paper_list": ["83353996"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"Switch DMARDs": "384", "Add DMARDs": "762"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.62 lower (1.84 lower to 0.6 higher)(The study ORAL Strategy found that the RR of improvement in FACIT-F≥ 4 was 0.92 (95% CI 0.83 to 1.01), absolute risk reduction 55 fewer per 1000 (95%CI 117 fewer to 7 more).)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "21a", "Database": "2021 ACR RA"}
{"outcome_uid": "f1ccf0e0", "clinical_question": "Should patients with RA on DMARD(s) who are NOT at target switch to another DMARD versus add a 2nd DMARD?", "population": "Patients with RA on non-biologic DMARD(s) who are not at target", "intervention": "Switch to another DMARD", "comparator": "Add another DMARD", "outcome": "Quality of Life (follow up: 1 year; assessed with:  SF-36 MCS (Higher values – > benefit) (MCID 3.1)", "importance": "IMPORTANT", "related_paper_list": ["83353996"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"Switch DMARDs": "384", "Add DMARDs": "762"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.97 lower (2.1 lower to 0.16 higher)(The study ORAL Strategy found that the RR of improvement in SF-36 MCS ≥ 2.5 was 0.94 (95% CI 0.84 to 1.05), absolute risk reduction 37 fewer per 1000 (95%CI 100 fewer to 31 more).)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "21a", "Database": "2021 ACR RA"}
{"outcome_uid": "3172e5ba", "clinical_question": "Should patients with RA on DMARD(s) who are NOT at target switch to another DMARD versus add a 2nd DMARD?", "population": "Patients with RA on non-biologic DMARD(s) who are not at target", "intervention": "Switch to another DMARD", "comparator": "Add another DMARD", "outcome": "Quality of Life (follow up: 1 year; assessed with: SF-36 PCS (Higher values – > benefit) (MCID 4.4)", "importance": "IMPORTANT", "related_paper_list": ["83353996"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"Switch DMARDs": "384", "Add DMARDs": "762"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.87 lower (1.9 lower to 0.16 higher)(The studies ADORE, ORAL strategy and Strand 2006, found that the RR of improvement in HAQ-DI (≥0.22 or ≥0.25 change from baseline) was 0.94 (95%CI 0.83 to 1.07), absolute risk reduction 39 fewer per 1000 (95%CI 112 fewer to 46 more).)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "21a", "Database": "2021 ACR RA"}
{"outcome_uid": "85274402", "clinical_question": "Should patients with RA on DMARD(s) who are NOT at target switch to another DMARD versus add a 2nd DMARD?", "population": "Patients with RA on non-biologic DMARD(s) who are not at target", "intervention": "Switch to another DMARD", "comparator": "Add another DMARD", "outcome": "Quality of Life (follow up: range 4 months to 2 years; assessed with: RAQol or EQ-5D VAS (lower values --> benefit) (values>0.2 are considered clinically important)", "importance": "IMPORTANT", "related_paper_list": ["d76da5a9", "39e9c906", "cdb4d7a1"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit. According to the Cochrane's handbook, Cohen suggested that SMD=0.2 be considered a 'small' effect size, 0.5 represents a 'medium' effect size and 0.8 a 'large' effect size. This means that if two groups' means do not differ by 0.2 standard deviations or more, the difference is trivial, even if it is statistically significant."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"Switch DMARDs": "533", "Add DMARDs": "529"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "SMD 0.13 lower (0.25 lower to 0.01 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "21a", "Database": "2021 ACR RA"}
{"outcome_uid": "ce87d1b3", "clinical_question": "Should patients with RA on DMARD(s) who are NOT at target switch to another DMARD versus add a 2nd DMARD?", "population": "Patients with RA on non-biologic DMARD(s) who are not at target", "intervention": "Switch to another DMARD", "comparator": "Add another DMARD", "outcome": "Withdrawal due to lack of efficacy (follow up: range 4 months to 1 year)", "importance": "IMPORTANT", "related_paper_list": ["39e9c906", "8f68ef49", "d40d9e70", "bcdcb109", "49208898", "71272a3e"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm. According to the Cochrane's handbook, Cohen suggested that SMD=0.2 be considered a 'small' effect size, 0.5 represents a 'medium' effect size and 0.8 a 'large' effect size. This means that if two groups' means do not differ by 0.2 standard deviations or more, the difference is trivial, even if it is statistically significant."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"Switch DMARDs": "32/591 (5.4%)", "Add DMARDs": "16/446 (3.6%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.18 (0.59 to 2.36)", "Absolute Effect (95% CI)": "6 more per 1,000 (from 15 fewer to 49 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "21a", "Database": "2021 ACR RA"}
{"outcome_uid": "de4f4469", "clinical_question": "Should patients with RA on DMARD(s) who are NOT at target switch to another DMARD versus add a 2nd DMARD?", "population": "Patients with RA on non-biologic DMARD(s) who are not at target", "intervention": "Switch to another DMARD", "comparator": "Add another DMARD", "outcome": "Withdrawal due to adverse events (follow up: range 3 months to 2 years)", "importance": "IMPORTANT", "related_paper_list": ["f8f1a82c", "323b4f71", "39e9c906", "8f68ef49", "d40d9e70", "bcdcb109", "49208898", "ce4b2bdc", "553e309f"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": "Four studies at high risk of bias represent 40% of the weight. This is accounted for when downgrading for imprecision."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Switch DMARDs": "101/1017 (9.9%)", "Add DMARDs": "145/1392 (10.4%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.91 (0.66 to 1.25)", "Absolute Effect (95% CI)": "9 fewer per 1,000 (from 35 fewer to 26 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "21a", "Database": "2021 ACR RA"}
{"outcome_uid": "b8fe9f01", "clinical_question": "Should patients with RA on DMARD(s) who are NOT at target switch to another DMARD versus add a 2nd DMARD?", "population": "Patients with RA on non-biologic DMARD(s) who are not at target", "intervention": "Switch to another DMARD", "comparator": "Add another DMARD", "outcome": "Serious adverse events (follow up: range 3 months to 2 years)", "importance": "IMPORTANT", "related_paper_list": ["f8f1a82c", "323b4f71", "39e9c906", "d40d9e70", "bcdcb109", "71272a3e"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and blinding."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm. According to the Cochrane's handbook, Cohen suggested that SMD=0.2 be considered a 'small' effect size, 0.5 represents a 'medium' effect size and 0.8 a 'large' effect size. This means that if two groups' means do not differ by 0.2 standard deviations or more, the difference is trivial, even if it is statistically significant."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Switch DMARDs": "94/1009 (9.3%)", "Add DMARDs": "113/1371 (8.2%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.10 (0.85 to 1.42)", "Absolute Effect (95% CI)": "8 more per 1,000 (from 12 fewer to 35 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "21a", "Database": "2021 ACR RA"}
{"outcome_uid": "14ee7637", "clinical_question": "Should patients with RA on DMARD(s) who are NOT at target switch to another DMARD versus add a 2nd DMARD?", "population": "Patients with RA on non-biologic DMARD(s) who are not at target", "intervention": "Switch to another DMARD", "comparator": "Add another DMARD", "outcome": "Malignancy (follow up: range 4 months to 2 years)", "importance": "IMPORTANT", "related_paper_list": ["f8f1a82c", "323b4f71", "39e9c906"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and blinding."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due serious imprecision. Low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Switch DMARDs": "3/598 (0.5%)", "Add DMARDs": "6/978 (0.6%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.65 (0.11 to 3.70)", "Absolute Effect (95% CI)": "2 fewer per 1,000 (from 5 fewer to 17 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "21a", "Database": "2021 ACR RA"}
{"outcome_uid": "c1da4e7a", "clinical_question": "Should patients with RA on DMARD(s) who are NOT at target switch to another DMARD versus add a 2nd DMARD?", "population": "Patients with RA on non-biologic DMARD(s) who are not at target", "intervention": "Switch to another DMARD", "comparator": "Add another DMARD", "outcome": "Death (follow up: range 4 months to 2 years)", "importance": "IMPORTANT", "related_paper_list": ["f8f1a82c", "323b4f71", "39e9c906", "bcdcb109"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and blinding."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due serious imprecision. Low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Switch DMARDs": "3/757 (0.4%)", "Add DMARDs": "4/1133 (0.4%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.92 (0.17 to 4.88)", "Absolute Effect (95% CI)": "0 fewer per 1,000 (from 3 fewer to 14 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "21a", "Database": "2021 ACR RA"}
{"outcome_uid": "14b80766", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Switch to Abatacept", "outcome": "Disease activity (follow up: 1 year; assessed with: ACR 20)", "importance": "CRITICAL", "related_paper_list": ["b6823603"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Switch to ABA": "11/31 (35.5%)", "Switch to a 2nd TNFi": "17/31 (54.8%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.65 (0.37 to 1.15)", "Absolute Effect (95% CI)": "192 fewer per 1,000 (from 345 fewer to 82 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "c432b80c", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Switch to Abatacept", "outcome": "Disease activity (follow up: 1 year; assessed with: ACR 50)", "importance": "CRITICAL", "related_paper_list": ["b6823603"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Switch to ABA": "6/32 (18.8%)", "Switch to a 2nd TNFi": "9/31 (29.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.65 (0.26 to 1.60)", "Absolute Effect (95% CI)": "102 fewer per 1,000 (from 215 fewer to 174 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "92787781", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Switch to Abatacept", "outcome": "Disease activity (follow up: 1 year; assessed with: ACR 70)", "importance": "CRITICAL", "related_paper_list": ["b6823603"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Switch to ABA": "3/32 (9.4%)", "Switch to a 2nd TNFi": "5/31 (16.1%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.58 (0.15 to 2.23)", "Absolute Effect (95% CI)": "68 fewer per 1,000 (from 137 fewer to 198 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "0e159bab", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Switch to Abatacept", "outcome": "Remission (follow up: 1 year; assessed with: DAS28-ESR <2.6)", "importance": "CRITICAL", "related_paper_list": ["fba7b4bd", "b6823603"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding and lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Very small sample size, low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Switch to ABA": "6/76 (7.9%)", "Switch to a 2nd TNFi": "17/80 (21.3%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.38 (0.16 to 0.91)", "Absolute Effect (95% CI)": "132 fewer per 1,000 (from 179 fewer to 19 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "48a4d3f9", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Switch to Abatacept", "outcome": "Disease activity (follow up: 1 year; assessed with: DAS28-ESR (MCID -1.17))", "importance": "CRITICAL", "related_paper_list": ["fba7b4bd", "b6823603"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding and lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Very small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Switch to ABA": "76", "Switch to a 2nd TNFi": "80"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.45 higher (0.02 higher to 0.88 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "f52ac903", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Switch to Abatacept", "outcome": "Disability (follow up: 1 year; assessed with: HAQ-DI (MCID -0.22))", "importance": "IMPORTANT", "related_paper_list": ["fba7b4bd", "b6823603"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding and lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm. Very small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Switch to ABA": "77", "Switch to a 2nd TNFi": "81"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.04 higher (0.17 lower to 0.25 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "a456d736", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Switch to Abatacept", "outcome": "Quality of life (follow up: 1 year; assessed with: RAQol (MCID 2))", "importance": "IMPORTANT", "related_paper_list": ["b6823603"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Switch to ABA": "34", "Switch to a 2nd TNFi": "30"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 1.5 lower (6.36 lower to 3.36 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "c1dafc22", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Switch to Abatacept", "outcome": "Pain (follow up: 1 year; assessed with: VAS 0-100 (MCID -11.9))", "importance": "IMPORTANT", "related_paper_list": ["b6823603"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Switch to ABA": "34", "Switch to a 2nd TNFi": "31"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 2.5 higher (14.99 lower to 19.99 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "136e3685", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Switch to Abatacept", "outcome": "Serious adverse events (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["fba7b4bd", "b6823603"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding and lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm. Very small sample size, low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Switch to ABA": "5/63 (7.9%)", "Switch to a 2nd TNFi": "1/65 (1.5%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 3.75 (0.64 to 22.11)", "Absolute Effect (95% CI)": "42 more per 1,000 (from 6 fewer to 325 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "3476fa5f", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Switch to Abatacept", "outcome": "Withdrawal due to lack of efficacy (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["b6823603"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Switch to ABA": "3/41 (7.3%)", "Switch to a 2nd TNFi": "2/41 (4.9%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.50 (0.26 to 8.51)", "Absolute Effect (95% CI)": "24 more per 1,000 (from 36 fewer to 366 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "c7db6936", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Switch to Abatacept", "outcome": "Withdrawal due to adverse events (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["b6823603"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Very small sample size, low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Switch to ABA": "1/41 (2.4%)", "Switch to a 2nd TNFi": "0/41 (0.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 3.00 (0.13 to 71.56)", "Absolute Effect (95% CI)": "0 fewer per 1,000 (from 0 fewer to 0 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "b1811a92", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Switch to Abatacept", "outcome": "Malignancy (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["fba7b4bd"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding and lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Very small sample size, low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Switch to ABA": "0/22 (0.0%)", "Switch to a 2nd TNFi": "0/24 (0.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "Not estimable", "Absolute Effect (95% CI)": "Not estimable", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "65b709b1", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Switch to Abatacept", "outcome": "Cardiovascular disease (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["fba7b4bd"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding and lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Switch to ABA": "1/22 (4.5%)", "Switch to a 2nd TNFi": "2/24 (8.3%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.55 (0.05 to 5.60)", "Absolute Effect (95% CI)": "37 fewer per 1,000 (from 79 fewer to 383 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "365959f6", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Switch to Abatacept", "outcome": "Death (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["b6823603"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding and lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Switch to ABA": "1/41 (2.4%)", "Switch to a 2nd TNFi": "0/41 (0.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 3.00 (0.13 to 71.56)", "Absolute Effect (95% CI)": "0 fewer per 1,000 (from 0 fewer to 0 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "492992b6", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Switch to Rituximab", "outcome": "Disease activity (follow up: 1 year; assessed with: ACR 20)", "importance": "CRITICAL", "related_paper_list": ["b6823603"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to RTX": "12/28 (42.9%)", "Switch to a 2nd TNFi": "17/31 (54.8%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.78 (0.46 to 1.33)", "Absolute Effect (95% CI)": "121 fewer per 1,000 (from 296 fewer to 181 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "d3cc1c8d", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Switch to Rituximab", "outcome": "Disease activity (follow up: 1 year; assessed with: ACR 50)", "importance": "CRITICAL", "related_paper_list": ["b6823603"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to RTX": "6/29 (20.7%)", "Switch to a 2nd TNFi": "9/31 (29.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.71 (0.29 to 1.75)", "Absolute Effect (95% CI)": "84 fewer per 1,000 (from 206 fewer to 218 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "3c20d126", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Switch to Rituximab", "outcome": "Disease activity (follow up: 1 year; assessed with: ACR 70)", "importance": "CRITICAL", "related_paper_list": ["b6823603"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to RTX": "3/30 (10.0%)", "Switch to a 2nd TNFi": "5/31 (16.1%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.62 (0.16 to 2.37)", "Absolute Effect (95% CI)": "61 fewer per 1,000 (from 135 fewer to 221 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "0a4849d2", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Switch to Rituximab", "outcome": "Disease activity (follow up: 1 year; assessed with: DAS28 ESR (Lower values – > benefit) (MCID -1.17)", "importance": "CRITICAL", "related_paper_list": ["b6823603", "fba7b4bd"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding and lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to RTX": "73", "Switch to a 2nd TNFi": "80"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.13 higher (0.44 lower to 0.7 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "300715a0", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Switch to Rituximab", "outcome": "Remission (follow up: 1 year; assessed with: DAS28-ESR <2.6)", "importance": "CRITICAL", "related_paper_list": ["b6823603", "fba7b4bd"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding and lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to RTX": "16/73 (21.9%)", "Switch to a 2nd TNFi": "17/80 (21.3%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.96 (0.38 to 2.40)", "Absolute Effect (95% CI)": "9 fewer per 1,000 (from 132 fewer to 298 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "d19c1efc", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Switch to Rituximab", "outcome": "Disability (follow up: 1 year; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22)", "importance": "IMPORTANT", "related_paper_list": ["b6823603", "fba7b4bd"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding and lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm. Very small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to RTX": "76", "Switch to a 2nd TNFi": "81"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.08 higher (0.13 lower to 0.29 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "39e60e52", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Switch to Rituximab", "outcome": "Quality of life (follow up: 1 year; assessed with: RAQol (Lower values – > benefit) (MCID 2)", "importance": "IMPORTANT", "related_paper_list": ["b6823603"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to RTX": "30", "Switch to a 2nd TNFi": "30"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.5 higher (4.56 lower to 5.56 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "1e7a3259", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Switch to Rituximab", "outcome": "Pain (follow up: 1 year; assessed with: VAS 0-100 (Lower values – > benefit) (MCID -11.9)", "importance": "IMPORTANT", "related_paper_list": ["b6823603"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm. Very small sample size, low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to RTX": "30", "Switch to a 2nd TNFi": "31"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 8 higher (6.43 lower to 22.43 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "295c7f44", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Switch to Rituximab", "outcome": "Serious adverse events (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["b6823603", "fba7b4bd"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding and lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to RTX": "4/74 (5.4%)", "Switch to a 2nd TNFi": "1/65 (1.5%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 4.10 (0.48 to 35.11)", "Absolute Effect (95% CI)": "48 more per 1,000 (from 8 fewer to 525 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "c719dd1d", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Switch to Rituximab", "outcome": "Withdrawal due to lack of efficacy (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["b6823603"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to RTX": "0/40 (0.0%)", "Switch to a 2nd TNFi": "2/41 (4.9%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.20 (0.01 to 4.14)", "Absolute Effect (95% CI)": "39 fewer per 1,000 (from 48 fewer to 153 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "fdabfb2c", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Switch to Rituximab", "outcome": "Withdrawal due to adverse events (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["b6823603"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Very small sample size, very low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to RTX": "0/40 (0.0%)", "Switch to a 2nd TNFi": "0/41 (0.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "not estimable", "Absolute Effect (95% CI)": "-", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "5ffdb388", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Switch to Rituximab", "outcome": "Death (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["b6823603"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Very small sample size, very low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to RTX": "1/40 (2.5%)", "Switch to a 2nd TNFi": "0/41 (0.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 3.07 (0.13 to 73.28)", "Absolute Effect (95% CI)": "0 fewer per 1,000 (from 0 fewer to 0 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "283b6da5", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Switch to Rituximab", "outcome": "CVD (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["fba7b4bd"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding and lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to RTX": "2/34 (5.9%)", "Switch to a 2nd TNFi": "2/24 (8.3%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.71 (0.11 to 4.67)", "Absolute Effect (95% CI)": "24 fewer per 1,000 (from 74 fewer to 306 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "1b03ddfe", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Switch to Rituximab", "outcome": "Malignancy (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["fba7b4bd"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding and lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Very small sample size, very low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to RTX": "3/34 (8.8%)", "Switch to a 2nd TNFi": "0/24 (0.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 5.00 (0.27 to 92.56)", "Absolute Effect (95% CI)": "0 fewer per 1,000 (from 0 fewer to 0 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "e0734d5d", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Switch to IL-6 Receptor Inhibitor", "outcome": "Disease activity (follow up: 6 months; assessed with: DAS 28-ESR)", "importance": "CRITICAL", "related_paper_list": ["05c073e4"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Observational Study", "Certainty": "VERY LOW", "No of participants": {"Switch to 2nd TNFi": "390", "Switch to IL-6 inhibitor": "147"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 1.3 lower (1.63 lower to 0.97 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "f540f84e", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Switch to IL-6 Receptor Inhibitor", "outcome": "Low disease activity (follow up: 6 months; assessed with: DAS28-ESR <3.2)", "importance": "IMPORTANT", "related_paper_list": ["05c073e4"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Observational Study", "Certainty": "LOW", "No of participants": {"Switch to 2nd TNFi": "43/103 (41.7%)", "Switch to IL-6 inhibitor": "29/44 (65.9%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.63 (0.46 to 0.87)", "Absolute Effect (95% CI)": "244 fewer per 1,000 (from 356 fewer to 86 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "2bc8f148", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Switch to IL-6 Receptor Inhibitor", "outcome": "Pain (follow up: 6 months; assessed with: VAS 100)", "importance": "IMPORTANT", "related_paper_list": ["05c073e4"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Observational Study", "Certainty": "LOW", "No of participants": {"Switch to 2nd TNFi": "185", "Switch to IL-6 inhibitor": "74"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 1.1 lower (7.52 lower to 5.32 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "b8a0dd44", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Switch to IL-6 Receptor Inhibitor", "outcome": "Disability (follow up: 6 months; assessed with: HAQ-DI)", "importance": "IMPORTANT", "related_paper_list": ["05c073e4"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Observational Study", "Certainty": "VERY LOW", "No of participants": {"Switch to 2nd TNFi": "185", "Switch to IL-6 inhibitor": "74"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.2 lower (0.4 lower to 0)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "043a48e4", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Switch to IL-6 Receptor Inhibitor", "outcome": "Withdrawal due to adverse events (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["05c073e4"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Observational Study", "Certainty": "LOW", "No of participants": {"Switch to 2nd TNFi": "49/217 (22.6%)", "Switch to IL-6 inhibitor": "19/35 (54.3%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.42 (0.28 to 0.62)", "Absolute Effect (95% CI)": "315 fewer per 1,000 (from 391 fewer to 206 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "de3b109f", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Switch to IL-6 Receptor Inhibitor", "outcome": "Withdrawal due to lack of efficacy (follow up: 6 months)", "importance": "IMPORTANT", "related_paper_list": ["05c073e4"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Observational Study", "Certainty": "LOW", "No of participants": {"Switch to 2nd TNFi": "137/217 (63.1%)", "Switch to IL-6 inhibitor": "11/35 (31.4%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 2.01 (1.22 to 3.31)", "Absolute Effect (95% CI)": "317 more per 1,000 (from 69 more to 726 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "dee366b9", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Continue same management", "outcome": "Disease activity (follow up: 4 months; assessed with: ACR 20)", "importance": "CRITICAL", "related_paper_list": ["ca0be03a"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to serious risk of bias. Lack of blinding (except for radiographic outcomes) and lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, very low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to a 2nd TNFi": "8/13 (61.5%)", "Continue 1st TNFi": "4/14 (28.6%)"}, "Annotation": {"data": "1. Switch to IFX.\n2. Continue ETN.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 2.15 (0.85 to 5.48)", "Absolute Effect (95% CI)": "329 more per 1,000 (from 43 fewer to 1,000 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "b2f660d4", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Continue same management", "outcome": "Disease activity (follow up: 4 months; assessed with: ACR 50)", "importance": "CRITICAL", "related_paper_list": ["ca0be03a"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to serious risk of bias. Lack of blinding (except for radiographic outcomes) and lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, very low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to a 2nd TNFi": "4/13 (30.8%)", "Continue 1st TNFi": "2/14 (14.3%)"}, "Annotation": {"data": "1. Switch to IFX.\n2. Continue ETN.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 2.15 (0.47 to 9.85)", "Absolute Effect (95% CI)": "164 more per 1,000 (from 76 fewer to 1,000 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "cbb72349", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Continue same management", "outcome": "Disease activity (follow up: 4 months; assessed with: DAS28-ESR)", "importance": "CRITICAL", "related_paper_list": ["ca0be03a"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to serious risk of bias. Lack of blinding (except for radiographic outcomes) and lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting no effect. Very small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to a 2nd TNFi": "13", "Continue 1st TNFi": "14"}, "Annotation": {"data": "1. Switch to IFX.\n2. Continue ETN.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 1.2 lower (2.37 lower to 0.03 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "58ff0876", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Continue same management", "outcome": "Remission (follow up: 4 months; assessed with: DAS28-ESR <2.6)", "importance": "CRITICAL", "related_paper_list": ["ca0be03a"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to serious risk of bias. Lack of blinding (except for radiographic outcomes) and lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Very small sample size, very low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to a 2nd TNFi": "8/13 (61.5%)", "Continue 1st TNFi": "2/14 (14.3%)"}, "Annotation": {"data": "1. Switch to IFX.\n2. Continue ETN.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 4.31 (1.11 to 16.67)", "Absolute Effect (95% CI)": "473 more per 1,000 (from 16 more to 1,000 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "fff04d15", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Continue same management", "outcome": "Radiographic progression (follow up: 4 months; assessed with: Sharp/ van der Heijde)", "importance": "IMPORTANT", "related_paper_list": ["ca0be03a"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding of patients and personnel and lack of allocation concealment. Outcome assessors for radiographic outcomes were blinded."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Very small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to a 2nd TNFi": "12", "Continue 1st TNFi": "12"}, "Annotation": {"data": "1. Switch to IFX.\n2. Continue ETN.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.6 higher (1.78 lower to 2.98 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "533c4bd1", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Continue same management", "outcome": "Serious adverse events (follow up: 4 months)", "importance": "IMPORTANT", "related_paper_list": ["ca0be03a"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to serious risk of bias. Lack of blinding (except for radiographic outcomes) and lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, very low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to a 2nd TNFi": "0/13 (0.0%)", "Continue 1st TNFi": "2/14 (14.3%)"}, "Annotation": {"data": "1. Switch to IFX.\n2. Continue ETN.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.21 (0.01 to 4.08)", "Absolute Effect (95% CI)": "113 fewer per 1,000 (from 141 fewer to 440 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "69adfd2a", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Continue same management", "outcome": "Serious adverse events (from SR of harms)", "related_paper_list": ["a1e03f7a", "21011e18"], "assessment_results": {"GRADE": {"result_interpretation": "The Systematic Review RefID=5595, 2011 comparing Infliximab vs Etanercept among RA and AS, Psoriasis, PsA, IBD, Cancer showed that for Serious adverse events, the result was OR=0.93 (0.60 to 1.42). The Systematic Review RefID=1403, 2017 comparing Infliximab vs Etanercept among RA showed that for Serious adverse events, the result was RR=4.90 (0.23 to 104) [Direct Evidence, Low certainty].", "Study design": "Systematic Review"}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "860632b4", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their first TNF Inhibitor who are not at target", "intervention": "Switch to a 2nd TNF Inhibitor", "comparator": "Continue same management", "outcome": "Withdrawal due to adverse events (follow up: 4 months)", "importance": "IMPORTANT", "related_paper_list": ["ca0be03a"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to serious risk of bias. Lack of blinding (except for radiographic outcomes) and lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, very low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to a 2nd TNFi": "2/13 (15.4%)", "Continue 1st TNFi": "1/14 (7.1%)"}, "Annotation": {"data": "1. Switch to IFX.\n2. Continue ETN.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 2.15 (0.22 to 21.03)", "Absolute Effect (95% CI)": "82 more per 1,000 (from 56 fewer to 1,000 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "24", "Database": "2021 ACR RA"}
{"outcome_uid": "703e261b", "clinical_question": "Should patients with RA on their 2nd TNF Inhibitor who are NOT at target, switch to a 3rd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their 2nd TNF Inhibitor who are not at target", "intervention": "Switch to a 3rd TNF Inhibitor", "comparator": "Switch to Abatacept", "outcome": "Disease activity (follow up: 1 year; assessed with: ACR 20)", "importance": "CRITICAL", "related_paper_list": ["b6823603"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population on their first TNF Inhibitor who are NOT at target and the intervention is second TNFi rather than third TNFi."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to ABA": "11/31 (35.5%)", "switch to a 3rd TNFi": "17/31 (54.8%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.65 (0.37 to 1.15)", "Absolute Effect (95% CI)": "192 fewer per 1,000 (from 345 fewer to 82 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "25", "Database": "2021 ACR RA"}
{"outcome_uid": "b191c642", "clinical_question": "Should patients with RA on their 2nd TNF Inhibitor who are NOT at target, switch to a 3rd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their 2nd TNF Inhibitor who are not at target", "intervention": "Switch to a 3rd TNF Inhibitor", "comparator": "Switch to Abatacept", "outcome": "Disease activity (follow up: 1 year; assessed with: ACR 50)", "importance": "CRITICAL", "related_paper_list": ["b6823603"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population on their first TNF Inhibitor who are NOT at target and the intervention is second TNFi rather than third TNFi."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to ABA": "6/32 (18.8%)", "switch to a 3rd TNFi": "9/31 (29.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.65 (0.26 to 1.60)", "Absolute Effect (95% CI)": "102 fewer per 1,000 (from 215 fewer to 174 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "25", "Database": "2021 ACR RA"}
{"outcome_uid": "fe967f2c", "clinical_question": "Should patients with RA on their 2nd TNF Inhibitor who are NOT at target, switch to a 3rd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their 2nd TNF Inhibitor who are not at target", "intervention": "Switch to a 3rd TNF Inhibitor", "comparator": "Switch to Abatacept", "outcome": "Disease activity (follow up: 1 year; assessed with: ACR 70)", "importance": "CRITICAL", "related_paper_list": ["b6823603"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population on their first TNF Inhibitor who are NOT at target and the intervention is second TNFi rather than third TNFi."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to ABA": "3/32 (9.4%)", "switch to a 3rd TNFi": "5/31 (16.1%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.58 (0.15 to 2.23)", "Absolute Effect (95% CI)": "68 fewer per 1,000 (from 137 fewer to 198 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "25", "Database": "2021 ACR RA"}
{"outcome_uid": "7dea6221", "clinical_question": "Should patients with RA on their 2nd TNF Inhibitor who are NOT at target, switch to a 3rd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their 2nd TNF Inhibitor who are not at target", "intervention": "Switch to a 3rd TNF Inhibitor", "comparator": "Switch to Abatacept", "outcome": "Remission (follow up: 1 year; assessed with: DAS28-ESR <2.6)", "importance": "CRITICAL", "related_paper_list": ["b6823603", "fba7b4bd"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding and lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population on their first TNF Inhibitor who are NOT at target and the intervention is second TNFi rather than third TNFi."}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Very small sample size, low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to ABA": "6/76 (7.9%)", "switch to a 3rd TNFi": "17/80 (21.3%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.38 (0.16 to 0.91)", "Absolute Effect (95% CI)": "132 fewer per 1,000 (from 179 fewer to 19 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "25", "Database": "2021 ACR RA"}
{"outcome_uid": "b05e05ed", "clinical_question": "Should patients with RA on their 2nd TNF Inhibitor who are NOT at target, switch to a 3rd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their 2nd TNF Inhibitor who are not at target", "intervention": "Switch to a 3rd TNF Inhibitor", "comparator": "Switch to Abatacept", "outcome": "Disease activity (follow up: 1 year; assessed with: DAS28-ESR (Lower values – > benefit) (MCID -1.17)", "importance": "CRITICAL", "related_paper_list": ["b6823603", "fba7b4bd"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding and lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population on their first TNF Inhibitor who are NOT at target and the intervention is second TNFi rather than third TNFi."}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Very small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to ABA": "76", "switch to a 3rd TNFi": "80"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.45 higher (0.02 higher to 0.88 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "25", "Database": "2021 ACR RA"}
{"outcome_uid": "262f21a0", "clinical_question": "Should patients with RA on their 2nd TNF Inhibitor who are NOT at target, switch to a 3rd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their 2nd TNF Inhibitor who are not at target", "intervention": "Switch to a 3rd TNF Inhibitor", "comparator": "Switch to Abatacept", "outcome": "Disability (follow up: 1 year; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22)", "importance": "IMPORTANT", "related_paper_list": ["b6823603", "fba7b4bd"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding and lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population on their first TNF Inhibitor who are NOT at target and the intervention is second TNFi rather than third TNFi."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm. Very small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to ABA": "77", "switch to a 3rd TNFi": "81"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.04 higher (0.17 lower to 0.25 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "25", "Database": "2021 ACR RA"}
{"outcome_uid": "36e2d748", "clinical_question": "Should patients with RA on their 2nd TNF Inhibitor who are NOT at target, switch to a 3rd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their 2nd TNF Inhibitor who are not at target", "intervention": "Switch to a 3rd TNF Inhibitor", "comparator": "Switch to Abatacept", "outcome": "Quality of life (follow up: 1 year; assessed with: RAQol (Lower values – > benefit) (MCID 2)", "importance": "IMPORTANT", "related_paper_list": ["b6823603"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population on their first TNF Inhibitor who are NOT at target and the intervention is second TNFi rather than third TNFi."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to ABA": "34", "switch to a 3rd TNFi": "30"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 1.5 lower (6.36 lower to 3.36 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "25", "Database": "2021 ACR RA"}
{"outcome_uid": "e276091a", "clinical_question": "Should patients with RA on their 2nd TNF Inhibitor who are NOT at target, switch to a 3rd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their 2nd TNF Inhibitor who are not at target", "intervention": "Switch to a 3rd TNF Inhibitor", "comparator": "Switch to Abatacept", "outcome": "Pain (follow up: 1 year; assessed with: VAS 0-100 (Lower values – > benefit) (MCID -11.9)", "importance": "IMPORTANT", "related_paper_list": ["b6823603"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population on their first TNF Inhibitor who are NOT at target and the intervention is second TNFi rather than third TNFi."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to ABA": "34", "switch to a 3rd TNFi": "31"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 2.5 higher (14.99 lower to 19.99 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "25", "Database": "2021 ACR RA"}
{"outcome_uid": "78b9741b", "clinical_question": "Should patients with RA on their 2nd TNF Inhibitor who are NOT at target, switch to a 3rd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their 2nd TNF Inhibitor who are not at target", "intervention": "Switch to a 3rd TNF Inhibitor", "comparator": "Switch to Abatacept", "outcome": "Serious adverse events (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["b6823603", "fba7b4bd"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding and lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population on their first TNF Inhibitor who are NOT at target and the intervention is second TNFi rather than third TNFi."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm. Very small sample size, low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to ABA": "5/63 (7.9%)", "switch to a 3rd TNFi": "1/65 (1.5%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 3.75 (0.64 to 22.11)", "Absolute Effect (95% CI)": "42 more per 1,000 (from 6 fewer to 325 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "25", "Database": "2021 ACR RA"}
{"outcome_uid": "cbb8c64a", "clinical_question": "Should patients with RA on their 2nd TNF Inhibitor who are NOT at target, switch to a 3rd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their 2nd TNF Inhibitor who are not at target", "intervention": "Switch to a 3rd TNF Inhibitor", "comparator": "Switch to Abatacept", "outcome": "Withdrawal due to lack of efficacy (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["b6823603"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population on their first TNF Inhibitor who are NOT at target and the intervention is second TNFi rather than third TNFi."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to ABA": "3/41 (7.3%)", "switch to a 3rd TNFi": "2/41 (4.9%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.50 (0.26 to 8.51)", "Absolute Effect (95% CI)": "24 more per 1,000 (from 36 fewer to 366 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "25", "Database": "2021 ACR RA"}
{"outcome_uid": "6a8389af", "clinical_question": "Should patients with RA on their 2nd TNF Inhibitor who are NOT at target, switch to a 3rd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their 2nd TNF Inhibitor who are not at target", "intervention": "Switch to a 3rd TNF Inhibitor", "comparator": "Switch to Abatacept", "outcome": "Withdrawal due to adverse events (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["b6823603"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population on their first TNF Inhibitor who are NOT at target and the intervention is second TNFi rather than third TNFi."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Very small sample size, low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to ABA": "1/41 (2.4%)", "switch to a 3rd TNFi": "0/41 (0.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 3.00 (0.13 to 71.56)", "Absolute Effect (95% CI)": "0 fewer per 1,000 (from 0 fewer to 0 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "25", "Database": "2021 ACR RA"}
{"outcome_uid": "72a3aeea", "clinical_question": "Should patients with RA on their 2nd TNF Inhibitor who are NOT at target, switch to a 3rd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their 2nd TNF Inhibitor who are not at target", "intervention": "Switch to a 3rd TNF Inhibitor", "comparator": "Switch to Abatacept", "outcome": "Death (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["b6823603"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population on their first TNF Inhibitor who are NOT at target and the intervention is second TNFi rather than third TNFi."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Very small sample size, low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to ABA": "1/41 (2.4%)", "switch to a 3rd TNFi": "0/41 (0.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 3.00 (0.13 to 71.56)", "Absolute Effect (95% CI)": "0 fewer per 1,000 (from 0 fewer to 0 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "25", "Database": "2021 ACR RA"}
{"outcome_uid": "33aadb87", "clinical_question": "Should patients with RA on their 2nd TNF Inhibitor who are NOT at target, switch to a 3rd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their 2nd TNF Inhibitor who are not at target", "intervention": "Switch to a 3rd TNF Inhibitor", "comparator": "Switch to Abatacept", "outcome": "Malignancy (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["fba7b4bd"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding and lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population on their first TNF Inhibitor who are NOT at target and the intervention is second TNFi rather than third TNFi."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Very small sample size, low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to ABA": "0/22 (0.0%)", "switch to a 3rd TNFi": "0/24 (0.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "not estimable", "Absolute Effect (95% CI)": "", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "25", "Database": "2021 ACR RA"}
{"outcome_uid": "024aa2ae", "clinical_question": "Should patients with RA on their 2nd TNF Inhibitor who are NOT at target, switch to a 3rd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their 2nd TNF Inhibitor who are not at target", "intervention": "Switch to a 3rd TNF Inhibitor", "comparator": "Switch to Abatacept", "outcome": "Cardiovascular disease (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["fba7b4bd"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding and lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population on their first TNF Inhibitor who are NOT at target and the intervention is second TNFi rather than third TNFi."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to ABA": "1/22 (4.5%)", "switch to a 3rd TNFi": "2/24 (8.3%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.55 (0.05 to 5.60)", "Absolute Effect (95% CI)": "37 fewer per 1,000 (from 79 fewer to 383 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "25", "Database": "2021 ACR RA"}
{"outcome_uid": "e0cf3c4a", "clinical_question": "Should patients with RA on their 2nd TNF Inhibitor who are NOT at target, switch to a 3rd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their 2nd TNF Inhibitor who are not at target", "intervention": "Switch to a 3rd TNF Inhibitor", "comparator": "Switch to Abatacept", "outcome": "Serious adverse events (from SR of harms)", "related_paper_list": ["a1e03f7a"], "assessment_results": {"GRADE": {"result_interpretation": "The Systematic Review RefID=1403, 2017 comparing Rituximab vs Etanercept, Adalimumab, Certolizumab, Golimumab, and Infliximab among RA showed that for Serious adverse events, the result was RR=1.13 (0.79 to 1.62) [Low certainty], RR=1.24 (0.89 to 1.73) [Low certainty], RR=1.56 (1.03 to 2.37) [Moderate certainty], RR=1.15 (0.71 to 1.86) [Very low certainty], and RR=1.20 (0.082 to 1.74) [Low certainty] respectively. All are Indirect evidence.", "Study design": "Systematic Review"}}, "PICO_IDX": "25", "Database": "2021 ACR RA"}
{"outcome_uid": "38c014e9", "clinical_question": "Should patients with RA on their 2nd TNF Inhibitor who are NOT at target, switch to a 3rd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their 2nd TNF Inhibitor who are not at target", "intervention": "Switch to a 3rd TNF Inhibitor", "comparator": "Switch to Rituximab", "outcome": "Disease activity (follow up: 6 months; assessed with DAS 28-ESR (Lower values – > benefit) (MCID -1.17)", "importance": "CRITICAL", "related_paper_list": ["5f4ff353"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "'Other limitations of this observational study are the relative low numbers of patients and the high number of missing data.'"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting no effect. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Observational Study", "Certainty": "VERY LOW", "No of participants": {"Switching to a 3rd TNF Inhibitor": "43", "switching to rituximab": "58"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.35 lower (1.82 lower to 1.12 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "25", "Database": "2021 ACR RA"}
{"outcome_uid": "67c7b09b", "clinical_question": "Should patients with RA on their 2nd TNF Inhibitor who are NOT at target, switch to a 3rd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their 2nd TNF Inhibitor who are not at target", "intervention": "Switch to a 3rd TNF Inhibitor", "comparator": "Switch to Rituximab", "outcome": "Low disease activity (follow up: 6 months; assessed with DAS28 ≤ 3.2)", "importance": "IMPORTANT", "related_paper_list": ["5f4ff353"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "'Other limitations of this observational study are the relative low numbers of patients and the high number of missing data.'"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Observational Study", "Certainty": "VERY LOW", "No of participants": {"Switching to a 3rd TNF Inhibitor": "6/35 (17.1%)", "switching to rituximab": "20/69 (29.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.59 (0.26 to 1.34)", "Absolute Effect (95% CI)": "119 fewer per 1,000 (from 214 fewer to 99 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "25", "Database": "2021 ACR RA"}
{"outcome_uid": "d082600d", "clinical_question": "Should patients with RA on their 2nd TNF Inhibitor who are NOT at target, switch to a 3rd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their 2nd TNF Inhibitor who are not at target", "intervention": "Switch to a 3rd TNF Inhibitor", "comparator": "Switch to Rituximab", "outcome": "Disability (follow up: 1 year; assessed with HAQ-DI (Lower values – > benefit) (MCID -0.22 )", "importance": "IMPORTANT", "related_paper_list": ["5f4ff353"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "'Other limitations of this observational study are the relative low numbers of patients and the high number of missing data.'"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Observational Study", "Certainty": "VERY LOW", "No of participants": {"Switching to a 3rd TNF Inhibitor": "35", "switching to rituximab": "54"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0 (0.53 lower to 0.53 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "25", "Database": "2021 ACR RA"}
{"outcome_uid": "bb7ff9b9", "clinical_question": "Should patients with RA on their 2nd TNF Inhibitor who are NOT at target, switch to a 3rd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their 2nd TNF Inhibitor who are not at target", "intervention": "Switch to a 3rd TNF Inhibitor", "comparator": "Switch to Rituximab", "outcome": "Withdrawal due to lack of efficacy (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["5f4ff353"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "'Other limitations of this observational study are the relative low numbers of patients and the high number of missing data.'"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to very serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Observational Study", "Certainty": "VERY LOW", "No of participants": {"Switching to a 3rd TNF Inhibitor": "15/64 (23.4%)", "switching to rituximab": "10/90 (11.1%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 2.11 (1.01 to 4.39)", "Absolute Effect (95% CI)": "123 more per 1,000 (from 1 more to 377 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "25", "Database": "2021 ACR RA"}
{"outcome_uid": "ef1f4075", "clinical_question": "Should patients with RA on their 2nd TNF Inhibitor who are NOT at target, switch to a 3rd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their 2nd TNF Inhibitor who are not at target", "intervention": "Switch to a 3rd TNF Inhibitor", "comparator": "Switch to Rituximab", "outcome": "Withdrawal due to adverse events (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["5f4ff353"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "'Other limitations of this observational study are the relative low numbers of patients and the high number of missing data.'"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to very serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Observational Study", "Certainty": "VERY LOW", "No of participants": {"Switching to a 3rd TNF Inhibitor": "14/64 (21.9%)", "switching to rituximab": "1/90 (1.1%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 19.69 (2.66 to 145.95)", "Absolute Effect (95% CI)": "208 more per 1,000 (from 18 more to 1,000 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "25", "Database": "2021 ACR RA"}
{"outcome_uid": "7a0cd46f", "clinical_question": "Should patients with RA on their 2nd TNF Inhibitor who are NOT at target, switch to a 3rd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their 2nd TNF Inhibitor who are not at target", "intervention": "Switch to a 3rd TNF Inhibitor", "comparator": "Continue same management", "outcome": "Disease activity (follow up: 4 months; assessed with: ACR 20)", "importance": "CRITICAL", "related_paper_list": ["ca0be03a"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to serious risk of bias. Lack of blinding (except for radiographic outcomes) and lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population on their first TNF Inhibitor who are NOT at target and the intervention is second TNFi rather than third TNFi."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, very low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to a 3rd TNFi": "8/13 (61.5%)", "Continue same management": "4/14 (28.6%)"}, "Annotation": {"data": "1. Switch to IFX.\n2. Continue ETN.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 2.15 (0.85 to 5.48)", "Absolute Effect (95% CI)": "329 more per 1,000 (from 43 fewer to 1,000 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "25", "Database": "2021 ACR RA"}
{"outcome_uid": "c4fd801b", "clinical_question": "Should patients with RA on their 2nd TNF Inhibitor who are NOT at target, switch to a 3rd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their 2nd TNF Inhibitor who are not at target", "intervention": "Switch to a 3rd TNF Inhibitor", "comparator": "Continue same management", "outcome": "Disease activity (follow up: 4 months; assessed with: ACR 50)", "importance": "CRITICAL", "related_paper_list": ["ca0be03a"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to serious risk of bias. Lack of blinding (except for radiographic outcomes) and lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population on their first TNF Inhibitor who are NOT at target and the intervention is second TNFi rather than third TNFi."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, very low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to a 3rd TNFi": "4/13 (30.8%)", "Continue same management": "2/14 (14.3%)"}, "Annotation": {"data": "1. Switch to IFX.\n2. Continue ETN.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 2.15 (0.47 to 9.85)", "Absolute Effect (95% CI)": "164 more per 1,000 (from 76 fewer to 1,000 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "25", "Database": "2021 ACR RA"}
{"outcome_uid": "23fa4f68", "clinical_question": "Should patients with RA on their 2nd TNF Inhibitor who are NOT at target, switch to a 3rd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their 2nd TNF Inhibitor who are not at target", "intervention": "Switch to a 3rd TNF Inhibitor", "comparator": "Continue same management", "outcome": "Disease activity (follow up: 4 months; assessed with: DAS28-ESR (Lower values – > benefit) (MCID -1.17)", "importance": "CRITICAL", "related_paper_list": ["ca0be03a"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to serious risk of bias. Lack of blinding (except for radiographic outcomes) and lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population on their first TNF Inhibitor who are NOT at target and the intervention is second TNFi rather than third TNFi."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting no effect. Very small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to a 3rd TNFi": "13", "Continue same management": "14"}, "Annotation": {"data": "1. Switch to IFX.\n2. Continue ETN.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 1.2 lower (2.37 lower to 0.03 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "25", "Database": "2021 ACR RA"}
{"outcome_uid": "90584df6", "clinical_question": "Should patients with RA on their 2nd TNF Inhibitor who are NOT at target, switch to a 3rd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their 2nd TNF Inhibitor who are not at target", "intervention": "Switch to a 3rd TNF Inhibitor", "comparator": "Continue same management", "outcome": "Remission (follow up: 4 months; assessed with: DAS28-ESR <2.6)", "importance": "CRITICAL", "related_paper_list": ["ca0be03a"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to serious risk of bias. Lack of blinding (except for radiographic outcomes) and lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population on their first TNF Inhibitor who are NOT at target and the intervention is second TNFi rather than third TNFi."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Very small sample size, very low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to a 3rd TNFi": "8/13 (61.5%)", "Continue same management": "2/14 (14.3%)"}, "Annotation": {"data": "1. Switch to IFX.\n2. Continue ETN.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 4.31 (1.11 to 16.67)", "Absolute Effect (95% CI)": "473 more per 1,000 (from 16 more to 1,000 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "25", "Database": "2021 ACR RA"}
{"outcome_uid": "e9c2fd6f", "clinical_question": "Should patients with RA on their 2nd TNF Inhibitor who are NOT at target, switch to a 3rd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their 2nd TNF Inhibitor who are not at target", "intervention": "Switch to a 3rd TNF Inhibitor", "comparator": "Continue same management", "outcome": "Radiographic progression (follow up: 4 months; assessed with: Sharp/ van der Heijde (Lower values – > benefit) (MCID 4.6)", "importance": "IMPORTANT", "related_paper_list": ["ca0be03a"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding of patients and personnel and lack of allocation concealment. Outcome assessors for radiographic outcomes were blinded."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population on their first TNF Inhibitor who are NOT at target and the intervention is second TNFi rather than third TNFi."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Very small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to a 3rd TNFi": "12", "Continue same management": "12"}, "Annotation": {"data": "1. Switch to IFX.\n2. Continue ETN.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.6 higher (1.78 lower to 2.98 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "25", "Database": "2021 ACR RA"}
{"outcome_uid": "35cb23cf", "clinical_question": "Should patients with RA on their 2nd TNF Inhibitor who are NOT at target, switch to a 3rd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their 2nd TNF Inhibitor who are not at target", "intervention": "Switch to a 3rd TNF Inhibitor", "comparator": "Continue same management", "outcome": "Serious adverse events (follow up: 4 months)", "importance": "IMPORTANT", "related_paper_list": ["ca0be03a"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to serious risk of bias. Lack of blinding (except for radiographic outcomes) and lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population on their first TNF Inhibitor who are NOT at target and the intervention is second TNFi rather than third TNFi."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, very low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to a 3rd TNFi": "0/13 (0.0%)", "Continue same management": "2/14 (14.3%)"}, "Annotation": {"data": "1. Switch to IFX.\n2. Continue ETN.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.21 (0.01 to 4.08)", "Absolute Effect (95% CI)": "113 fewer per 1,000 (from 141 fewer to 440 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "25", "Database": "2021 ACR RA"}
{"outcome_uid": "9a10d9ca", "clinical_question": "Should patients with RA on their 2nd TNF Inhibitor who are NOT at target, switch to a 3rd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their 2nd TNF Inhibitor who are not at target", "intervention": "Switch to a 3rd TNF Inhibitor", "comparator": "Continue same management", "outcome": "Withdrawal due to adverse events (follow up: 4 months)", "importance": "IMPORTANT", "related_paper_list": ["ca0be03a"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to serious risk of bias. Lack of blinding (except for radiographic outcomes) and lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population on their first TNF Inhibitor who are NOT at target and the intervention is second TNFi rather than third TNFi."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, very low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Switch to a 3rd TNFi": "2/13 (15.4%)", "Continue same management": "1/14 (7.1%)"}, "Annotation": {"data": "1. Switch to IFX.\n2. Continue ETN.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 2.15 (0.22 to 21.03)", "Absolute Effect (95% CI)": "82 more per 1,000 (from 56 fewer to 1,000 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "25", "Database": "2021 ACR RA"}
{"outcome_uid": "708bd0c0", "clinical_question": "Should patients with RA on their 2nd TNF Inhibitor who are NOT at target, switch to a 3rd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on their 2nd TNF Inhibitor who are not at target", "intervention": "Switch to a 3rd TNF Inhibitor", "comparator": "Continue same management", "outcome": "Serious adverse events (from SR of harms)", "related_paper_list": ["a1e03f7a", "21011e18"], "assessment_results": {"GRADE": {"result_interpretation": "The Systematic Review RefID=5595, 2011 comparing Infliximab vs Etanercept among RA and AS, Psoriasis, PsA, IBD, Cancer showed that for Serious adverse events, the result was OR=0.93 (0.60 to 1.42). \nThe Systematic Review RefID=1403, 2017 comparing Infliximab vs Etanercept among RA showed that for Serious adverse events, the result was RR=4.90 (0.23 to 104) [Direct Evidence, Low certainty].", "Study design": "Systematic Review"}}, "PICO_IDX": "25", "Database": "2021 ACR RA"}
{"outcome_uid": "b14eac22", "clinical_question": "Should patients with RA on DMARDs who are NOT at target receive IA corticosteroids alone or add/switch DMARDs or IA corticosteroids and add/switch DMARD(s)?", "population": "Patients with RA on DMARDs who are not at target", "intervention": "IA steroids", "comparator": "add/Switch DMARD(s)", "outcome": "Disease activity (follow up: 3 months; assessed with: ACR 20)", "importance": "CRITICAL", "related_paper_list": ["5c2f0c43"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious risk of bias. Lack of allocation concealment, lack of blinding, and selective reporting."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. Study compared IA GCs + csDMARD to csDMARDs."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting no effect and value suggesting harm. Very small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"IA corticosteroids alone": "25/25 (100.0%)", "Add/Switch DMARD(s)": "21/25 (84.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.19 (0.99 to 1.43)", "Absolute Effect (95% CI)": "160 more per 1,000 (from 8 fewer to 361 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "28", "Database": "2021 ACR RA"}
{"outcome_uid": "c6748830", "clinical_question": "Should patients with RA on DMARDs who are NOT at target receive IA corticosteroids alone or add/switch DMARDs or IA corticosteroids and add/switch DMARD(s)?", "population": "Patients with RA on DMARDs who are not at target", "intervention": "IA steroids", "comparator": "add/Switch DMARD(s)", "outcome": "Disease activity (follow up: 3 months; assessed with: ACR 50)", "importance": "CRITICAL", "related_paper_list": ["5c2f0c43"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by two levels due to very serious risk of bias. Lack of allocation concealment, lack of blinding, and selective reporting."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. Study compared IA GCs + csDMARD to csDMARDs."}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Very small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"IA corticosteroids alone": "15/25 (60.0%)", "Add/Switch DMARD(s)": "5/25 (20.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 3.00 (1.29 to 7.00)", "Absolute Effect (95% CI)": "400 more per 1,000 (from 58 more to 1,000 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "28", "Database": "2021 ACR RA"}
{"outcome_uid": "564a2b56", "clinical_question": "Should patients with RA on DMARDs who are NOT at target receive IA corticosteroids alone or add/switch DMARDs or IA corticosteroids and add/switch DMARD(s)?", "population": "Patients with RA on DMARDs who are not at target", "intervention": "IA steroids", "comparator": "add/Switch DMARD(s)", "outcome": "Disease activity (follow up: 3 months; assessed with: ACR 70)", "importance": "CRITICAL", "related_paper_list": ["5c2f0c43"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious risk of bias. Lack of allocation concealment, lack of blinding, and selective reporting."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. Study compared IA GCs + csDMARD to csDMARDs."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Very small sample size and low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"IA corticosteroids alone": "9/25 (36.0%)", "Add/Switch DMARD(s)": "0/25 (0.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 19.00 (1.17 to 309.77)", "Absolute Effect (95% CI)": "0 fewer per 1,000 (from 0 fewer to 0 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "28", "Database": "2021 ACR RA"}
{"outcome_uid": "192d97ba", "clinical_question": "Should patients with RA on DMARDs who are NOT at target receive IA corticosteroids alone or add/switch DMARDs or IA corticosteroids and add/switch DMARD(s)?", "population": "Patients with RA on DMARDs who are not at target", "intervention": "IA steroids", "comparator": "add/Switch DMARD(s)", "outcome": "Disease activity (follow up: 3 months; assessed with: DAS28-ESR)", "importance": "CRITICAL", "related_paper_list": ["5c2f0c43"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious risk of bias. Lack of allocation concealment, lack of blinding, and selective reporting."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. Study compared IA GCs + csDMARD to csDMARDs."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting no effect. Very small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"IA corticosteroids alone": "25", "Add/Switch DMARD(s)": "25"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 1.6 lower (2.21 lower to 0.99 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "28", "Database": "2021 ACR RA"}
{"outcome_uid": "0b64669d", "clinical_question": "Should patients with RA on DMARDs who are NOT at target receive IA corticosteroids alone or add/switch DMARDs or IA corticosteroids and add/switch DMARD(s)?", "population": "Patients with RA on DMARDs who are not at target", "intervention": "IA steroids", "comparator": "add/Switch DMARD(s)", "outcome": "Disability (follow up: 3 months; assessed with: HAQ-DI)", "importance": "IMPORTANT", "related_paper_list": ["5c2f0c43"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious risk of bias. Lack of allocation concealment, lack of blinding, and selective reporting."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. Study compared IA GCs + csDMARD to csDMARDs."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting no effect. Very small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"IA corticosteroids alone": "25", "Add/Switch DMARD(s)": "25"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.24 lower (0.42 lower to 0.06 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "28", "Database": "2021 ACR RA"}
{"outcome_uid": "b21f52d2", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or an alternative csDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "SSZ", "outcome": "Disease activity (follow up: 1 year; assessed with: DAS28-ESR (Lower values – > benefit) (MCID -1.17)", "importance": "CRITICAL", "related_paper_list": ["fd4777bd", "d7a31839"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation and lack of blinding of outcome assessors of non-radiographic outcomes in the study with the higher weight"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": "I2= 41%"}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"MTX monotherapy": "104", "SSZ": "102"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.14 higher(0.18 lower to 0.47 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "2a", "Database": "2021 ACR RA"}
{"outcome_uid": "3cdcf796", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or an alternative csDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "SSZ", "outcome": "Disability (follow up: 1 year; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22)", "importance": "IMPORTANT", "related_paper_list": ["fd4777bd", "d7a31839"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation and lack of blinding of outcome assessors of non-radiographic outcomes in the study with the higher weight"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"MTX monotherapy": "104", "SSZ": "102"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.04 lower(0.2 lower to 0.13 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "2a", "Database": "2021 ACR RA"}
{"outcome_uid": "77864ca9", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or an alternative csDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "SSZ", "outcome": "Pain (follow up: 1 year; assessed with: VAS 0-100 (Lower values – > benefit) (MCID -11.9)", "importance": "IMPORTANT", "related_paper_list": ["d7a31839"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"MTX monotherapy": "35", "SSZ": "34"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.1 higher(13.46 lower to 13.66 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "2a", "Database": "2021 ACR RA"}
{"outcome_uid": "7319701a", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or an alternative csDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "SSZ", "outcome": "Serious adverse events (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["d7a31839"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"MTX monotherapy": "0/35 (0.0%)", "SSZ": "3/34 (8.8%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.14(0.01 to 2.59) ", "Absolute Effect (95% CI)": "76 fewer per 1,000(from 87 fewer to 140 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "2a", "Database": "2021 ACR RA"}
{"outcome_uid": "617efe0d", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or an alternative csDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "SSZ", "outcome": "Withdrawal due to lack of efficacy (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["fd4777bd", "d7a31839"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation and lack of blinding of outcome assessors of non-radiographic outcomes in the study with the higher weight"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Small sample size and low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"MTX monotherapy": "5/104 (4.8%)", "SSZ": "10/102 (9.8%) "}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.51(0.19 to 1.39)", "Absolute Effect (95% CI)": "48 fewer per 1,000(from 79 fewer to 38 more) ", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "2a", "Database": "2021 ACR RA"}
{"outcome_uid": "6e817020", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or an alternative csDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "SSZ", "outcome": "Withdrawal due to adverse events (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["fd4777bd", "d7a31839"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation and lack of blinding of outcome assessors of non-radiographic outcomes in the study with the higher weight"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": "I2= 44% "}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting no effect. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"MTX monotherapy": "9/104 (8.7%)", "SSZ": "19/102 (18.6%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.46(0.22 to 0.98) ", "Absolute Effect (95% CI)": "101 fewer per 1,000(from 145 fewer to 4 fewer) ", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "2a", "Database": "2021 ACR RA"}
{"outcome_uid": "7bb30f8f", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or an alternative csDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "LEF", "outcome": "Disease activity (follow up: 6 months; assessed with: DAS28-ESR (Lower values – > benefit) (MCID -1.17)", "importance": "CRITICAL", "related_paper_list": ["fd4777bd", "fa180e46"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "VERY_SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and lack of blinding of patients, personnel, and outcome assessors."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"MTX monotherapy": "147", "LEF": "147"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.1 lower (0.27 lower to 0.07 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "2a", "Database": "2021 ACR RA"}
{"outcome_uid": "b21f52d2", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or an alternative csDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "SSZ", "outcome": "Disease activity (follow up: 1 year; assessed with: DAS28-ESR (Lower values – > benefit) (MCID -1.17)", "importance": "CRITICAL", "related_paper_list": ["fd4777bd", "d7a31839"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation and lack of blinding of outcome assessors of non-radiographic outcomes in the study with the higher weight"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": "I2= 41%"}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population who are non-MTX csDMARD naive."}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"MTX monotherapy": "104", "SSZ": "102"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.14 higher (0.18 lower to 0.47 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "2b", "Database": "2021 ACR RA"}
{"outcome_uid": "3cdcf796", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or an alternative csDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "SSZ", "outcome": "Disability (follow up: 1 year; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22)", "importance": "IMPORTANT", "related_paper_list": ["fd4777bd", "d7a31839"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation and lack of blinding of outcome assessors of non-radiographic outcomes in the study with the higher weight"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population who are non-MTX csDMARD naive."}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"MTX monotherapy": "104", "SSZ": "102"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.04 lower (0.2 lower to 0.13 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "2b", "Database": "2021 ACR RA"}
{"outcome_uid": "77864ca9", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or an alternative csDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "SSZ", "outcome": "Pain (follow up: 1 year; assessed with: VAS 0-100 (Lower values – > benefit) (MCID -11.9)", "importance": "IMPORTANT", "related_paper_list": ["d7a31839"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population who are non-MTX csDMARD naive."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"MTX monotherapy": "35", "SSZ": "34"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.1 higher (13.46 lower to 13.66 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "2b", "Database": "2021 ACR RA"}
{"outcome_uid": "7319701a", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or an alternative csDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "SSZ", "outcome": "Serious adverse events (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["d7a31839"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population who are non-MTX csDMARD naive."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"MTX monotherapy": "0/35 (0.0%)", "SSZ": "3/34 (8.8%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.14 (0.01 to 2.59)", "Absolute Effect (95% CI)": "76 fewer per 1,000 (from 87 fewer to 140 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "2b", "Database": "2021 ACR RA"}
{"outcome_uid": "617efe0d", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or an alternative csDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "SSZ", "outcome": "Withdrawal due to lack of efficacy (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["fd4777bd", "d7a31839"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation and lack of blinding of outcome assessors of non-radiographic outcomes in the study with the higher weight"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population who are non-MTX csDMARD naive."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Small sample size and low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"MTX monotherapy": "5/104 (4.8%)", "SSZ": "10/102 (9.8%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.51 (0.19 to 1.39)", "Absolute Effect (95% CI)": "48 fewer per 1,000 (from 79 fewer to 38 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "2b", "Database": "2021 ACR RA"}
{"outcome_uid": "6e817020", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or an alternative csDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "SSZ", "outcome": "Withdrawal due to adverse events (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["fd4777bd", "d7a31839"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation and lack of blinding of outcome assessors of non-radiographic outcomes in the study with the higher weight"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": "I2= 44% "}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population who are non-MTX csDMARD naive."}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting no effect. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"MTX monotherapy": "9/104 (8.7%)", "SSZ": "19/102 (18.6%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.46 (0.22 to 0.98)", "Absolute Effect (95% CI)": "101 fewer per 1,000 (from 145 fewer to 4 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "2b", "Database": "2021 ACR RA"}
{"outcome_uid": "24d63215", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or an alternative csDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "LEF", "outcome": "Disease activity (follow up: 4 months; assessed with: ACR 20)", "importance": "CRITICAL", "related_paper_list": ["ade90865"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"MTX monotherapy": "88/180 (48.9%)", "LEF": "95/182 (52.2%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.94 (0.76 to 1.15)", "Absolute Effect (95% CI)": "31 fewer per 1,000 (from 125 fewer to 78 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "2b", "Database": "2021 ACR RA"}
{"outcome_uid": "72bb08ec", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or an alternative csDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "LEF", "outcome": "Disease activity (follow up: 4 months; assessed with: DAS28-ESR (Lower values – > benefit) (MCID -1.17)", "importance": "CRITICAL", "related_paper_list": ["ad9d3d6b"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding of patients, personnel, and outcome assessors."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting no effect. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"MTX monotherapy": "21", "LEF": "19"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.67 lower (1.5 lower to 0.16 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "2b", "Database": "2021 ACR RA"}
{"outcome_uid": "dc1f8460", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and low disease activity receive csDMARD monotherapy or csDMARD combination (double or triple) therapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and low disease activity", "intervention": "csDMARD monotherapy", "comparator": "csDMARD double combination therapy", "outcome": "Disease activity (follow up: 1 year; assessed with: DAS 44 (Lower values – > benefit) (MCID -1.2 based on the EULAR criteria)", "importance": "CRITICAL", "related_paper_list": ["fd4777bd", "d7a31839"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment in both studies, high risk of attrition bias in one of the two studies."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population with moderate to high disease activity."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"CSDMARD double therapy": "104", "CSDMARD monotherapy": "206"}, "Annotation": {"data": "1. csDMARD double therapy includes: MTZ+SSZ\n2. csDMARD monotherapy includes: MTX or SSZ\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.3 lower (0.57 lower to 0.02 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "3a", "Database": "2021 ACR RA"}
{"outcome_uid": "ecf94e31", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and low disease activity receive csDMARD monotherapy or csDMARD combination (double or triple) therapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and low disease activity", "intervention": "csDMARD monotherapy", "comparator": "csDMARD double combination therapy", "outcome": "Disability (follow up: 1 year; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22 )", "importance": "IMPORTANT", "related_paper_list": ["fd4777bd", "d7a31839"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment in both studies, high risk of attrition bias in one of the two studies."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population with moderate to high disease activity."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"CSDMARD double therapy": "104", "CSDMARD monotherapy": "206"}, "Annotation": {"data": "1. csDMARD double therapy includes: MTZ+SSZ\n2. csDMARD monotherapy includes: MTX or SSZ\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.01 lower (0.16 lower to 0.14 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "3a", "Database": "2021 ACR RA"}
{"outcome_uid": "bfa659d6", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and low disease activity receive csDMARD monotherapy or csDMARD combination (double or triple) therapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and low disease activity", "intervention": "csDMARD monotherapy", "comparator": "csDMARD double combination therapy", "outcome": "Pain (follow up: 1 year; assessed with: VAS 0-100 (Lower values – > benefit) (MCID -11.9)", "importance": "IMPORTANT", "related_paper_list": ["d7a31839"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population with moderate to high disease activity."}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Low sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"CSDMARD double therapy": "36", "CSDMARD monotherapy": "69"}, "Annotation": {"data": "1. csDMARD double therapy includes: MTZ+SSZ\n2. csDMARD monotherapy includes: MTX or SSZ\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.05 higher (10.89 lower to 10.99 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "3a", "Database": "2021 ACR RA"}
{"outcome_uid": "66a7af81", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and low disease activity receive csDMARD monotherapy or csDMARD combination (double or triple) therapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and low disease activity", "intervention": "csDMARD monotherapy", "comparator": "csDMARD double combination therapy", "outcome": "Serious adverse events (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["d7a31839"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population with moderate to high disease activity."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence intervals includes both values suggesting benefit and values suggesting harm. Small sample size, very low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"CSDMARD double therapy": "0/36 (0.0%)", "CSDMARD monotherapy": "3/69 (4.3%)"}, "Annotation": {"data": "1. csDMARD double therapy includes: MTZ+SSZ\n2. csDMARD monotherapy includes: MTX or SSZ\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.27 (0.01 to 5.09)", "Absolute Effect (95% CI)": "32 fewer per 1,000 (from 43 fewer to 178 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "3a", "Database": "2021 ACR RA"}
{"outcome_uid": "061730e3", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and low disease activity receive csDMARD monotherapy or csDMARD combination (double or triple) therapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and low disease activity", "intervention": "csDMARD monotherapy", "comparator": "csDMARD double combination therapy", "outcome": "Withdrawal due to lack of efficacy (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["fd4777bd", "d7a31839"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment in both studies, high risk of attrition bias in one of the two studies."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population with moderate to high disease activity."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence intervals includes both values suggesting benefit and values suggesting harm. Small sample size, very low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"CSDMARD double therapy": "4/104 (3.8%)", "CSDMARD monotherapy": "15/206 (7.3%)"}, "Annotation": {"data": "1. csDMARD double therapy includes: MTZ+SSZ\n2. csDMARD monotherapy includes: MTX or SSZ\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.53 (0.18 to 1.56)", "Absolute Effect (95% CI)": "34 fewer per 1,000 (from 60 fewer to 41 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "3a", "Database": "2021 ACR RA"}
{"outcome_uid": "75132089", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and low disease activity receive csDMARD monotherapy or csDMARD combination (double or triple) therapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and low disease activity", "intervention": "csDMARD monotherapy", "comparator": "csDMARD double combination therapy", "outcome": "Withdrawal due to adverse events (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["fd4777bd", "d7a31839"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment in both studies, high risk of attrition bias in one of the two studies."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population with moderate to high disease activity."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence intervals includes both values suggesting benefit and values suggesting harm. Small sample size, very low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"CSDMARD double therapy": "14/104 (13.5%)", "CSDMARD monotherapy": "28/206 (13.6%)"}, "Annotation": {"data": "1. csDMARD double therapy includes: MTZ+SSZ\n2. csDMARD monotherapy includes: MTX or SSZ\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.99 (0.54 to 1.79)", "Absolute Effect (95% CI)": "1 fewer per 1,000 (from 63 fewer to 107 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "3a", "Database": "2021 ACR RA"}
{"outcome_uid": "1c0b87ee", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and low disease activity receive csDMARD monotherapy or csDMARD combination (double or triple) therapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and low disease activity", "intervention": "csDMARD monotherapy", "comparator": "csDMARD triple combination therapy", "outcome": "Disease activity (follow up: 3 months; assessed with: DAS 44 (Lower values --> benefit)", "importance": "CRITICAL", "related_paper_list": ["ca2ae2ab"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serous imprecision. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"csDMARD triple therapy": "89", "csDMARD monotherapy": "90"}, "Annotation": {"data": "1. csDMARD triple therapy includes: MTX+SSZ+HCQ\n2. csDMARD monotherapy includes: MTX\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.35 lower (0.64 lower to 0.06 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "3a", "Database": "2021 ACR RA"}
{"outcome_uid": "74ee272a", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and low disease activity receive csDMARD monotherapy or csDMARD combination (double or triple) therapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and low disease activity", "intervention": "csDMARD monotherapy", "comparator": "csDMARD triple combination therapy", "outcome": "Remission (follow up: 3 months; assessed with: DAS 44 <1.6)", "importance": "CRITICAL", "related_paper_list": ["ca2ae2ab"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"csDMARD triple therapy": "38/89 (42.7%)", "csDMARD monotherapy": "28/90 (31.1%)"}, "Annotation": {"data": "1. csDMARD triple therapy includes: MTX+SSZ+HCQ\n2. csDMARD monotherapy includes: MTX\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.37 (0.93 to 2.03)", "Absolute Effect (95% CI)": "115 more per 1,000 (from 22 fewer to 320 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "3a", "Database": "2021 ACR RA"}
{"outcome_uid": "269f6930", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and low disease activity receive csDMARD monotherapy or csDMARD combination (double or triple) therapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and low disease activity", "intervention": "csDMARD monotherapy", "comparator": "csDMARD triple combination therapy", "outcome": "Disability (follow up: 3 months; assessed with: HAQ-DI (Lower values --> benefit) (MCID -0.22)", "importance": "IMPORTANT", "related_paper_list": ["ca2ae2ab"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"csDMARD triple therapy": "78", "csDMARD monotherapy": "78"}, "Annotation": {"data": "1. csDMARD triple therapy includes: MTX+SSZ+HCQ\n2. csDMARD monotherapy includes: MTX\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.03 lower (0.2 lower to 0.14 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "3a", "Database": "2021 ACR RA"}
{"outcome_uid": "c7d1d3f0", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and low disease activity receive csDMARD monotherapy or csDMARD combination (double or triple) therapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and low disease activity", "intervention": "csDMARD monotherapy", "comparator": "csDMARD triple combination therapy", "outcome": "Serious adverse events (follow up: 3 months)", "importance": "IMPORTANT", "related_paper_list": ["ca2ae2ab"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"csDMARD triple therapy": "4/89 (4.5%)", "csDMARD monotherapy": "6/90 (6.7%)"}, "Annotation": {"data": "1. csDMARD triple therapy includes: MTX+SSZ+HCQ\n2. csDMARD monotherapy includes: MTX\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.67 (0.20 to 2.31)", "Absolute Effect (95% CI)": "22 fewer per 1,000 (from 53 fewer to 87 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "3a", "Database": "2021 ACR RA"}
{"outcome_uid": "80f0d572", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and low disease activity receive csDMARD monotherapy or csDMARD combination (double or triple) therapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and low disease activity", "intervention": "csDMARD monotherapy", "comparator": "csDMARD triple combination therapy", "outcome": "Withdrawal due to Adverse events (follow up: 3 months)", "importance": "IMPORTANT", "related_paper_list": ["ca2ae2ab"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"csDMARD triple therapy": "0/93 (0.0%)", "csDMARD monotherapy": "3/97 (3.1%)"}, "Annotation": {"data": "1. csDMARD triple therapy includes: MTX+SSZ+HCQ\n2. csDMARD monotherapy includes: MTX\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.15 (0.01 to 2.84)", "Absolute Effect (95% CI)": "26 fewer per 1,000 (from 31 fewer to 57 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "3a", "Database": "2021 ACR RA"}
{"outcome_uid": "7b4ee3d2", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and low disease activity receive csDMARD monotherapy or csDMARD combination (double or triple) therapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and low disease activity", "intervention": "csDMARD monotherapy", "comparator": "csDMARD triple combination therapy", "outcome": "Disease activity (follow up: 6 months; assessed with: DAS 28-ESR (Lower values – > benefit) (MCID -1.17)", "importance": "CRITICAL", "related_paper_list": ["ccd87125"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirecteness. The population has moderate disease activity."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"csDMARD triple therapy": "132", "csDMARD monotherapy": "379"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.64 lower (0.95 lower to 0.33 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "3b", "Database": "2021 ACR RA"}
{"outcome_uid": "23250272", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and low disease activity receive csDMARD monotherapy or csDMARD combination (double or triple) therapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and low disease activity", "intervention": "csDMARD monotherapy", "comparator": "csDMARD triple combination therapy", "outcome": "Disease activity (follow up: 6 months; assessed with: ACR 20)", "importance": "CRITICAL", "related_paper_list": ["ccd87125"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirecteness. The population has moderate disease activity."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"csDMARD triple therapy": "73/132 (55.3%)", "csDMARD monotherapy": "150/379 (39.6%)"}, "Annotation": {"data": "1. csDMARD triple therapy includes MTX + SSZ + HCQ.\n2. csDMARD monotherapy includes MTX.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.40 (1.15 to 1.70)", "Absolute Effect (95% CI)": "158 more per 1,000 (from 59 more to 277 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "3b", "Database": "2021 ACR RA"}
{"outcome_uid": "dbf6014a", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and low disease activity receive csDMARD monotherapy or csDMARD combination (double or triple) therapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and low disease activity", "intervention": "csDMARD monotherapy", "comparator": "csDMARD triple combination therapy", "outcome": "Disease activity (follow up: 6 months; assessed with: ACR 50)", "importance": "CRITICAL", "related_paper_list": ["ccd87125"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirecteness. The population has moderate disease activity."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"csDMARD triple therapy": "41/132 (31.1%)", "csDMARD monotherapy": "73/379 (19.3%)"}, "Annotation": {"data": "1. csDMARD triple therapy includes MTX + SSZ + HCQ.\n2. csDMARD monotherapy includes MTX.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.61 (1.16 to 2.24)", "Absolute Effect (95% CI)": "117 more per 1,000 (from 31 more to 239 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "3b", "Database": "2021 ACR RA"}
{"outcome_uid": "39545490", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and low disease activity receive csDMARD monotherapy or csDMARD combination (double or triple) therapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and low disease activity", "intervention": "csDMARD monotherapy", "comparator": "csDMARD triple combination therapy", "outcome": "Disease activity (follow up: 6 months; assessed with: ACR 70)", "importance": "CRITICAL", "related_paper_list": ["ccd87125"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirecteness. The population has moderate disease activity."}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm. Low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"csDMARD triple therapy": "11/132 (8.3%)", "csDMARD monotherapy": "13/379 (3.4%)"}, "Annotation": {"data": "1. csDMARD triple therapy includes MTX + SSZ + HCQ.\n2. csDMARD monotherapy includes MTX.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 2.43 (1.12 to 5.29)", "Absolute Effect (95% CI)": "49 more per 1,000 (from 4 more to 147 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "3b", "Database": "2021 ACR RA"}
{"outcome_uid": "2dc7a609", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive csDMARD monotherapy or combination (double or triple) therapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA who have moderate to high disease activity", "intervention": "csDMARD monotherapy", "comparator": "csDMARD double combination therapy", "outcome": "Disease activity (follow up: 1 year; assessed with: DAS 44 (Lower values – > benefit) (MCID -1.2 based on the EULAR criteria)", "importance": "CRITICAL", "related_paper_list": ["fd4777bd", "d7a31839"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment in both studies, high risk of attrition bias in one of the two studies."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"csDMARD double therapy": "104", "csDMARD monotherapy": "206"}, "Annotation": {"data": "1. csDMARD double therapy includes: MTZ+SSZ\n2. csDMARD monotherapy includes: MTX or SSZ\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.3 lower (0.57 lower to 0.02 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "4a", "Database": "2021 ACR RA"}
{"outcome_uid": "9132f476", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive csDMARD monotherapy or combination (double or triple) therapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA who have moderate to high disease activity", "intervention": "csDMARD monotherapy", "comparator": "csDMARD double combination therapy", "outcome": "Disability (follow up: 1 year; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22)", "importance": "IMPORTANT", "related_paper_list": ["fd4777bd", "d7a31839"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment in both studies, high risk of attrition bias in one of the two studies."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"csDMARD double therapy": "104", "csDMARD monotherapy": "206"}, "Annotation": {"data": "1. csDMARD double therapy includes: MTZ+SSZ\n2. csDMARD monotherapy includes: MTX or SSZ\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.01 lower (0.16 lower to 0.14 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "4a", "Database": "2021 ACR RA"}
{"outcome_uid": "f87e2ec4", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive csDMARD monotherapy or combination (double or triple) therapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA who have moderate to high disease activity", "intervention": "csDMARD monotherapy", "comparator": "csDMARD double combination therapy", "outcome": "Pain (follow up: 1 year; assessed with: VAS 0-100 (Lower values – > benefit) (MCID -11.9)", "importance": "IMPORTANT", "related_paper_list": ["d7a31839"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Low sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"csDMARD double therapy": "36", "csDMARD monotherapy": "69"}, "Annotation": {"data": "1. csDMARD double therapy includes: MTZ+SSZ\n2. csDMARD monotherapy includes: MTX or SSZ\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.05 higher (10.89 lower to 10.99 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "4a", "Database": "2021 ACR RA"}
{"outcome_uid": "be11ef8f", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive csDMARD monotherapy or combination (double or triple) therapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA who have moderate to high disease activity", "intervention": "csDMARD monotherapy", "comparator": "csDMARD double combination therapy", "outcome": "Serious adverse events (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["d7a31839"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence intervals include both values suggesting benefit and values suggesting harm. Small sample size, very low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"csDMARD double therapy": "0/36 (0.0%)", "csDMARD monotherapy": "3/69 (4.3%)"}, "Annotation": {"data": "1. csDMARD double therapy includes: MTZ+SSZ\n2. csDMARD monotherapy includes: MTX or SSZ\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.27 (0.01 to 5.09)", "Absolute Effect (95% CI)": "32 fewer per 1,000 (from 43 fewer to 178 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "4a", "Database": "2021 ACR RA"}
{"outcome_uid": "f297c8dc", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive csDMARD monotherapy or combination (double or triple) therapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA who have moderate to high disease activity", "intervention": "csDMARD monotherapy", "comparator": "csDMARD double combination therapy", "outcome": "Withdrawal due to lack of efficacy (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["fd4777bd", "d7a31839"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment in both studies, high risk of attrition bias in one of the two studies."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence intervals include both values suggesting benefit and values suggesting harm. Small sample size, very low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"csDMARD double therapy": "4/104 (3.8%)", "csDMARD monotherapy": "15/206 (7.3%)"}, "Annotation": {"data": "1. csDMARD double therapy includes: MTZ+SSZ\n2. csDMARD monotherapy includes: MTX or SSZ\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.53 (0.18 to 1.56)", "Absolute Effect (95% CI)": "34 fewer per 1,000 (from 60 fewer to 41 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "4a", "Database": "2021 ACR RA"}
{"outcome_uid": "6e5debf6", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive csDMARD monotherapy or combination (double or triple) therapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA who have moderate to high disease activity", "intervention": "csDMARD monotherapy", "comparator": "csDMARD double combination therapy", "outcome": "Withdrawal due to Adverse events (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["fd4777bd", "d7a31839"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment in both studies, high risk of attrition bias in one of the two studies."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence intervals include both values suggesting benefit and values suggesting harm. Small sample size, very low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"csDMARD double therapy": "14/104 (13.5%)", "csDMARD monotherapy": "28/206 (13.6%)"}, "Annotation": {"data": "1. csDMARD double therapy includes: MTZ+SSZ\n2. csDMARD monotherapy includes: MTX or SSZ\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.99 (0.54 to 1.79)", "Absolute Effect (95% CI)": "1 fewer per 1,000 (from 63 fewer to 107 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "4a", "Database": "2021 ACR RA"}
{"outcome_uid": "704512e6", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive csDMARD monotherapy or combination (double or triple) therapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA who have moderate to high disease activity", "intervention": "csDMARD monotherapy", "comparator": "csDMARD triple combination therapy", "outcome": "Disease activity (follow up: 3 months; assessed with: DAS 44 (Lower values – > benefit) (MCID -1.2)", "importance": "CRITICAL", "related_paper_list": ["1f1358a6"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"csDMARD triple therapy": "89", "csDMARD monotherapy": "90"}, "Annotation": {"data": "1. csDMARD triple therapy includes: MTX+SSZ+HCQ\n2. csDMARD monotherapy includes: MTX\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.35 lower (0.64 lower to 0.06 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "4a", "Database": "2021 ACR RA"}
{"outcome_uid": "7c13259c", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive csDMARD monotherapy or combination (double or triple) therapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA who have moderate to high disease activity", "intervention": "csDMARD monotherapy", "comparator": "csDMARD triple combination therapy", "outcome": "Remission (follow up: 3 months; assessed with: DAS 44 < 1.6)", "importance": "CRITICAL", "related_paper_list": ["1f1358a6"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values of no effect and benefit. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"csDMARD triple therapy": "38/89 (42.7%)", "csDMARD monotherapy": "28/90 (31.1%)"}, "Annotation": {"data": "1. csDMARD triple therapy includes: MTX+SSZ+HCQ\n2. csDMARD monotherapy includes: MTX\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.37 (0.93 to 2.03)", "Absolute Effect (95% CI)": "115 more per 1,000 (from 22 fewer to 320 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "4a", "Database": "2021 ACR RA"}
{"outcome_uid": "4792052e", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive csDMARD monotherapy or combination (double or triple) therapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA who have moderate to high disease activity", "intervention": "csDMARD monotherapy", "comparator": "csDMARD triple combination therapy", "outcome": "Disability (follow up: 3 months; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22)", "importance": "IMPORTANT", "related_paper_list": ["1f1358a6"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"csDMARD triple therapy": "89", "csDMARD monotherapy": "90"}, "Annotation": {"data": "1. csDMARD triple therapy includes: MTX+SSZ+HCQ\n2. csDMARD monotherapy includes: MTX\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.03 lower (0.19 lower to 0.13 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "4a", "Database": "2021 ACR RA"}
{"outcome_uid": "275f118d", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive csDMARD monotherapy or combination (double or triple) therapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA who have moderate to high disease activity", "intervention": "csDMARD monotherapy", "comparator": "csDMARD triple combination therapy", "outcome": "Serious adverse events (follow up: 3 months)", "importance": "IMPORTANT", "related_paper_list": ["1f1358a6"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"csDMARD triple therapy": "4/89 (4.5%)", "csDMARD monotherapy": "6/90 (6.7%)"}, "Annotation": {"data": "1. csDMARD triple therapy includes: MTX+SSZ+HCQ\n2. csDMARD monotherapy includes: MTX\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.67 (0.20 to 2.31)", "Absolute Effect (95% CI)": "22 fewer per 1,000 (from 53 fewer to 87 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "4a", "Database": "2021 ACR RA"}
{"outcome_uid": "b5505ade", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive csDMARD monotherapy or combination (double or triple) therapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA who have moderate to high disease activity", "intervention": "csDMARD monotherapy", "comparator": "csDMARD triple combination therapy", "outcome": "Withdrawal due to adverse events (follow up: 3 months)", "importance": "IMPORTANT", "related_paper_list": ["1f1358a6"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"csDMARD triple therapy": "0/93 (0.0%)", "csDMARD monotherapy": "3/97 (3.1%)"}, "Annotation": {"data": "1. csDMARD triple therapy includes: MTX+SSZ+HCQ\n2. csDMARD monotherapy includes: MTX\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.15 (0.01 to 2.84)", "Absolute Effect (95% CI)": "26 fewer per 1,000 (from 31 fewer to 57 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "4a", "Database": "2021 ACR RA"}
{"outcome_uid": "2dc7a609", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive csDMARD monotherapy or combination (double or triple) therapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA who have moderate to high disease activity", "intervention": "csDMARD monotherapy", "comparator": "csDMARD double combination therapy", "outcome": "Disease activity (follow up: 1 year; assessed with: DAS 44 (Lower values – > benefit) (MCID -1.2 based on the EULAR criteria)", "importance": "CRITICAL", "related_paper_list": ["fd4777bd", "26ed4e54"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment in both studies, high risk of attrition bias in one of the two studies."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population who are non-MTX csDMARD naive."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"csDMARD double therapy": "104", "csDMARD monotherapy": "206"}, "Annotation": {"data": "1. csDMARD double therapy includes: MTZ+SSZ\n2. csDMARD monotherapy includes: MTX or SSZ\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.3 lower (0.57 lower to 0.02 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "4b", "Database": "2021 ACR RA"}
{"outcome_uid": "9132f476", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive csDMARD monotherapy or combination (double or triple) therapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA who have moderate to high disease activity", "intervention": "csDMARD monotherapy", "comparator": "csDMARD double combination therapy", "outcome": "Disability (follow up: 1 year; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22)", "importance": "IMPORTANT", "related_paper_list": ["fd4777bd", "26ed4e54"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment in both studies, high risk of attrition bias in one of the two studies."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population who are non-MTX csDMARD naive."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"csDMARD double therapy": "104", "csDMARD monotherapy": "206"}, "Annotation": {"data": "1. csDMARD double therapy includes: MTZ+SSZ\n2. csDMARD monotherapy includes: MTX or SSZ\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.01 lower (0.16 lower to 0.14 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "4b", "Database": "2021 ACR RA"}
{"outcome_uid": "f87e2ec4", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive csDMARD monotherapy or combination (double or triple) therapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA who have moderate to high disease activity", "intervention": "csDMARD monotherapy", "comparator": "csDMARD double combination therapy", "outcome": "Pain (follow up: 1 year; assessed with: VAS 0-100 (Lower values – > benefit) (MCID -11.9)", "importance": "IMPORTANT", "related_paper_list": ["26ed4e54"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population who are non-MTX csDMARD naive."}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Low sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"csDMARD double therapy": "36", "csDMARD monotherapy": "69"}, "Annotation": {"data": "1. csDMARD double therapy includes: MTZ+SSZ\n2. csDMARD monotherapy includes: MTX or SSZ\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.05 higher (10.89 lower to 10.99 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "4b", "Database": "2021 ACR RA"}
{"outcome_uid": "be11ef8f", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive csDMARD monotherapy or combination (double or triple) therapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA who have moderate to high disease activity", "intervention": "csDMARD monotherapy", "comparator": "csDMARD double combination therapy", "outcome": "Serious adverse events (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["26ed4e54"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population who are non-MTX csDMARD naive."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence intervals include both values suggesting benefit and values suggesting harm. Small sample size, very low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"csDMARD double therapy": "0/36 (0.0%)", "csDMARD monotherapy": "3/69 (4.3%)"}, "Annotation": {"data": "1. csDMARD double therapy includes: MTZ+SSZ\n2. csDMARD monotherapy includes: MTX or SSZ\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.27 (0.01 to 5.09)", "Absolute Effect (95% CI)": "32 fewer per 1,000 (from 43 fewer to 178 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "4b", "Database": "2021 ACR RA"}
{"outcome_uid": "f297c8dc", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive csDMARD monotherapy or combination (double or triple) therapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA who have moderate to high disease activity", "intervention": "csDMARD monotherapy", "comparator": "csDMARD double combination therapy", "outcome": "Withdrawal due to lack of efficacy (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["fd4777bd", "26ed4e54"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment in both studies, high risk of attrition bias in one of the two studies."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population who are non-MTX csDMARD naive."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence intervals include both values suggesting benefit and values suggesting harm. Small sample size, very low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"csDMARD double therapy": "4/104 (3.8%)", "csDMARD monotherapy": "15/206 (7.3%)"}, "Annotation": {"data": "1. csDMARD double therapy includes: MTZ+SSZ\n2. csDMARD monotherapy includes: MTX or SSZ\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.53 (0.18 to 1.56)", "Absolute Effect (95% CI)": "34 fewer per 1,000 (from 60 fewer to 41 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "4b", "Database": "2021 ACR RA"}
{"outcome_uid": "92e36d84", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive csDMARD monotherapy or combination (double or triple) therapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA who have moderate to high disease activity", "intervention": "csDMARD monotherapy", "comparator": "csDMARD double combination therapy", "outcome": "Withdrawal due to adverse events (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["fd4777bd", "26ed4e54"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment in both studies, high risk of attrition bias in one of the two studies."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population who are non-MTX csDMARD naive."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence intervals include both values suggesting benefit and values suggesting harm. Small sample size, very low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"csDMARD double therapy": "14/104 (13.5%)", "csDMARD monotherapy": "28/206 (13.6%)"}, "Annotation": {"data": "1. csDMARD double therapy includes: MTZ+SSZ\n2. csDMARD monotherapy includes: MTX or SSZ\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.99 (0.54 to 1.79)", "Absolute Effect (95% CI)": "1 fewer per 1,000 (from 63 fewer to 107 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "4b", "Database": "2021 ACR RA"}
{"outcome_uid": "56ad1be9", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive csDMARD monotherapy or combination (double or triple) therapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA who have moderate to high disease activity", "intervention": "csDMARD monotherapy", "comparator": "csDMARD triple combination therapy", "outcome": "Disease activity (follow up: 6 months; assessed with: DAS 28-ESR (Lower values – > benefit) (MCID -1.17)", "importance": "CRITICAL", "related_paper_list": ["ccd87125"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"csDMARD triple therapy": "132", "csDMARD monotherapy": "379"}, "Annotation": {"data": "1. csDMARD triple therapy includes MTX + SSZ + HCQ.\n2. csDMARD monotherapy includes MTX.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.64 lower (0.95 lower to 0.33 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "4b", "Database": "2021 ACR RA"}
{"outcome_uid": "61478ab4", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive csDMARD monotherapy or combination (double or triple) therapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA who have moderate to high disease activity", "intervention": "csDMARD monotherapy", "comparator": "csDMARD triple combination therapy", "outcome": "Disease activity (follow up: 6 months; assessed with: ACR 20)", "importance": "CRITICAL", "related_paper_list": ["ccd87125"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"csDMARD triple therapy": "73/132 (55.3%)", "csDMARD monotherapy": "150/379 (39.6%)"}, "Annotation": {"data": "1. csDMARD triple therapy includes MTX + SSZ + HCQ.\n2. csDMARD monotherapy includes MTX.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.40 (1.15 to 1.70)", "Absolute Effect (95% CI)": "158 more per 1,000 (from 59 more to 277 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "4b", "Database": "2021 ACR RA"}
{"outcome_uid": "b0cd62ec", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive csDMARD monotherapy or combination (double or triple) therapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA who have moderate to high disease activity", "intervention": "csDMARD monotherapy", "comparator": "csDMARD triple combination therapy", "outcome": "Disease activity (follow up: 6 months; assessed with: ACR 50)", "importance": "CRITICAL", "related_paper_list": ["ccd87125"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"csDMARD triple therapy": "41/132 (31.1%)", "csDMARD monotherapy": "73/379 (19.3%)"}, "Annotation": {"data": "1. csDMARD triple therapy includes MTX + SSZ + HCQ.\n2. csDMARD monotherapy includes MTX.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.61 (1.16 to 2.24)", "Absolute Effect (95% CI)": "117 more per 1,000 (from 31 more to 239 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "4b", "Database": "2021 ACR RA"}
{"outcome_uid": "49a6891e", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive csDMARD monotherapy or combination (double or triple) therapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA who have moderate to high disease activity", "intervention": "csDMARD monotherapy", "comparator": "csDMARD triple combination therapy", "outcome": "Disease activity (follow up: 6 months; assessed with: ACR 70)", "importance": "CRITICAL", "related_paper_list": ["ccd87125"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm. Low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"csDMARD triple therapy": "11/132 (8.3%)", "csDMARD monotherapy": "13/379 (3.4%)"}, "Annotation": {"data": "1. csDMARD triple therapy includes MTX + SSZ + HCQ.\n2. csDMARD monotherapy includes MTX.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 2.43 (1.12 to 5.29)", "Absolute Effect (95% CI)": "49 more per 1,000 (from 4 more to 147 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "4b", "Database": "2021 ACR RA"}
{"outcome_uid": "e9c6e061", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on DMARDs who are in low disease activity", "intervention": "Taper off DMARDs (as long as the patient remains on at least one DMARD)", "comparator": "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)", "outcome": "Disease activity (follow up: range 9 months to 12 months; assessed with: DAS28-ESR)", "importance": "CRITICAL", "related_paper_list": ["d783a7f7", "0570bda2"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "CI includes both values suggesting benefit and values suggesting no effect"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"Taper off DMARDs": "264", "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)": "262"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.95 lower (1.18 lower to 0.72 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "52", "Database": "2021 ACR RA"}
{"outcome_uid": "4a90bd05", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on DMARDs who are in low disease activity", "intervention": "Taper off DMARDs (as long as the patient remains on at least one DMARD)", "comparator": "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)", "outcome": "Flare (follow up: range 6 months to 12 months)", "importance": "CRITICAL", "related_paper_list": ["506166f3", "60bbc82c"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious inconsistency. Unexplained heterogeneity I2=78%"}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Small number of events"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Taper off DMARDs": "18/153 (11.8%)", "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)": "30/102 (29.4%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.48 (0.32 to 0.71)", "Absolute Effect (95% CI)": "153 fewer per 1,000 (from 200 fewer to 85 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "52", "Database": "2021 ACR RA"}
{"outcome_uid": "de34d2eb", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on DMARDs who are in low disease activity", "intervention": "Taper off DMARDs (as long as the patient remains on at least one DMARD)", "comparator": "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)", "outcome": "Radiographic progression (follow up: range 9 months to 12 months; assessed with: mTSS)", "importance": "IMPORTANT", "related_paper_list": ["d783a7f7", "0570bda2"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Study contributing most of the weight is at risk of bias associated with missing data and selective outcome reporting"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"Taper off DMARDs": "247", "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)": "232"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.09 higher (0.34 lower to 0.53 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "52", "Database": "2021 ACR RA"}
{"outcome_uid": "c72df777", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on DMARDs who are in low disease activity", "intervention": "Taper off DMARDs (as long as the patient remains on at least one DMARD)", "comparator": "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)", "outcome": "Fatigue (follow up: range 9 months to 12 months; assessed with: FACIT-F)", "importance": "IMPORTANT", "related_paper_list": ["48d24eba", "4e39bd02"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": "I2=16%"}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"Taper off DMARDs": "264", "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)": "262"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 3.19 higher (1.53 higher to 4.85 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "52", "Database": "2021 ACR RA"}
{"outcome_uid": "45ead543", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on DMARDs who are in low disease activity", "intervention": "Taper off DMARDs (as long as the patient remains on at least one DMARD)", "comparator": "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)", "outcome": "Quality of Life (follow up: 9 months; assessed with: SF-36 PCS)", "importance": "IMPORTANT", "related_paper_list": ["4e39bd02"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Risk of bias associated with missing data and selective outcome reporting"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "CI includes both values suggesting benefit and values suggesting no effect"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Taper off DMARDs": "63", "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)": "65"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 2.3 higher (0.47 lower to 5.07 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "52", "Database": "2021 ACR RA"}
{"outcome_uid": "b3a0e27f", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on DMARDs who are in low disease activity", "intervention": "Taper off DMARDs (as long as the patient remains on at least one DMARD)", "comparator": "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)", "outcome": "Quality of Life (follow up: 9 months; assessed with: SF-36 MCS)", "importance": "IMPORTANT", "related_paper_list": ["4e39bd02"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Risk of bias associated with missing data and selective outcome reporting"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "CI includes both values suggesting benefit and values suggesting no effect"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Taper off DMARDs": "63", "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)": "65"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 1.8 higher (0.97 lower to 4.57 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "52", "Database": "2021 ACR RA"}
{"outcome_uid": "eb136673", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on DMARDs who are in low disease activity", "intervention": "Taper off DMARDs (as long as the patient remains on at least one DMARD)", "comparator": "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)", "outcome": "Disability (follow up: 12 months; assessed with: HAQ-DI)", "importance": "IMPORTANT", "related_paper_list": ["d783a7f7"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "CI includes both values suggesting benefit and values suggesting no effect"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"Taper off DMARDs": "201", "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)": "197"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.2 lower (0.31 lower to 0.09 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "52", "Database": "2021 ACR RA"}
{"outcome_uid": "08ee8250", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on DMARDs who are in low disease activity", "intervention": "Taper off DMARDs (as long as the patient remains on at least one DMARD)", "comparator": "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)", "outcome": "Pain (follow up: 12 months; assessed with: VAS Pain)", "importance": "IMPORTANT", "related_paper_list": ["d783a7f7"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "CI includes both values suggesting benefit and values suggesting no effect"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"Taper off DMARDs": "201", "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)": "197"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 12.6 lower (17.05 lower to 8.15 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "52", "Database": "2021 ACR RA"}
{"outcome_uid": "eb683e20", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on DMARDs who are in low disease activity", "intervention": "Taper off DMARDs (as long as the patient remains on at least one DMARD)", "comparator": "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)", "outcome": "Withdrawal due to lack of efficacy (follow up: 12 months)", "importance": "IMPORTANT", "related_paper_list": ["d783a7f7"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Small number of events"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"Taper off DMARDs": "11/202 (5.4%)", "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)": "43/200 (21.5%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.25 (0.13 to 0.48)", "Absolute Effect (95% CI)": "161 fewer per 1,000 (from 187 fewer to 112 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "52", "Database": "2021 ACR RA"}
{"outcome_uid": "034432dc", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on DMARDs who are in low disease activity", "intervention": "Taper off DMARDs (as long as the patient remains on at least one DMARD)", "comparator": "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)", "outcome": "Withdrawal due to adverse events (follow up: range 9 months to 12 months)", "importance": "IMPORTANT", "related_paper_list": ["d783a7f7", "0570bda2"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Small number of events\nCI includes both values suggesting benefit and values suggesting harm"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Taper off DMARDs": "4/267 (1.5%)", "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)": "6/265 (2.3%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.69 (0.21 to 2.26)", "Absolute Effect (95% CI)": "7 fewer per 1,000 (from 18 fewer to 29 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "52", "Database": "2021 ACR RA"}
{"outcome_uid": "1555510b", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on DMARDs who are in low disease activity", "intervention": "Taper off DMARDs (as long as the patient remains on at least one DMARD)", "comparator": "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)", "outcome": "Serious adverse events (follow up: range 9 months to 12 months)", "importance": "IMPORTANT", "related_paper_list": ["d783a7f7", "0570bda2"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Small number of events\nCI includes both values suggesting benefit and values suggesting harm"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Taper off DMARDs": "9/267 (3.4%)", "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)": "17/265 (6.4%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.53 (0.24 to 1.16)", "Absolute Effect (95% CI)": "30 fewer per 1,000 (from 49 fewer to 10 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "52", "Database": "2021 ACR RA"}
{"outcome_uid": "673d6491", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on DMARDs who are in low disease activity", "intervention": "Taper off DMARDs (as long as the patient remains on at least one DMARD)", "comparator": "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)", "outcome": "Malignancy (follow up: range 9 months to 12 months)", "importance": "IMPORTANT", "related_paper_list": ["d783a7f7", "0570bda2"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Small number of events\nCI includes both values suggesting harm and values suggesting no effect"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Taper off DMARDs": "4/267 (1.5%)", "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)": "1/265 (0.4%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 3.96 (0.45 to 35.12)", "Absolute Effect (95% CI)": "11 more per 1,000 (from 2 fewer to 129 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "52", "Database": "2021 ACR RA"}
{"outcome_uid": "c0dc5d1a", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on DMARDs who are in low disease activity", "intervention": "Taper off DMARDs (as long as the patient remains on at least one DMARD)", "comparator": "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)", "outcome": "Death (follow up: 12 months)", "importance": "IMPORTANT", "related_paper_list": ["d783a7f7"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Small number of events"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Taper off DMARDs": "0/202 (0.0%)", "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)": "0/200 (0.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "not estimable", "Absolute Effect (95% CI)": "-", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "52", "Database": "2021 ACR RA"}
{"outcome_uid": "4cb7900f", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on DMARDs who are in low disease activity", "intervention": "Taper off DMARDs (as long as the patient remains on at least one DMARD)", "comparator": "Continue DMARDs at same doses", "outcome": "Disease activity (follow up: 1 year; assessed with: DAS28-ESR)", "importance": "CRITICAL", "related_paper_list": ["d783a7f7"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"Continue DMARDs at same doses": "200", "Taper off DMARDs": "201"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.1 lower (0.31 lower to 0.11 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "52", "Database": "2021 ACR RA"}
{"outcome_uid": "ac9b9cc1", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on DMARDs who are in low disease activity", "intervention": "Taper off DMARDs (as long as the patient remains on at least one DMARD)", "comparator": "Continue DMARDs at same doses", "outcome": "Flare (follow up: range 11 months to 18 months)", "importance": "CRITICAL", "related_paper_list": ["60bbc82c", "47043953"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded for risk of bias associated with lack of blinding of participants, providers and outcome assessors\nDowngraded for risk of bias associated with lack of allocation concealment"}, "Inconsistency": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious inconsistency. I2= 77%"}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Continue DMARDs at same doses": "82 participants", "Taper off DMARDs": "148 participants(69.9%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "HR 0.46 (0.31 to 0.67)", "Absolute Effect (95% CI)": "275 fewer per 1,000 (from 388 fewer to 146 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "52", "Database": "2021 ACR RA"}
{"outcome_uid": "eaee869b", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on DMARDs who are in low disease activity", "intervention": "Taper off DMARDs (as long as the patient remains on at least one DMARD)", "comparator": "Continue DMARDs at same doses", "outcome": "Radiographic progression (follow up: 1 year; assessed with: mTSS)", "importance": "IMPORTANT", "related_paper_list": ["d783a7f7"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "CI includes both values suggesting benefit and values suggesting harm"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Continue DMARDs at same doses": "184", "Taper off DMARDs": "184"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 3.7 higher (8.42 lower to 15.82 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "52", "Database": "2021 ACR RA"}
{"outcome_uid": "0ae636e1", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on DMARDs who are in low disease activity", "intervention": "Taper off DMARDs (as long as the patient remains on at least one DMARD)", "comparator": "Continue DMARDs at same doses", "outcome": "Fatigue (follow up: 1 year; assessed with: FACIT-F)", "importance": "IMPORTANT", "related_paper_list": ["48d24eba"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"Continue DMARDs at same doses": "201", "Taper off DMARDs": "201"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.1 higher (1.63 lower to 1.83 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "52", "Database": "2021 ACR RA"}
{"outcome_uid": "5654b196", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on DMARDs who are in low disease activity", "intervention": "Taper off DMARDs (as long as the patient remains on at least one DMARD)", "comparator": "Continue DMARDs at same doses", "outcome": "Pain (follow up: 1 year; assessed with: VAS pain (0-100))", "importance": "IMPORTANT", "related_paper_list": ["d783a7f7"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"Continue DMARDs at same doses": "200", "Taper off DMARDs": "201"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 2.8 lower (6.6 lower to 1 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "52", "Database": "2021 ACR RA"}
{"outcome_uid": "0773dbf8", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on DMARDs who are in low disease activity", "intervention": "Taper off DMARDs (as long as the patient remains on at least one DMARD)", "comparator": "Continue DMARDs at same doses", "outcome": "Disability (follow up: 1 year; assessed with: HAQ-DI)", "importance": "IMPORTANT", "related_paper_list": ["d783a7f7"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"Continue DMARDs at same doses": "201", "Taper off DMARDs": "201"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.1 lower (0.2 lower to 0)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "52", "Database": "2021 ACR RA"}
{"outcome_uid": "2cdd9da0", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on DMARDs who are in low disease activity", "intervention": "Taper off DMARDs (as long as the patient remains on at least one DMARD)", "comparator": "Continue DMARDs at same doses", "outcome": "Withdrawal due to lack of efficacy (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["d783a7f7"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "CI includes both values suggesting benefit and values suggesting harm"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Continue DMARDs at same doses": "4/202 (2.0%)", "Taper off DMARDs": "11/202 (5.4%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.36 (0.12 to 1.12)", "Absolute Effect (95% CI)": "35 fewer per 1,000 (from 48 fewer to 7 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "52", "Database": "2021 ACR RA"}
{"outcome_uid": "a57db733", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on DMARDs who are in low disease activity", "intervention": "Taper off DMARDs (as long as the patient remains on at least one DMARD)", "comparator": "Continue DMARDs at same doses", "outcome": "Withdrawal due to adverse events (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["d783a7f7"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Small number of events\nCI includes both values suggesting harm and values suggesting no effect"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Continue DMARDs at same doses": "7/202 (3.5%)", "Taper off DMARDs": "4/202 (2.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.75 (0.52 to 5.89)", "Absolute Effect (95% CI)": "15 more per 1,000 (from 10 fewer to 97 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "52", "Database": "2021 ACR RA"}
{"outcome_uid": "1c135ce8", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on DMARDs who are in low disease activity", "intervention": "Taper off DMARDs (as long as the patient remains on at least one DMARD)", "comparator": "Continue DMARDs at same doses", "outcome": "Serious adverse events (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["d783a7f7"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Small number of events\nCI includes both values suggesting harm and values suggesting no effect"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Continue DMARDs at same doses": "12/202 (5.9%)", "Taper off DMARDs": "7/202 (3.5%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.71 (0.69 to 4.27)", "Absolute Effect (95% CI)": "25 more per 1,000 (from 11 fewer to 113 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "52", "Database": "2021 ACR RA"}
{"outcome_uid": "d71d3aaa", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on DMARDs who are in low disease activity", "intervention": "Taper off DMARDs (as long as the patient remains on at least one DMARD)", "comparator": "Continue DMARDs at same doses", "outcome": "Malignancy (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["d783a7f7"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Small number of events\nCI includes both values suggesting benefit and values suggesting harm"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Continue DMARDs at same doses": "2/202 (1.0%)", "Taper off DMARDs": "4/202 (2.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.50 (0.09 to 2.70)", "Absolute Effect (95% CI)": "10 fewer per 1,000 (from 18 fewer to 34 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "52", "Database": "2021 ACR RA"}
{"outcome_uid": "fdc1d0ec", "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?", "population": "Patients with RA on DMARDs who are in low disease activity", "intervention": "Taper off DMARDs (as long as the patient remains on at least one DMARD)", "comparator": "Continue DMARDs at same doses", "outcome": "Death (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["d783a7f7"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Small number of events\nCI includes both values suggesting benefit and values suggesting harm"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Continue DMARDs at same doses": "2/202 (1.0%)", "Taper off DMARDs": "0/202 (0.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 5.00 (0.24 to 103.50)", "Absolute Effect (95% CI)": "0 fewer per 1,000 (from 0 fewer to 0 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "52", "Database": "2021 ACR RA"}
{"outcome_uid": "385f342d", "clinical_question": "Should patients with RA on DMARDs who are in remission gradually taper off DMARDs, Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD), or continue DMARDS at the same doses?", "population": "Patients with RA on DMARDs in remission", "intervention": "Taper off DMARDs (as long as the patient remains on at least one DMARD)", "comparator": "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)", "outcome": "Disease activity (follow up: 9 months; assessed with: ACR 20)", "importance": "CRITICAL", "related_paper_list": ["0570bda2"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment, incomplete outcome data and selective reporting."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Taper off DMARDs": "56/63 (88.9%)", "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)": "48/63 (76.2%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.17 (0.99 to 1.37)", "Absolute Effect (95% CI)": "130 more per 1,000 (from 8 fewer to 282 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "53", "Database": "2021 ACR RA"}
{"outcome_uid": "f40b654c", "clinical_question": "Should patients with RA on DMARDs who are in remission gradually taper off DMARDs, Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD), or continue DMARDS at the same doses?", "population": "Patients with RA on DMARDs in remission", "intervention": "Taper off DMARDs (as long as the patient remains on at least one DMARD)", "comparator": "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)", "outcome": "Disease activity (follow up: 9 months; assessed with: ACR 50)", "importance": "CRITICAL", "related_paper_list": ["0570bda2"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment, incomplete outcome data and selective reporting."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Taper off DMARDs": "49/63 (77.8%)", "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)": "45/63 (71.4%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.09 (0.89 to 1.34)", "Absolute Effect (95% CI)": "64 more per 1,000 (from 79 fewer to 243 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "53", "Database": "2021 ACR RA"}
{"outcome_uid": "098828e1", "clinical_question": "Should patients with RA on DMARDs who are in remission gradually taper off DMARDs, Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD), or continue DMARDS at the same doses?", "population": "Patients with RA on DMARDs in remission", "intervention": "Taper off DMARDs (as long as the patient remains on at least one DMARD)", "comparator": "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)", "outcome": "Disease activity (follow up: 9 months; assessed with: ACR 70)", "importance": "CRITICAL", "related_paper_list": ["0570bda2"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment, incomplete outcome data and selective reporting."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Taper off DMARDs": "45/63 (71.4%)", "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)": "39/63 (61.9%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.15 (0.90 to 1.48)", "Absolute Effect (95% CI)": "93 more per 1,000 (from 62 fewer to 297 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "53", "Database": "2021 ACR RA"}
{"outcome_uid": "24130573", "clinical_question": "Should patients with RA on DMARDs who are in remission gradually taper off DMARDs, Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD), or continue DMARDS at the same doses?", "population": "Patients with RA on DMARDs in remission", "intervention": "Taper off DMARDs (as long as the patient remains on at least one DMARD)", "comparator": "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)", "outcome": "Disease activity (follow up: 9 months; assessed with: DAS28-ESR (Lower values – > benefit) (MCID -1.17)", "importance": "CRITICAL", "related_paper_list": ["0570bda2"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment, incomplete outcome data and selective reporting."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Taper off DMARDs": "63", "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)": "65"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.7 lower (1.25 lower to 0.15 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "53", "Database": "2021 ACR RA"}
{"outcome_uid": "e47f6881", "clinical_question": "Should patients with RA on DMARDs who are in remission gradually taper off DMARDs, Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD), or continue DMARDS at the same doses?", "population": "Patients with RA on DMARDs in remission", "intervention": "Taper off DMARDs (as long as the patient remains on at least one DMARD)", "comparator": "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)", "outcome": "Remission (follow up: 9 months; assessed with: DAS28ESR < 2.6)", "importance": "CRITICAL", "related_paper_list": ["0570bda2"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment, incomplete outcome data and selective reporting."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"Taper off DMARDs": "50/63 (79.4%)", "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)": "35/65 (53.8%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.47 (1.14 to 1.91)", "Absolute Effect (95% CI)": "253 more per 1,000 (from 75 more to 490 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "53", "Database": "2021 ACR RA"}
{"outcome_uid": "60ef53f1", "clinical_question": "Should patients with RA on DMARDs who are in remission gradually taper off DMARDs, Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD), or continue DMARDS at the same doses?", "population": "Patients with RA on DMARDs in remission", "intervention": "Taper off DMARDs (as long as the patient remains on at least one DMARD)", "comparator": "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)", "outcome": "Flare (follow up: 12 months)", "importance": "CRITICAL", "related_paper_list": ["506166f3"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Very low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Taper off DMARDs": "3/126 (2.4%)", "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)": "10/79 (12.7%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.19 (0.05 to 0.66)", "Absolute Effect (95% CI)": "103 fewer per 1,000 (from 120 fewer to 43 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "53", "Database": "2021 ACR RA"}
{"outcome_uid": "bc6321b5", "clinical_question": "Should patients with RA on DMARDs who are in remission gradually taper off DMARDs, Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD), or continue DMARDS at the same doses?", "population": "Patients with RA on DMARDs in remission", "intervention": "Taper off DMARDs (as long as the patient remains on at least one DMARD)", "comparator": "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)", "outcome": "Radiographic progression (follow up: 9 months; assessed with: mTSS (Lower values – > benefit) (MCID 4.6)", "importance": "IMPORTANT", "related_paper_list": ["0570bda2"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment, incomplete outcome data and selective reporting."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"Taper off DMARDs": "63", "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)": "65"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.1 higher (0.34 lower to 0.54 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "53", "Database": "2021 ACR RA"}
{"outcome_uid": "7d800e7a", "clinical_question": "Should patients with RA on DMARDs who are in remission gradually taper off DMARDs, Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD), or continue DMARDS at the same doses?", "population": "Patients with RA on DMARDs in remission", "intervention": "Taper off DMARDs (as long as the patient remains on at least one DMARD)", "comparator": "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)", "outcome": "Quality of Life (follow up: 9 months; assessed with: SF-36 PCS (Higher values – > benefit) (MCID 4.4)", "importance": "IMPORTANT", "related_paper_list": ["4e39bd02"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment, incomplete outcome data and selective reporting."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Taper off DMARDs": "63", "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)": "65"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 2.3 higher (0.47 lower to 5.07 higher)(The study PRIZE found that the RR of improvement in SF-36 PCS (≥ 5 change from baseline) was 1.03 (95%CI 0.86 to 1.24), absolute risk increase 23 more per 1000 (95%CI 108 fewer to 185 more).)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "53", "Database": "2021 ACR RA"}
{"outcome_uid": "21da4e90", "clinical_question": "Should patients with RA on DMARDs who are in remission gradually taper off DMARDs, Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD), or continue DMARDS at the same doses?", "population": "Patients with RA on DMARDs in remission", "intervention": "Taper off DMARDs (as long as the patient remains on at least one DMARD)", "comparator": "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)", "outcome": "Quality of Life (follow up: 9 months; assessed with: SF-36 MCS (Higher values – > benefit) (MCID 3.1)", "importance": "IMPORTANT", "related_paper_list": ["4e39bd02"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment, incomplete outcome data and selective reporting."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Taper off DMARDs": "63", "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)": "65"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 1.8 higher (0.97 lower to 4.57 higher)(The study PRIZE found that the RR of improvement in SF-36 MCS (≥ 5 change from baseline) was 1.27 (95%CI 0.91 to 1.78), absolute risk increase 125 more per 1000 (95%CI 42 fewer to 360 more).)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "53", "Database": "2021 ACR RA"}
{"outcome_uid": "cdaead90", "clinical_question": "Should patients with RA on DMARDs who are in remission gradually taper off DMARDs, Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD), or continue DMARDS at the same doses?", "population": "Patients with RA on DMARDs in remission", "intervention": "Taper off DMARDs (as long as the patient remains on at least one DMARD)", "comparator": "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)", "outcome": "Fatigue (follow up: 9 months; assessed with: FACIT-F (Higher values – > benefit) (MCID 15.9)", "importance": "IMPORTANT", "related_paper_list": ["4e39bd02"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment, incomplete outcome data and selective reporting."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"Taper off DMARDs": "63", "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)": "65"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 1.8 higher (1.25 lower to 4.85 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "53", "Database": "2021 ACR RA"}
{"outcome_uid": "470f4c10", "clinical_question": "Should patients with RA on DMARDs who are in remission gradually taper off DMARDs, Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD), or continue DMARDS at the same doses?", "population": "Patients with RA on DMARDs in remission", "intervention": "Taper off DMARDs (as long as the patient remains on at least one DMARD)", "comparator": "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)", "outcome": "Withdrawal due to adverse events (follow up: 9 months)", "importance": "IMPORTANT", "related_paper_list": ["0570bda2"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment, incomplete outcome data and selective reporting."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Very low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Taper off DMARDs": "3/63 (4.8%)", "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)": "0/65 (0.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 7.22 (0.38 to 136.98)", "Absolute Effect (95% CI)": "0 fewer per 1,000 (from 0 fewer to 0 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "53", "Database": "2021 ACR RA"}
{"outcome_uid": "57cf7c47", "clinical_question": "Should patients with RA on DMARDs who are in remission gradually taper off DMARDs, Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD), or continue DMARDS at the same doses?", "population": "Patients with RA on DMARDs in remission", "intervention": "Taper off DMARDs (as long as the patient remains on at least one DMARD)", "comparator": "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)", "outcome": "Serious adverse events (follow up: 9 months)", "importance": "IMPORTANT", "related_paper_list": ["0570bda2"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment, incomplete outcome data and selective reporting."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Very low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Taper off DMARDs": "3/63 (4.8%)", "Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)": "2/65 (3.1%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.55 (0.27 to 8.95)", "Absolute Effect (95% CI)": "17 more per 1,000 (from 22 fewer to 245 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "53", "Database": "2021 ACR RA"}
{"outcome_uid": "f2733cca", "clinical_question": "Should patients with RA on two or more DMARDs who are at target for less than six months withdraw DMARDs or continue DMARDs?", "population": "Patients with RA on two or more DMARDs at target for less than six months", "intervention": "Withdraw one DMARD (or more than one DMARD as long as the patient remains on at least one DMARD)", "comparator": "Continue current therapy", "outcome": "Disease activity (follow up: 1 year; assessed with: DAS28-ESR (Lower values – > benefit) (MCID -1.17)", "importance": "CRITICAL", "related_paper_list": ["d783a7f7"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"Withdraw one DMARD": "398", "Continue current therapy": "201"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.59 higher (0.4 higher to 0.78 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "54a", "Database": "2021 ACR RA"}
{"outcome_uid": "a9916bd7", "clinical_question": "Should patients with RA on two or more DMARDs who are at target for less than six months withdraw DMARDs or continue DMARDs?", "population": "Patients with RA on two or more DMARDs at target for less than six months", "intervention": "Withdraw one DMARD (or more than one DMARD as long as the patient remains on at least one DMARD)", "comparator": "Continue current therapy", "outcome": "Remission (follow up: 1 year; assessed with: DAS28-ESR <2.6)", "importance": "CRITICAL", "related_paper_list": ["d783a7f7"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"Withdraw one DMARD": "179/398 (45.0%)", "Continue current therapy": "134/201 (66.7%) "}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.67 (0.58 to 0.78)", "Absolute Effect (95% CI)": "220 fewer per 1,000 (from 280 fewer to 147 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "54a", "Database": "2021 ACR RA"}
{"outcome_uid": "811c7368", "clinical_question": "Should patients with RA on two or more DMARDs who are at target for less than six months withdraw DMARDs or continue DMARDs?", "population": "Patients with RA on two or more DMARDs at target for less than six months", "intervention": "Withdraw one DMARD (or more than one DMARD as long as the patient remains on at least one DMARD)", "comparator": "Continue current therapy", "outcome": "Flare (follow up: range 7 months to 12 months)", "importance": "CRITICAL", "related_paper_list": ["04645c61", "47043953"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "A study contributing 27% of the weight is at very serious risk of bias, while the other study is at risk of bias due to the lack of blinding of participants and personnel."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": "I2=57%"}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"Withdraw one DMARD": "100/136 (73.5%)  ", "Continue current therapy": "24/75 (32.0%) "}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 2.40 (1.68 to 3.42)", "Absolute Effect (95% CI)": "448 more per 1,000 (from 218 more to 774 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "54a", "Database": "2021 ACR RA"}
{"outcome_uid": "7ea6a06f", "clinical_question": "Should patients with RA on two or more DMARDs who are at target for less than six months withdraw DMARDs or continue DMARDs?", "population": "Patients with RA on two or more DMARDs at target for less than six months", "intervention": "Withdraw one DMARD (or more than one DMARD as long as the patient remains on at least one DMARD)", "comparator": "Continue current therapy", "outcome": "Radiographic progression (follow up: 1 year; assessed with: mTSS (Lower values – > benefit) (MCID 4.6)", "importance": "IMPORTANT", "related_paper_list": ["d783a7f7"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "CI interval includes both values suggesting benefit and values suggesting harm"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Withdraw one DMARD": "351  ", "Continue current therapy": "184 "}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 1.77 lower (11.99 lower to 8.45 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "54a", "Database": "2021 ACR RA"}
{"outcome_uid": "70984b86", "clinical_question": "Should patients with RA on two or more DMARDs who are at target for less than six months withdraw DMARDs or continue DMARDs?", "population": "Patients with RA on two or more DMARDs at target for less than six months", "intervention": "Withdraw one DMARD (or more than one DMARD as long as the patient remains on at least one DMARD)", "comparator": "Continue current therapy", "outcome": "Fatigue (follow up: 1 year; assessed with: FACIT-F (Higher values – > benefit) (MCID 15.9)", "importance": "IMPORTANT", "related_paper_list": ["48d24eba"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"Withdraw one DMARD": "398  ", "Continue current therapy": "201  "}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 1.98 lower (3.57 lower to 0.39 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "54a", "Database": "2021 ACR RA"}
{"outcome_uid": "9a724fef", "clinical_question": "Should patients with RA on two or more DMARDs who are at target for less than six months withdraw DMARDs or continue DMARDs?", "population": "Patients with RA on two or more DMARDs at target for less than six months", "intervention": "Withdraw one DMARD (or more than one DMARD as long as the patient remains on at least one DMARD)", "comparator": "Continue current therapy", "outcome": "Pain (follow up: 1 year; assessed with: VAS pain (0-100) (Lower values – > benefit) (MCID -11.9)", "importance": "IMPORTANT", "related_paper_list": ["d783a7f7"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "CI interval includes both values suggesting harm and values suggesting no effect"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"Withdraw one DMARD": "398  ", "Continue current therapy": "201  "}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 9.04 higher (5.62 higher to 12.46 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "54a", "Database": "2021 ACR RA"}
{"outcome_uid": "13560f5e", "clinical_question": "Should patients with RA on two or more DMARDs who are at target for less than six months withdraw DMARDs or continue DMARDs?", "population": "Patients with RA on two or more DMARDs at target for less than six months", "intervention": "Withdraw one DMARD (or more than one DMARD as long as the patient remains on at least one DMARD)", "comparator": "Continue current therapy", "outcome": "Disability (follow up: 1 year; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22)", "importance": "IMPORTANT", "related_paper_list": ["d783a7f7"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "CI interval includes both values suggesting harm and values suggesting no effect"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"Withdraw one DMARD": " 398", "Continue current therapy": "201  "}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.2 higher (0.11 higher to 0.29 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "54a", "Database": "2021 ACR RA"}
{"outcome_uid": "8f58eb6b", "clinical_question": "Should patients with RA on two or more DMARDs who are at target for less than six months withdraw DMARDs or continue DMARDs?", "population": "Patients with RA on two or more DMARDs at target for less than six months", "intervention": "Withdraw one DMARD (or more than one DMARD as long as the patient remains on at least one DMARD)", "comparator": "Continue current therapy", "outcome": "Quality of Life (follow up: 1 year; assessed with: EuroQol-5 (Higher values – > benefit) (MCID 0.1)", "importance": "IMPORTANT", "related_paper_list": ["d783a7f7"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"Withdraw one DMARD": "398 ", "Continue current therapy": "201 "}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.05 lower (0.09 lower to 0.01 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "54a", "Database": "2021 ACR RA"}
{"outcome_uid": "dce41141", "clinical_question": "Should patients with RA on two or more DMARDs who are at target for less than six months withdraw DMARDs or continue DMARDs?", "population": "Patients with RA on two or more DMARDs at target for less than six months", "intervention": "Withdraw one DMARD (or more than one DMARD as long as the patient remains on at least one DMARD)", "comparator": "Continue current therapy", "outcome": "Withdrawal due to lack of efficacy (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["d783a7f7"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Very small number of events"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"Withdraw one DMARD": "54/402 (13.4%) ", "Continue current therapy": "4/202 (2.0%)  "}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 6.78(2.49 to 18.47", "Absolute Effect (95% CI)": "114 more per 1,000(from 30 more to 346 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "54a", "Database": "2021 ACR RA"}
{"outcome_uid": "f8cddb49", "clinical_question": "Should patients with RA on two or more DMARDs who are at target for less than six months withdraw DMARDs or continue DMARDs?", "population": "Patients with RA on two or more DMARDs at target for less than six months", "intervention": "Withdraw one DMARD (or more than one DMARD as long as the patient remains on at least one DMARD)", "comparator": "Continue current therapy", "outcome": "Withdrawal due to adverse events (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["d783a7f7"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "CI interval includes both values suggesting benefit and values suggesting harm"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Withdraw one DMARD": "9/402 (2.2%) ", "Continue current therapy": "7/202 (3.5%)  "}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "RR 0.65 (0.24 to 1.71)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "54a", "Database": "2021 ACR RA"}
{"outcome_uid": "a60df4d8", "clinical_question": "Should patients with RA on two or more DMARDs who are at target for less than six months withdraw DMARDs or continue DMARDs?", "population": "Patients with RA on two or more DMARDs at target for less than six months", "intervention": "Withdraw one DMARD (or more than one DMARD as long as the patient remains on at least one DMARD)", "comparator": "Continue current therapy", "outcome": "Serious adverse events (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["d783a7f7"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "CI interval includes both values suggesting harm and values suggesting no effect"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Withdraw one DMARD": "22/402 (5.5%)  ", "Continue current therapy": "12/202 (5.9%)  "}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "RR 0.92 (0.47 to 1.82)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "54a", "Database": "2021 ACR RA"}
{"outcome_uid": "2c55271b", "clinical_question": "Should patients with RA on two or more DMARDs who are at target for less than six months withdraw DMARDs or continue DMARDs?", "population": "Patients with RA on two or more DMARDs at target for less than six months", "intervention": "Withdraw one DMARD (or more than one DMARD as long as the patient remains on at least one DMARD)", "comparator": "Continue current therapy", "outcome": "Malignancy (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["d783a7f7"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "CI interval includes both values suggesting harm and values suggesting no effect\nVery small number of events"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Withdraw one DMARD": "5/402 (1.2%) ", "Continue current therapy": "2/202 (1.0%)  "}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "RR 0.75 (0.17 to 3.33)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "54a", "Database": "2021 ACR RA"}
{"outcome_uid": "918aa04b", "clinical_question": "Should patients with RA on two or more DMARDs who are at target for six months and longer withdraw DMARDs or continue DMARDs?", "population": "Patients with RA on two or more DMARDs at target for six months and longer", "intervention": "Withdraw one DMARD (or more than one DMARD as long as the patient remains on at least one DMARD)", "comparator": "Continue current therapy", "outcome": "Disease activity (follow up: 3 months; assessed with: DAS28-ESR (Lower values – > benefit) (MCID -1.17)", "importance": "CRITICAL", "related_paper_list": ["3ca3e366"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Concern about the lack of blinding of participants and providers"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"Withdraw one DMARD": "64", "Continue current therapy": "73"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.1 higher (0.02 higher to 0.18 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "54b", "Database": "2021 ACR RA"}
{"outcome_uid": "251b7771", "clinical_question": "Should patients with RA on two or more DMARDs who are at target for six months and longer withdraw DMARDs or continue DMARDs?", "population": "Patients with RA on two or more DMARDs at target for six months and longer", "intervention": "Withdraw one DMARD (or more than one DMARD as long as the patient remains on at least one DMARD)", "comparator": "Continue current therapy", "outcome": "Flare (follow up: range 11 months to 18 months)", "importance": "CRITICAL", "related_paper_list": ["3ca3e366", "60bbc82c", "1ce3bb38"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "All included studies are at risk of bias"}, "Inconsistency": {"result": "SERIOUS", "rationales": "I2=55%"}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Withdraw one DMARD": "645", "Continue current therapy": "382(25.4%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "HR 2.61 (2.11 to 3.23)", "Absolute Effect (95% CI)": "281 more per 1,000 (from 207 more to 358 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "54b", "Database": "2021 ACR RA"}
{"outcome_uid": "832b89f9", "clinical_question": "Should patients with RA on two or more DMARDs who are at target for six months and longer withdraw DMARDs or continue DMARDs?", "population": "Patients with RA on two or more DMARDs at target for six months and longer", "intervention": "Withdraw one DMARD (or more than one DMARD as long as the patient remains on at least one DMARD)", "comparator": "Continue current therapy", "outcome": "Disability (follow up: 3 months; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22)", "importance": "IMPORTANT", "related_paper_list": ["3ca3e366"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Concern about the lack of blinding of participants and providers"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "CI includes both values suggesting harms and values suggesting no effect"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Withdraw one DMARD": "64", "Continue current therapy": "73"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.09 higher (0.11 lower to 0.29 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "54b", "Database": "2021 ACR RA"}
{"outcome_uid": "12e2afe9", "clinical_question": "Should patients with RA on DMARD monotherapy who are in low disease activity gradually taper off DMARD, abruptly withdraw DMARD, or continue DMARD at the same dose?", "population": "Patients with RA on DMARD monotherapy who are in low disease activity", "intervention": "Taper off DMARD", "comparator": "Abruptly withdraw DMARD", "outcome": "Relapse (follow up: 1 year; assessed with DAS28 CRP>2.7 )", "importance": "CRITICAL", "related_paper_list": ["03c1b15a"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Study did not report on handling confounding; also high rate of missing data"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Very low number of participants and number of events"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Observational Study", "Certainty": "VERY LOW", "No of participants": {"Abruptly withdraw DMARD": "8/16 (50.0%)", "continue DMARD at same dose": "2/20 (10.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 5.00 (1.23 to 20.34)", "Absolute Effect (95% CI)": "400 more per 1,000 (from 23 more to 1,000 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "57", "Database": "2021 ACR RA"}
{"outcome_uid": "fba2e58c", "clinical_question": "Should patients with RA on MTX + boDMARD or MTX + tsDMARD who are at target withdraw (taper off or abruptly stop) MTX or withdraw (taper off or abruptly stop) the boDMARD or the tsDMARD?", "population": "Patients with RA on MTX + boDMARD or MTX + tsDMARD who are at target", "intervention": "Withdraw (taper off or abruptly stop) MTX", "comparator": "Continue same management", "outcome": "Disease activity (follow up: 3 months; assessed with: DAS28-ESR (Lower values – > benefit) (MCID -1.17)", "importance": "CRITICAL", "related_paper_list": ["fab0cce3"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": "Concern with risk of bias. Missing data was not appropriately handled in the trial."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Very small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"Continue": "80", "Withdraw (Taper/Stop) MTX": "79"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.07 lower (0.4 lower to 0.27 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "59", "Database": "2021 ACR RA"}
{"outcome_uid": "c1ea71ee", "clinical_question": "Should patients with RA on MTX + boDMARD or MTX + tsDMARD who are at target withdraw (taper off or abruptly stop) MTX or withdraw (taper off or abruptly stop) the boDMARD or the tsDMARD?", "population": "Patients with RA on MTX + boDMARD or MTX + tsDMARD who are at target", "intervention": "Withdraw (taper off or abruptly stop) MTX", "comparator": "Continue same management", "outcome": "Disability (follow up: 3 months; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22)", "importance": "CRITICAL", "related_paper_list": ["fab0cce3"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": "Concern with risk of bias. Missing data was not appropriately handled in the trial."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Very small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"Continue": "82", "Withdraw (Taper/Stop) MTX": "82"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.04 higher (0.11 lower to 0.19 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "59", "Database": "2021 ACR RA"}
{"outcome_uid": "62de13cd", "clinical_question": "Should patients with RA on MTX + boDMARD or MTX + tsDMARD who are at target withdraw (taper off or abruptly stop) MTX or withdraw (taper off or abruptly stop) the boDMARD or the tsDMARD?", "population": "Patients with RA on MTX + boDMARD or MTX + tsDMARD who are at target", "intervention": "Withdraw (taper off or abruptly stop) MTX", "comparator": "Continue same management", "outcome": "Quality of life (follow up: 3 months; assessed with: SF-36 PCS (Higher values – > benefit) (MCID 4.4)", "importance": "IMPORTANT", "related_paper_list": ["fab0cce3"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": "Concern with risk of bias. Missing data was not appropriately handled in the trial."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit. Very small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"Continue": "82", "Withdraw (Taper/Stop) MTX": "82"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 3.38 higher (0.69 higher to 6.07 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "59", "Database": "2021 ACR RA"}
{"outcome_uid": "e3029d33", "clinical_question": "Should patients with RA on MTX + boDMARD or MTX + tsDMARD who are at target withdraw (taper off or abruptly stop) MTX or withdraw (taper off or abruptly stop) the boDMARD or the tsDMARD?", "population": "Patients with RA on MTX + boDMARD or MTX + tsDMARD who are at target", "intervention": "Withdraw (taper off or abruptly stop) MTX", "comparator": "Continue same management", "outcome": "Quality of life (follow up: 3 months; assessed with:  SF-36 MCS (Higher values – > benefit) (MCID 3.1)", "importance": "IMPORTANT", "related_paper_list": ["fab0cce3"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": "Concern with risk of bias. Missing data was not appropriately handled in the trial."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to very serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm. Very small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"Continue": "82", "Withdraw (Taper/Stop) MTX": "82"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 1.88 lower (4.78 lower to 1.02 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "59", "Database": "2021 ACR RA"}
{"outcome_uid": "38450c06", "clinical_question": "Should patients with RA on MTX + boDMARD or MTX + tsDMARD who are at target withdraw (taper off or abruptly stop) MTX or withdraw (taper off or abruptly stop) the boDMARD or the tsDMARD?", "population": "Patients with RA on MTX + boDMARD or MTX + tsDMARD who are at target", "intervention": "Withdraw (taper off or abruptly stop) MTX", "comparator": "Continue same management", "outcome": "Serious adverse events (follow up: 3 months)", "importance": "IMPORTANT", "related_paper_list": ["fab0cce3"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": "Concern with risk of bias. Missing data was not appropriately handled in the trial."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, and low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Continue": "1/83 (1.2%)", "Withdraw (Taper/Stop) MTX": "4/82 (4.9%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.25 (0.03 to 2.16)", "Absolute Effect (95% CI)": "37 fewer per 1,000 (from 47 fewer to 57 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "59", "Database": "2021 ACR RA"}
{"outcome_uid": "1cc42739", "clinical_question": "Should patients with RA on MTX + boDMARD or MTX + tsDMARD who are at target withdraw (taper off or abruptly stop) MTX or withdraw (taper off or abruptly stop) the boDMARD or the tsDMARD?", "population": "Patients with RA on MTX + boDMARD or MTX + tsDMARD who are at target", "intervention": "Withdraw (taper off or abruptly stop) MTX", "comparator": "Continue same management", "outcome": "Withdrawal due to lack of efficacy (follow up: 3 months)", "importance": "IMPORTANT", "related_paper_list": ["fab0cce3"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": "Concern with risk of bias. Missing data was not appropriately handled in the trial."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, and low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Continue": "0/83 (0.0%)", "Withdraw (Taper/Stop) MTX": "1/82 (1.2%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.33 (0.01 to 7.97)", "Absolute Effect (95% CI)": "8 fewer per 1,000 (from 12 fewer to 85 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "59", "Database": "2021 ACR RA"}
{"outcome_uid": "a5c515ab", "clinical_question": "Should patients with RA on MTX + boDMARD or MTX + tsDMARD who are at target withdraw (taper off or abruptly stop) MTX or withdraw (taper off or abruptly stop) the boDMARD or the tsDMARD?", "population": "Patients with RA on MTX + boDMARD or MTX + tsDMARD who are at target", "intervention": "Withdraw (taper off or abruptly stop) MTX", "comparator": "Continue same management", "outcome": "Withdrawal due to adverse events (follow up: 3 months)", "importance": "IMPORTANT", "related_paper_list": ["fab0cce3"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": "Concern with risk of bias. Missing data was not appropriately handled in the trial."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit. Very small sample size, and low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"Continue": "3/83 (3.6%)", "Withdraw (Taper/Stop) MTX": "1/82 (1.2%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 2.96 (0.31 to 27.91)", "Absolute Effect (95% CI)": "24 more per 1,000 (from 8 fewer to 328 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "59", "Database": "2021 ACR RA"}
{"outcome_uid": "f1bceaf4", "clinical_question": "Should patients with RA on MTX + boDMARD or MTX + tsDMARD who are at target withdraw (taper off or abruptly stop) MTX or withdraw (taper off or abruptly stop) the boDMARD or the tsDMARD?", "population": "Patients with RA on MTX + boDMARD or MTX + tsDMARD who are at target", "intervention": "Withdraw (taper off or abruptly stop) MTX", "comparator": "Continue same management", "outcome": "Death (follow up: 3 months)", "importance": "IMPORTANT", "related_paper_list": ["fab0cce3"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": "Concern with risk of bias. Missing data was not appropriately handled in the trial."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Very small sample size, and very low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Continue": "0/83 (0.0%)", "Withdraw (Taper/Stop) MTX": "0/82 (0.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "not estimable", "Absolute Effect (95% CI)": "", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "59", "Database": "2021 ACR RA"}
{"outcome_uid": "34283940", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor", "outcome": "Disease activity (follow up: 2 years; assessed with: ACR 20 )", "importance": "CRITICAL", "related_paper_list": ["eafc116f", "2140c6ee"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious inconsistency. Unexplained heterogeneity I2=65%. "}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"TNF inhibitor": "207/467 (44.3%)", "MTX monotherapy": "205/459 (44.7%)"}, "Annotation": {"data": "1. TNFi includes ETN or ADA.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.99 (0.86 to 1.15)", "Absolute Effect (95% CI)": "4 fewer per 1,000 (from 63 fewer to 67 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "5ca468ce", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor", "outcome": "Disease activity (follow up: 2 years; assessed with: ACR 50)", "importance": "CRITICAL", "related_paper_list": ["eafc116f", "2140c6ee"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious inconsistency. Unexplained heterogeneity I2=75%."}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"TNF inhibitor": "188/451 (41.7%)", "MTX monotherapy": "182/426 (42.7%)"}, "Annotation": {"data": "1. TNFi includes ETN or ADA.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.98 (0.84 to 1.14)", "Absolute Effect (95% CI)": "9 fewer per 1,000 (from 68 fewer to 60 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "bbc4a6f5", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor", "outcome": "Disease activity (follow up: 2 years; assessed with: ACR 70)", "importance": "CRITICAL", "related_paper_list": ["eafc116f", "2140c6ee"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"TNF inhibitor": "128/451 (28.4%)", "MTX monotherapy": "113/426 (26.5%)"}, "Annotation": {"data": "1. TNFi includes ETN or ADA.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.07 (0.86 to 1.33)", "Absolute Effect (95% CI)": "19 more per 1,000 (from 37 fewer to 88 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "110c2ef2", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor", "outcome": "Remission (follow up: 2 years; assessed with: DAS28-ESR <2.6)", "importance": "CRITICAL", "related_paper_list": ["2140c6ee"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"TNF inhibitor": "69/274 (25.2%)", "MTX monotherapy": "64/257 (24.9%)"}, "Annotation": {"data": "1. TNFi includes ETN or ADA.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.01 (0.75 to 1.36)", "Absolute Effect (95% CI)": "2 more per 1,000 (from 62 fewer to 90 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "345b5313", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor", "outcome": "Radiographic progression (follow up: 2 years; assessed with: mTSS (Lower values – > benefit) (MCID 4.6)", "importance": "CRITICAL", "related_paper_list": ["eafc116f"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"TNF inhibitor": "177", "MTX monotherapy": "169"}, "Annotation": {"data": "1. TNFi includes ETN or ADA.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 1.9 lower (3.19 lower to 0.61 lower)(The study PREMIER found that the RR of developing no radiographic progression (change in mTSS ≤0.5) was 1.33 (95%CI 1.07 to 1.65), absolute risk increase 112 more per 1000 (95%CI 24 more to 220 more).)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "3b74d64c", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor", "outcome": "Disability (follow up: range 1 year to 2 years; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22)", "importance": "IMPORTANT", "related_paper_list": ["2140c6ee", "1059324c"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"TNF inhibitor": "481", "MTX monotherapy": "474"}, "Annotation": {"data": "1. TNFi includes ETN or ADA.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.01 higher (0.07 lower to 0.1 higher)(The study PREMIER found that the RR of improvement in HAQ-DI (≥0.22 change from baseline) was 0.92 (95%CI 0.80 to 1.06), absolute risk reduction 50 fewer per 1000 (95%CI 126 fewer to 38 more).)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "ae9a4b36", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor", "outcome": "Fatigue (follow up: 2 years; assessed with: FACIT-F (Higher values – > benefit) (MCID 15.9)", "importance": "IMPORTANT", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"TNF inhibitor": "272", "MTX monotherapy": "254"}, "Annotation": {"data": "1. TNFi includes ETN or ADA.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 1.7 lower (3.09 lower to 0.31 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "f49da68c", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor", "outcome": "Pain (follow up: 2 years; assessed with: VAS 0-100 (Lower values – > benefit) (MCID -11.9)", "importance": "IMPORTANT", "related_paper_list": ["c45ae481"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"TNF inhibitor": "273", "MTX monotherapy": "256"}, "Annotation": {"data": "1. TNFi includes ETN or ADA.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 7.1 higher (4.34 higher to 9.86 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "9ab1e8d5", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor", "outcome": "Quality of life (follow up: range 1 year to 2 years; assessed with: SF-36 PCS (Higher values – > benefit) (MCID 4.4)", "importance": "IMPORTANT", "related_paper_list": ["1059324c", "c45ae481"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious inconsistency. I2=67%. Question whether heterogeneity might be related to the use of different TNFis."}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"TNF inhibitor": "471", "MTX monotherapy": "464"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.56 lower (1.73 lower to 0.6 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "defd362f", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor", "outcome": "Quality of life (follow up: range 1 year to 2 years; assessed with: SF-36 MCS (Higher values – > benefit) (MCID 3.1)", "importance": "IMPORTANT", "related_paper_list": ["1059324c", "c45ae481"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": "Indication of serious inconsistency I2=59% (taken into consideration when downgrading for imprecision). Question whether heterogeneity might be related to the use of different TNFis."}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"TNF inhibitor": "471", "MTX monotherapy": "464"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 1.98 lower (3.18 lower to 0.78 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "869465c1", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor", "outcome": "Serious adverse events (follow up: 2 years)", "importance": "IMPORTANT", "related_paper_list": ["2140c6ee"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"TNF inhibitor": "92/274 (33.6%)", "MTX monotherapy": "68/257 (26.5%)"}, "Annotation": {"data": "1. TNFi includes ETN or ADA.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.27 (0.98 to 1.65)", "Absolute Effect (95% CI)": "71 more per 1,000 (from 5 fewer to 172 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "b063c26d", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor", "outcome": "Withdrawal due to lack of efficacy (2 years)", "importance": "IMPORTANT", "related_paper_list": ["eafc116f", "2140c6ee"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"TNF inhibitor": "68/481 (14.1%)", "MTX monotherapy": "69/474 (14.6%)"}, "Annotation": {"data": "1. TNFi includes ETN or ADA.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.95 (0.70 to 1.30)", "Absolute Effect (95% CI)": "7 fewer per 1,000 (from 44 fewer to 44 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "0980d01d", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor", "outcome": "Withdrawal due to adverse events (follow up: 2 years)", "importance": "IMPORTANT", "related_paper_list": ["eafc116f", "2140c6ee"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious inconsistency. Unexplained heterogeneity I2=72%."}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"TNF inhibitor": "41/481 (8.5%)", "MTX monotherapy": "46/474 (9.7%)"}, "Annotation": {"data": "1. TNFi includes ETN or ADA.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.88 (0.59 to 1.32)", "Absolute Effect (95% CI)": "12 fewer per 1,000 (from 40 fewer to 31 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "d86e16a1", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor", "outcome": "Death (follow up: 2 years)", "importance": "IMPORTANT", "related_paper_list": ["2140c6ee"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm. Low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"TNF inhibitor": "4/274 (1.5%)", "MTX monotherapy": "1/257 (0.4%)"}, "Annotation": {"data": "1. TNFi includes ETN or ADA.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 3.75 (0.42 to 33.35)", "Absolute Effect (95% CI)": "11 more per 1,000 (from 2 fewer to 126 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "272a05dc", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor", "outcome": "Malignancy (follow up: 2 years)", "importance": "IMPORTANT", "related_paper_list": ["eafc116f", "2140c6ee"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm. Low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"TNF inhibitor": "8/481 (1.7%)", "MTX monotherapy": "7/474 (1.5%)"}, "Annotation": {"data": "1. TNFi includes ETN or ADA.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.13 (0.41 to 3.08)", "Absolute Effect (95% CI)": "2 more per 1,000 (from 9 fewer to 31 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "8c6d7bdd", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor", "outcome": "Malignancy (from SRs on harms)", "related_paper_list": ["2bf70fbf"], "assessment_results": {"GRADE": {"result_interpretation": "The systematic review RefID=3394, 2014 (RCTs=28, n=11741) comparing any TNFi vs placebo + MTX among RA showed that for cancer, the result was OR=1.30 (95% CI 0.80,2.14 Modified ITT model) [OR=1.06 (95% CI 0.64,1.75; p=0.82) Per protocol model]", "Study design": "Systematic Review"}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "400b7c86", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor", "outcome": "Cardiovascular disease (from SRs on harms)", "related_paper_list": ["542001cd"], "assessment_results": {"GRADE": {"result_interpretation": "The systematic review RefID=1105, 2017 (NRS=7, n=49003) comparing any TNFi vs csDMARDs among RA showed that for Cardiovascular disease, the result was RR = 0.62 (95% CI 0.44–0.88), p=0.007", "Study design": "Systematic Review"}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "0cb89835", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor", "outcome": "Death (from SRs on harms)", "related_paper_list": ["542001cd"], "assessment_results": {"GRADE": {"result_interpretation": "The systematic review RefID=1105, 2017 (NRS=5, n=41579) comparing any TNFi vs csDMARD among RA showed that for Death, the result was RR = 0.60 (95% CI 0.38–0.94), p=0.03", "Study design": "Systematic Review"}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "c332fbab", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept", "outcome": "Remission (follow up: 1 year; assessed with: DAS28 - CRP < 2.6)", "importance": "CRITICAL", "related_paper_list": ["2a7a858b"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"ABA": "48/113 (42.5%)", "MTX monotherapy": "52/115 (45.2%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.94 (0.70 to 1.26)", "Absolute Effect (95% CI)": "27 fewer per 1,000 (from 136 fewer to 118 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "4aebaaf2", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept", "outcome": "Disability (follow up: 1 year; assessed with: HAQ - DI ≥ 0.3)", "importance": "IMPORTANT", "related_paper_list": ["2a7a858b"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"ABA": "61/113 (54.0%)", "MTX monotherapy": "51/115 (44.3%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.22 (0.93 to 1.59)", "Absolute Effect (95% CI)": "98 more per 1,000 (from 31 fewer to 262 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "25ad7b5e", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept", "outcome": "Serious adverse events (1 year)", "importance": "IMPORTANT", "related_paper_list": ["2a7a858b"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"ABA": "14/116 (12.1%)", "MTX monotherapy": "9/116 (7.8%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.56 (0.70 to 3.45)", "Absolute Effect (95% CI)": "43 more per 1,000 (from 23 fewer to 190 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "a6610de9", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept", "outcome": "Withdrawal due to adverse events (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["2a7a858b"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"ABA": "8/116 (6.9%)", "MTX monotherapy": "5/116 (4.3%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.60 (0.54 to 4.75)", "Absolute Effect (95% CI)": "26 more per 1,000 (from 20 fewer to 162 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "e24b57d2", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept", "outcome": "Withdrawal due to lack of efficacy (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["2a7a858b"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"ABA": "6/116 (5.2%)", "MTX monotherapy": "11/116 (9.5%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.55 (0.21 to 1.43)", "Absolute Effect (95% CI)": "43 fewer per 1,000 (from 75 fewer to 41 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "614a8019", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept", "outcome": "Death (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["2a7a858b"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Small sample size and very low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"ABA": "0/116 (0.0%)", "MTX monotherapy": "0/116 (0.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "not estimable", "Absolute Effect (95% CI)": "", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "0957c585", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept", "outcome": "Malignancy (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["2a7a858b"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Small sample size and very low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"ABA": "2/116 (1.7%)", "MTX monotherapy": "1/116 (0.9%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 2.00 (0.18 to 21.75)", "Absolute Effect (95% CI)": "9 more per 1,000 (from 7 fewer to 179 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "3f5df505", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept", "outcome": "Malignancy (from SR of harms) ABA vs MTX", "related_paper_list": ["1fbf0f4e"], "assessment_results": {"GRADE": {"result_interpretation": "The Systematic Review RefID=1220, 2017 (RCTs=4, n=Not provided) comparing Abatacept vs Placebo + csDMARD among RA and showed that for Cancer, the result was Peto OR=1.12 (0.33, 3.81)", "Study design": "Systematic Review"}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "7c3df3e3", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor", "outcome": "Disease activity (follow up: 1 year; assessed with: ACR 20)", "importance": "CRITICAL", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population exposed to non-MTX csDMARDs."}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"IL-6i": "184/292 (63.0%)", "MTX monotherapy": "164/287 (57.1%)"}, "Annotation": {"data": "1. IL-6i includes TCZ.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.10 (0.97 to 1.26)", "Absolute Effect (95% CI)": "57 more per 1,000 (from 17 fewer to 149 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "17214cb9", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor", "outcome": "Disease activity (follow up: 1 year; assessed with: ACR 50)", "importance": "CRITICAL", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population exposed to non-MTX csDMARDs."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"IL-6i": "145/292 (49.7%)", "MTX monotherapy": "117/287 (40.8%)"}, "Annotation": {"data": "1. IL-6i includes TCZ.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.22 (1.02 to 1.46)", "Absolute Effect (95% CI)": "90 more per 1,000 (from 8 more to 188 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "09a28767", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor", "outcome": "Disease activity (follow up: 1 year; assessed with: ACR 70)", "importance": "CRITICAL", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population exposed to non-MTX csDMARDs."}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"IL-6i": "107/292 (36.6%)", "MTX monotherapy": "84/287 (29.3%)"}, "Annotation": {"data": "1. IL-6i includes TCZ.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.25 (0.99 to 1.58)", "Absolute Effect (95% CI)": "73 more per 1,000 (from 3 fewer to 170 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "58091cc4", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor", "outcome": "Disease activity (follow up: 1 year; assessed with: DAS28-ESR (Lower values –> benefit) (MCID -1.17)", "importance": "CRITICAL", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population exposed to non-MTX csDMARDs."}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"IL-6i": "292", "MTX monotherapy": "287"}, "Annotation": {"data": "1. IL-6i includes TCZ.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.96 lower (1.24 lower to 0.68 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "d6891f4f", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor", "outcome": "Remission (follow up: 1 year; assessed with: DAS28-ESR <2.6)", "importance": "CRITICAL", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population exposed to non-MTX csDMARDs."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"IL-6i": "115/292 (39.4%)", "MTX monotherapy": "56/287 (19.5%)"}, "Annotation": {"data": "1. IL-6i includes TCZ.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 2.02 (1.53 to 2.66)", "Absolute Effect (95% CI)": "199 more per 1,000 (from 103 more to 324 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "f1a9ad8a", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor", "outcome": "Radiographic progression (follow up: 1 year; assessed with: mTSS (Lower values –> benefit) (MCID 4.6)", "importance": "IMPORTANT", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population exposed to non-MTX csDMARDs."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"IL-6i": "275", "MTX monotherapy": "267"}, "Annotation": {"data": "1. IL-6i includes TCZ.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.88 lower (1.44 lower to 0.32 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "6e6642b7", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor", "outcome": "Disability (follow up: 1 year; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22)", "importance": "IMPORTANT", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population exposed to non-MTX csDMARDs."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"IL-6i": "0", "MTX monotherapy": "0"}, "Annotation": {"data": "1. IL-6i includes TCZ.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.03 lower (0.15 lower to 0.09 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "059a6185", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor", "outcome": "Quality of life (follow up: 1 year; assessed with: SF-36 PCS (Higher values – > benefit) (MCID 4.4)", "importance": "IMPORTANT", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population exposed to non-MTX csDMARDs."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"IL-6i": "0", "MTX monotherapy": "0"}, "Annotation": {"data": "1. IL-6i includes TCZ.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.14 higher (0.13 lower to 0.41 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "650473d6", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor", "outcome": "Quality of life (1 year) (follow up: 1 year; assessed with: SF-36 MCS (Higher values – > benefit) (MCID 3.1)", "importance": "IMPORTANT", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population exposed to non-MTX csDMARDs."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"IL-6i": "0", "MTX monotherapy": "0"}, "Annotation": {"data": "1. IL-6i includes TCZ.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.34 higher (0.68 lower to 1.36 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "10e6160f", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor", "outcome": "Serious adverse events (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population exposed to non-MTX csDMARDs."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"IL-6i": "25/292(8.6%)", "MTX monotherapy": "24/282 (8.5%)"}, "Annotation": {"data": "1. IL-6i includes TCZ.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.01 (0.59 to 1.72)", "Absolute Effect (95% CI)": "1 more per 1,000 (from 35 fewer to 61 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "2290dc10", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor", "outcome": "Withdrawal due to lack of efficacy (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population exposed to non-MTX csDMARDs."}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"IL-6i": "34/292(11.6%)", "MTX monotherapy": "21/282 (7.4%)"}, "Annotation": {"data": "1. IL-6i includes TCZ.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.56 (0.93 to 2.63)", "Absolute Effect (95% CI)": "42 more per 1,000 (from 5 fewer to 121 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "1d58748f", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor", "outcome": "Death (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population exposed to non-MTX csDMARDs."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"IL-6i": "1/292 (0.3%)", "MTX monotherapy": "2/282 (0.7%)"}, "Annotation": {"data": "1. IL-6i includes TCZ.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.48 (0.04 to 5.30)", "Absolute Effect (95% CI)": "4 fewer per 1,000 (from 7 fewer to 30 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "21e8f78c", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor", "outcome": "Malignancy (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population exposed to non-MTX csDMARDs."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"IL-6i": "2/292 (0.7%)", "MTX monotherapy": "3/282 (1.1%)"}, "Annotation": {"data": "1. IL-6i includes TCZ.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.64 (0.11 to 3.82)", "Absolute Effect (95% CI)": "4 fewer per 1,000 (from 9 fewer to 30 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "a714a4cc", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor", "outcome": "Myocardial infarction (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population exposed to non-MTX csDMARDs."}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"IL-6i": "1/292 (0.3%)", "MTX monotherapy": "0/282 (0.0%)"}, "Annotation": {"data": "1. IL-6i includes TCZ.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 2.90 (0.12 to 70.83)", "Absolute Effect (95% CI)": "0 fewer per 1,000 (from 0 fewer to 0 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "db42a57d", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor", "outcome": "Malignancy (from SRs of harms)", "related_paper_list": ["45b0286b"], "assessment_results": {"GRADE": {"result_interpretation": "The Systematic Review RefID=4638, 2012 (RCTs=1, n=302) comparing IL-6 Receptor Inhibitors vs Placebo + MTX among RA showed that for Cancer, the result was RR=6.5 (0.34-124.2) at 1 year and RR=0.33 (0.01-8.0) at 6 months (RCTs=2, n=697 at 6 months)", "Study design": "Systematic Review"}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "ba620d56", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor", "outcome": "Serious adverse events (from SRs of harms)", "related_paper_list": ["f1b7a867"], "assessment_results": {"GRADE": {"result_interpretation": "The systematic review RefID=18, 2018 (RCTs=2, n=785) comparing IL-6 inhibitors vs MTX among TCZ naïve RA patients showed that for serious adverse events, the result was RR=2.57 (95% 0.61-10.93, p=0.2).", "Study design": "Systematic Review"}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "6b386898", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "JAK Inhibitor", "outcome": "Disease activity (follow up: 2 years; assessed with: ACR 20)", "importance": "CRITICAL", "related_paper_list": ["456cb129"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population exposed to non-MTX csDMARDs."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"JAKi (Tofa)": "239/373 (64.1%)", "MTX monotherapy": "79/186 (42.5%)"}, "Annotation": {"data": "1. JAKi include TOFA.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.51 (1.26 to 1.81)", "Absolute Effect (95% CI)": "217 more per 1,000 (from 110 more to 344 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "1860a726", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "JAK Inhibitor", "outcome": "Disease activity (follow up: 2 years; assessed with: ACR 50)", "importance": "CRITICAL", "related_paper_list": ["456cb129"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population exposed to non-MTX csDMARDs."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"JAKi (Tofa)": "184/373 (49.3%)", "MTX monotherapy": "53/186 (28.5%)"}, "Annotation": {"data": "1. JAKi include TOFA.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.73 (1.35 to 2.22)", "Absolute Effect (95% CI)": "208 more per 1,000 (from 100 more to 348 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "02bba0b7", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "JAK Inhibitor", "outcome": "Disease activity (follow up: 2 years; assessed with: ACR 70)", "importance": "CRITICAL", "related_paper_list": ["456cb129"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population exposed to non-MTX csDMARDs."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"JAKi (Tofa)": "128/373 (34.3%)", "MTX monotherapy": "28/186 (15.1%)"}, "Annotation": {"data": "1. JAKi include TOFA.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 2.28 (1.58 to 3.30)", "Absolute Effect (95% CI)": "193 more per 1,000 (from 87 more to 346 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "abe32804", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "JAK Inhibitor", "outcome": "Disease activity (follow up: 2 years; assessed with: DAS28-ESR (Lower values – > benefit) (MCID -1.17)", "importance": "CRITICAL", "related_paper_list": ["456cb129"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population exposed to non-MTX csDMARDs."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"JAKi (Tofa)": "373", "MTX monotherapy": "186"}, "Annotation": {"data": "1. JAKi include TOFA.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.6 lower (0.88 lower to 0.32 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "94bcfcc0", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "JAK Inhibitor", "outcome": "Remission (follow up: 2 years; assessed with: DAS28-ESR < 2.6)", "importance": "CRITICAL", "related_paper_list": ["456cb129"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population exposed to non-MTX csDMARDs."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"JAKi (Tofa)": "78/373 (20.9%)", "MTX monotherapy": "18/186 (9.7%)"}, "Annotation": {"data": "1. JAKi include TOFA.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 2.16 (1.34 to 3.50)", "Absolute Effect (95% CI)": "112 more per 1,000 (from 33 more to 242 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "c361348f", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "JAK Inhibitor", "outcome": "Radiographic progression (follow up: 2 years; assessed with: mTSS (Lower values – > benefit) (MCID 4.6)", "importance": "IMPORTANT", "related_paper_list": ["456cb129"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population exposed to non-MTX csDMARDs."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"JAKi (Tofa)": "373", "MTX monotherapy": "186"}, "Annotation": {"data": "1. JAKi include TOFA.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 1.53 lower (2.36 lower to 0.7 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "f2498391", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "JAK Inhibitor", "outcome": "Disability (follow up: 2 years; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22)", "importance": "IMPORTANT", "related_paper_list": ["456cb129"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population exposed to non-MTX csDMARDs."}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting no effect."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"JAKi (Tofa)": "373", "MTX monotherapy": "186"}, "Annotation": {"data": "1. JAKi include TOFA.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.2 lower (0.31 lower to 0.09 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "13c12062", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "JAK Inhibitor", "outcome": "Serious adverse events (follow up: 2 years)", "importance": "IMPORTANT", "related_paper_list": ["456cb129"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population exposed to non-MTX csDMARDs."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"JAKi (Tofa)": "40/373 (10.7%)", "MTX monotherapy": "22/186 (11.8%)"}, "Annotation": {"data": "1. JAKi include TOFA.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.91 (0.56 to 1.48)", "Absolute Effect (95% CI)": "11 fewer per 1,000 (from 52 fewer to 57 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "dbbc5f4a", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "JAK Inhibitor", "outcome": "Withdrawal due to adverse events (follow up: 2 years)", "importance": "IMPORTANT", "related_paper_list": ["456cb129"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population exposed to non-MTX csDMARDs."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"JAKi (Tofa)": "40/373 (10.7%)", "MTX monotherapy": "25/186 (13.4%)"}, "Annotation": {"data": "1. JAKi include TOFA.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.80 (0.50 to 1.27)", "Absolute Effect (95% CI)": "27 fewer per 1,000 (from 67 fewer to 36 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "878f85eb", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "JAK Inhibitor", "outcome": "Death (follow up: 2 years)", "importance": "IMPORTANT", "related_paper_list": ["456cb129"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population exposed to non-MTX csDMARDs."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Very low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"JAKi (Tofa)": "3/373 (0.8%)", "MTX monotherapy": "0/186 (0.0%)"}, "Annotation": {"data": "1. JAKi include TOFA.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 3.50 (0.18 to 67.41)", "Absolute Effect (95% CI)": "0 fewer per 1,000 (from 0 fewer to 0 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "4c2b6f5b", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "JAK Inhibitor", "outcome": "Malignancy (follow up: 2 years)", "importance": "IMPORTANT", "related_paper_list": ["456cb129"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population exposed to non-MTX csDMARDs."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting no effect."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"JAKi (Tofa)": "2/373 (0.5%)", "MTX monotherapy": "1/186 (0.5%)"}, "Annotation": {"data": "1. JAKi include TOFA.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.00 (0.09 to 10.93)", "Absolute Effect (95% CI)": "0 fewer per 1,000 (from 5 fewer to 53 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "8e1a9bd9", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "JAK Inhibitor", "outcome": "Malignancy (from SRs on harms)", "related_paper_list": ["1fbf0f4e"], "assessment_results": {"GRADE": {"result_interpretation": "The systematic review RefID=1220, 2017 (RCTs=3) comparing tofacitinib 5mg vs placebo + csDMARD among RA showed that for cancer, the result was Peto OR=2.39 (0.50, 11.50)", "Study design": "Systematic Review"}}, "PICO_IDX": "5a", "Database": "2021 ACR RA"}
{"outcome_uid": "9b96b387", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor", "outcome": "Disease activity (follow up: 2 years; assessed with: ACR 20 )", "importance": "CRITICAL", "related_paper_list": ["eafc116f", "2140c6ee"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious inconsistency. Unexplained heterogeneity I2=65%."}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"TNFi": "207/467 (44.3%)", "MTX monotherapy": "205/459 (44.7%)"}, "Annotation": {"data": "1. TNFi includes ETN or ADA.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.99 (0.86 to 1.15)", "Absolute Effect (95% CI)": "4 fewer per 1,000 (from 63 fewer to 67 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "935c1d75", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor", "outcome": "Disease activity (follow up: 2 years; assessed with: ACR 50)", "importance": "CRITICAL", "related_paper_list": ["eafc116f", "2140c6ee"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious inconsistency. Unexplained heterogeneity I2=75%."}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"TNFi": "188/451 (41.7%)", "MTX monotherapy": "182/426 (42.7%)"}, "Annotation": {"data": "1. TNFi includes ETN or ADA.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.98 (0.84 to 1.14)", "Absolute Effect (95% CI)": "9 fewer per 1,000 (from 68 fewer to 60 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "671a18dc", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor", "outcome": "Disease activity (follow up: 2 years; assessed with: ACR 70)", "importance": "CRITICAL", "related_paper_list": ["eafc116f", "2140c6ee"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"TNFi": "128/451 (28.4%)", "MTX monotherapy": "113/426 (26.5%)"}, "Annotation": {"data": "1. TNFi includes ETN or ADA.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.07 (0.86 to 1.33)", "Absolute Effect (95% CI)": "19 more per 1,000 (from 37 fewer to 88 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "a8897d6e", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor", "outcome": "Remission (follow up: 2 years; assessed with: DAS28-ESR <2.6)", "importance": "CRITICAL", "related_paper_list": ["2140c6ee"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"TNFi": "69/274 (25.2%)", "MTX monotherapy": "64/257 (24.9%)"}, "Annotation": {"data": "1. TNFi includes ETN or ADA.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.01 (0.75 to 1.36)", "Absolute Effect (95% CI)": "2 more per 1,000 (from 62 fewer to 90 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "8f52efc9", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor", "outcome": "Radiographic progression (follow up: 2 years; assessed with: mTSS (Lower values – > benefit) (MCID 4.6)", "importance": "IMPORTANT", "related_paper_list": ["eafc116f"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"TNFi": "177", "MTX monotherapy": "169"}, "Annotation": {"data": "1. TNFi includes ETN or ADA.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 1.9 lower (3.19 lower to 0.61 lower)(The study PREMIER found that the RR of developing no radiographic progression (change in mTSS ≤0.5) was 1.33 (95%CI 1.07 to 1.65), absolute risk increase 112 more per 1000 (95%CI 24 more to 220 more).)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "e1eeb0a4", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor", "outcome": "Disability (follow up: range 1 year to 2 years; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22)", "importance": "IMPORTANT", "related_paper_list": ["2140c6ee", "1059324c"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"TNFi": "481", "MTX monotherapy": "474"}, "Annotation": {"data": "1. TNFi includes ETN or ADA.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.01 higher (0.07 lower to 0.1 higher)(The study PREMIER found that the RR of improvement in HAQ-DI (≥0.22 change from baseline) was 0.92 (95%CI 0.80 to 1.06), absolute risk reduction 50 fewer per 1000 (95%CI 126 fewer to 38 more).)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "b3d7016c", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor", "outcome": "Fatigue (follow up: 2 years; assessed with: FACIT-F (Higher values – > benefit) (MCID 15.9)", "importance": "IMPORTANT", "related_paper_list": ["c45ae481"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"TNFi": "272", "MTX monotherapy": "254"}, "Annotation": {"data": "1. TNFi includes ETN or ADA.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 1.7 lower (3.09 lower to 0.31 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "c3ab3d50", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor", "outcome": "Pain (follow up: 2 years; assessed with: VAS 0-100 (Lower values – > benefit) (MCID -11.9)", "importance": "IMPORTANT", "related_paper_list": ["c45ae481"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"TNFi": "273", "MTX monotherapy": "256"}, "Annotation": {"data": "1. TNFi includes ETN or ADA.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 7.1 higher (4.34 higher to 9.86 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "32d3d419", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor", "outcome": "Quality of life (follow up: range 1 year to 2 years; assessed with: SF-36 PCS (Higher values – > benefit) (MCID 4.4)", "importance": "IMPORTANT", "related_paper_list": ["1059324c", "c45ae481"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious inconsistency. I2=67%. Question whether heterogeneity might be related to the use of different TNFis."}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"TNFi": "471", "MTX monotherapy": "464"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.56 lower (1.73 lower to 0.6 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "08b87e42", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor", "outcome": "Quality of life (follow up: range 1 year to 2 years; assessed with: SF-36 MCS (Higher values – > benefit) (MCID 3.1)", "importance": "IMPORTANT", "related_paper_list": ["1059324c", "c45ae481"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": "Indication of serious inconsistency I2=59% (taken into consideration when downgrading for imprecision). Question whether heterogeneity might be related to the use of different TNFis."}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"TNFi": "471", "MTX monotherapy": "464"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 1.98 lower (3.18 lower to 0.78 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "dd2c804f", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor", "outcome": "Serious adverse events (follow up: 2 years)", "importance": "IMPORTANT", "related_paper_list": ["2140c6ee"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"TNFi": "92/274 (33.6%)", "MTX monotherapy": "68/257 (26.5%)"}, "Annotation": {"data": "1. TNFi includes ETN or ADA.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.27 (0.98 to 1.65)", "Absolute Effect (95% CI)": "71 more per 1,000 (from 5 fewer to 172 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "7097b643", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor", "outcome": "Withdrawal due to lack of efficacy (2 years)", "importance": "IMPORTANT", "related_paper_list": ["eafc116f", "2140c6ee"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"TNFi": "68/481 (14.1%)", "MTX monotherapy": "69/474 (14.6%)"}, "Annotation": {"data": "1. TNFi includes ETN or ADA.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.95 (0.70 to 1.30)", "Absolute Effect (95% CI)": "7 fewer per 1,000 (from 44 fewer to 44 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "379466a0", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor", "outcome": "Withdrawal due to adverse events (follow up: 2 years)", "importance": "IMPORTANT", "related_paper_list": ["eafc116f", "2140c6ee"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious inconsistency. Unexplained heterogeneity I2=72%."}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"TNFi": "41/481 (8.5%)", "MTX monotherapy": "46/474 (9.7%)"}, "Annotation": {"data": "1. TNFi includes ETN or ADA.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.88 (0.59 to 1.32)", "Absolute Effect (95% CI)": "12 fewer per 1,000 (from 40 fewer to 31 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "461e0a1b", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor", "outcome": "Death (follow up: 2 years)", "importance": "IMPORTANT", "related_paper_list": ["2140c6ee"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm. Low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"TNFi": "4/274 (1.5%)", "MTX monotherapy": "1/257 (0.4%)"}, "Annotation": {"data": "1. TNFi includes ETN or ADA.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 3.75 (0.42 to 33.35)", "Absolute Effect (95% CI)": "11 more per 1,000 (from 2 fewer to 126 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "63042a49", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor", "outcome": "Malignancy (follow up: 2 years)", "importance": "IMPORTANT", "related_paper_list": ["eafc116f", "2140c6ee"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm. Low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"TNFi": "8/481 (1.7%)", "MTX monotherapy": "7/474 (1.5%)"}, "Annotation": {"data": "1. TNFi includes ETN or ADA.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.13 (0.41 to 3.08)", "Absolute Effect (95% CI)": "2 more per 1,000 (from 9 fewer to 31 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "63181cbf", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor", "outcome": "Malignancy (from SRs on harms)", "related_paper_list": ["2bf70fbf"], "assessment_results": {"GRADE": {"result_interpretation": "The systematic review RefID=3394, 2014 (RCTs=28, n=11741) comparing any TNFi vs placebo + MTX among RA showed that for cancer, the result was OR=1.30 (95% CI 0.80,2.14 Modified ITT model) [OR=1.06 (95% CI 0.64,1.75; p=0.82) Per protocol model]", "Study design": "Systematic Review"}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "0b489433", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor", "outcome": "Cardiovascular disease (from SRs on harms)", "related_paper_list": ["542001cd"], "assessment_results": {"GRADE": {"result_interpretation": "The systematic review RefID=1105, 2017 (NRS=7, n=49003) comparing any TNFi vs csDMARDs among RA showed that for Cardiovascular disease, the result was RR = 0.62 (95% CI 0.44–0.88), p=0.007", "Study design": "Systematic Review"}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "8cad3342", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor", "outcome": "Death (from SRs on harms)", "related_paper_list": ["542001cd"], "assessment_results": {"GRADE": {"result_interpretation": "The systematic review RefID=1105, 2017 (NRS=5, n=41579) comparing any TNFi vs csDMARD among RA showed that for Death, the result was RR = 0.60 (95% CI 0.38–0.94), p=0.03", "Study design": "Systematic Review"}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "93fd0ee1", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept", "outcome": "Remission (follow up: 1 year; assessed with: DAS28-CRP < 2.6)", "importance": "CRITICAL", "related_paper_list": ["2a7a858b"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population naive to non-MTX csDMARDs."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"ABA": "48/113 (42.5%)", "MTX monotherapy": "52/115 (45.2%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.94 (0.70 to 1.26)", "Absolute Effect (95% CI)": "27 fewer per 1,000 (from 136 fewer to 118 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "de523343", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept", "outcome": "Disability (follow up: 1 year; assessed with: HAQ-DI (≥ 0.3)", "importance": "IMPORTANT", "related_paper_list": ["2a7a858b"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population naive to non-MTX csDMARDs."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"ABA": "61/113 (54.0%)", "MTX monotherapy": "51/115 (44.3%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.22 (0.93 to 1.59)", "Absolute Effect (95% CI)": "98 more per 1,000 (from 31 fewer to 262 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "54b32c64", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept", "outcome": "Serious adverse events (1 year)", "importance": "IMPORTANT", "related_paper_list": ["2a7a858b"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population naive to non-MTX csDMARDs."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"ABA": "14/116 (12.1%)", "MTX monotherapy": "9/116 (7.8%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.56 (0.70 to 3.45)", "Absolute Effect (95% CI)": "43 more per 1,000 (from 23 fewer to 190 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "39300870", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept", "outcome": "Withdrawal due to adverse events (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["2a7a858b"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population naive to non-MTX csDMARDs."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"ABA": "8/116 (6.9%)", "MTX monotherapy": "5/116 (4.3%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.60 (0.54 to 4.75)", "Absolute Effect (95% CI)": "26 more per 1,000 (from 20 fewer to 162 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "7581ffb3", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept", "outcome": "Withdrawal due to lack of efficacy (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["2a7a858b"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population naive to non-MTX csDMARDs."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"ABA": "6/116 (5.2%)", "MTX monotherapy": "11/116 (9.5%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.55 (0.21 to 1.43)", "Absolute Effect (95% CI)": "43 fewer per 1,000 (from 75 fewer to 41 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "4a48604a", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept", "outcome": "Death (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["2a7a858b"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population naive to non-MTX csDMARDs."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Small sample size and very low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"ABA": "0/116 (0.0%)", "MTX monotherapy": "0/116 (0.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "not estimable", "Absolute Effect (95% CI)": "", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "6af1a356", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept", "outcome": "Malignancy (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["2a7a858b"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population naive to non-MTX csDMARDs."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Small sample size and very low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"ABA": "2/116 (1.7%)", "MTX monotherapy": "1/116 (0.9%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 2.00 (0.18 to 21.75)", "Absolute Effect (95% CI)": "9 more per 1,000 (from 7 fewer to 179 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "c15d269c", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept", "outcome": "Malignancy (from SR of harms) ABA vs MTX", "related_paper_list": ["1fbf0f4e"], "assessment_results": {"GRADE": {"result_interpretation": "The Systematic Review RefID=1220, 2017 (RCTs=4, n=Not provided) comparing Abatacept vs Placebo + csDMARD among RA and showed that for Cancer, the result was Peto OR=1.12 (0.33, 3.81)", "Study design": "Systematic Review"}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "978f9b5a", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor", "outcome": "Disease activity (follow up: 1 year; assessed with: ACR 20)", "importance": "CRITICAL", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"IL-6i": "184/292 (63.0%)", "MTX monotherapy": "164/287 (57.1%)"}, "Annotation": {"data": "1. IL-6i includes TCZ.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.10 (0.97 to 1.26)", "Absolute Effect (95% CI)": "57 more per 1,000 (from 17 fewer to 149 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "c5384399", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor", "outcome": "Disease activity (follow up: 1 year; assessed with: ACR 50)", "importance": "CRITICAL", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"IL-6i": "145/292 (49.7%)", "MTX monotherapy": "117/287 (40.8%)"}, "Annotation": {"data": "1. IL-6i includes TCZ.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.22 (1.02 to 1.46)", "Absolute Effect (95% CI)": "90 more per 1,000 (from 8 more to 188 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "23241d45", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor", "outcome": "Disease activity (follow up: 1 year; assessed with: ACR 70)", "importance": "CRITICAL", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"IL-6i": "107/292 (36.6%)", "MTX monotherapy": "84/287 (29.3%)"}, "Annotation": {"data": "1. IL-6i includes TCZ.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.25 (0.99 to 1.58)", "Absolute Effect (95% CI)": "73 more per 1,000 (from 3 fewer to 170 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "f2baae3f", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor", "outcome": "Disease activity (follow up: 1 year; assessed with: DAS28-ESR (Lower values –> benefit) (MCID -1.17)", "importance": "CRITICAL", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"IL-6i": "292", "MTX monotherapy": "287"}, "Annotation": {"data": "1. IL-6i includes TCZ.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.96 lower (1.24 lower to 0.68 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "13226085", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor", "outcome": "Remission (follow up: 1 year; assessed with: DAS28-ESR <2.6)", "importance": "CRITICAL", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"IL-6i": "115/292 (39.4%)", "MTX monotherapy": "56/287 (19.5%)"}, "Annotation": {"data": "1. IL-6i includes TCZ.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 2.02 (1.53 to 2.66)", "Absolute Effect (95% CI)": "199 more per 1,000 (from 103 more to 324 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "7d15eac4", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor", "outcome": "Radiographic progression (follow up: 1 year; assessed with: mTSS (Lower values –> benefit) (MCID 4.6)", "importance": "IMPORTANT", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"IL-6i": "275", "MTX monotherapy": "267"}, "Annotation": {"data": "1. IL-6i includes TCZ.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.88 lower (1.44 lower to 0.32 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "5c19dbf2", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor", "outcome": "Disability (follow up: 1 year; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22)", "importance": "IMPORTANT", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"IL-6i": "0", "MTX monotherapy": "0"}, "Annotation": {"data": "1. IL-6i includes TCZ.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.03 lower (0.15 lower to 0.09 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "c416aa22", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor", "outcome": "Quality of life (follow up: 1 year; assessed with: SF-36 PCS (Higher values – > benefit) (MCID 4.4)", "importance": "IMPORTANT", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"IL-6i": "0", "MTX monotherapy": "0"}, "Annotation": {"data": "1. IL-6i includes TCZ.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.14 higher (0.13 lower to 0.41 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "74814e2c", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor", "outcome": "Quality of life (1 year) (follow up: 1 year; assessed with: SF-36 MCS (Higher values – > benefit) (MCID 3.1)", "importance": "IMPORTANT", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"IL-6i": "0", "MTX monotherapy": "0"}, "Annotation": {"data": "1. IL-6i includes TCZ.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.34 higher (0.68 lower to 1.36 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "ed3c8053", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor", "outcome": "Serious adverse events (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"IL-6i": "25/292 (8.6%)", "MTX monotherapy": "24/282 (8.5%)"}, "Annotation": {"data": "1. IL-6i includes TCZ.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.01 (0.59 to 1.72)", "Absolute Effect (95% CI)": "1 more per 1,000 (from 35 fewer to 61 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "be2bc5ad", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor", "outcome": "Withdrawal due to lack of efficacy (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"IL-6i": "34/292 (11.6%)", "MTX monotherapy": "21/282 (7.4%)"}, "Annotation": {"data": "1. IL-6i includes TCZ.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.56 (0.93 to 2.63)", "Absolute Effect (95% CI)": "42 more per 1,000 (from 5 fewer to 121 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "f40ae914", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor", "outcome": "Death (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"IL-6i": "1/292 (0.3%)", "MTX monotherapy": "2/282 (0.7%)"}, "Annotation": {"data": "1. IL-6i includes TCZ.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.48 (0.04 to 5.30)", "Absolute Effect (95% CI)": "4 fewer per 1,000 (from 7 fewer to 30 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "42e55334", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor", "outcome": "Malignancy (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"IL-6i": "2/292 (0.7%)", "MTX monotherapy": "3/282 (1.1%)"}, "Annotation": {"data": "1. IL-6i includes TCZ.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.64 (0.11 to 3.82)", "Absolute Effect (95% CI)": "4 fewer per 1,000 (from 9 fewer to 30 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "3b992469", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor", "outcome": "Myocardial infarction (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"IL-6i": "1/292 (0.3%)", "MTX monotherapy": "0/282 (0.0%)"}, "Annotation": {"data": "1. IL-6i includes TCZ.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 2.90 (0.12 to 70.83)", "Absolute Effect (95% CI)": "0 fewer per 1,000 (from 0 fewer to 0 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "6b0921f5", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor", "outcome": "Malignancy (from SRs of harms)", "related_paper_list": ["1fbf0f4e"], "assessment_results": {"GRADE": {"result_interpretation": "The Systematic Review RefID=1220, 2017 (RCTs=4) comparing abatacept vs placebo +csDMARD among RA showed that for cancer, the result was OR=1.12 (0.33, 3.81).", "Study design": "Systematic Review"}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "2a2685cc", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor", "outcome": "Serious adverse events (from SRs of harms)", "related_paper_list": ["f1b7a867"], "assessment_results": {"GRADE": {"result_interpretation": "The systematic review RefID=18, 2018 (RCTs=2, n=785) comparing IL-6 inhibitors vs MTX among TCZ naïve RA patients showed that for serious adverse events, the result was RR=2.57 (95% 0.61-10.93, p=0.2).", "Study design": "Systematic Review"}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "d0826449", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "JAK Inhibitor", "outcome": "Disease activity (follow up: 2 years; assessed with: ACR 20)", "importance": "CRITICAL", "related_paper_list": ["456cb129"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"JAKi (Tofa)": "239/373 (64.1%)", "MTX monotherapy": "79/186 (42.5%)"}, "Annotation": {"data": "1. JAKi include TOFA.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.51 (1.26 to 1.81)", "Absolute Effect (95% CI)": "217 more per 1,000 (from 110 more to 344 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "3b4a5ff2", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "JAK Inhibitor", "outcome": "Disease activity (follow up: 2 years; assessed with: ACR 50)", "importance": "CRITICAL", "related_paper_list": ["456cb129"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"JAKi (Tofa)": "184/373 (49.3%)", "MTX monotherapy": "53/186 (28.5%)"}, "Annotation": {"data": "1. JAKi include TOFA.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.73 (1.35 to 2.22)", "Absolute Effect (95% CI)": "208 more per 1,000 (from 100 more to 348 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "f85da7e6", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "JAK Inhibitor", "outcome": "Disease activity (follow up: 2 years; assessed with: ACR 70)", "importance": "CRITICAL", "related_paper_list": ["456cb129"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"JAKi (Tofa)": "128/373 (34.3%)", "MTX monotherapy": "28/186 (15.1%)"}, "Annotation": {"data": "1. JAKi include TOFA.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 2.28 (1.58 to 3.30)", "Absolute Effect (95% CI)": "193 more per 1,000 (from 87 more to 346 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "bf9ea5bc", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "JAK Inhibitor", "outcome": "Disease activity (follow up: 2 years; assessed with: DAS28-ESR (Lower values – > benefit) (MCID -1.17)", "importance": "CRITICAL", "related_paper_list": ["456cb129"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"JAKi (Tofa)": "373", "MTX monotherapy": "186"}, "Annotation": {"data": "1. JAKi include TOFA.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.6 lower (0.88 lower to 0.32 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "117c0af9", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "JAK Inhibitor", "outcome": "Remission (follow up: 2 years; assessed with: DAS28-ESR < 2.6)", "importance": "CRITICAL", "related_paper_list": ["456cb129"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"JAKi (Tofa)": "78/373 (20.9%)", "MTX monotherapy": "18/186 (9.7%)"}, "Annotation": {"data": "1. JAKi include TOFA.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 2.16 (1.34 to 3.50)", "Absolute Effect (95% CI)": "112 more per 1,000 (from 33 more to 242 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "479e960f", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "JAK Inhibitor", "outcome": "Radiographic progression (follow up: 2 years; assessed with: mTSS (Lower values – > benefit) (MCID 4.6)", "importance": "IMPORTANT", "related_paper_list": ["456cb129"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"JAKi (Tofa)": "373", "MTX monotherapy": "186"}, "Annotation": {"data": "1. JAKi include TOFA.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 1.53 lower (2.36 lower to 0.7 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "2dfe1252", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "JAK Inhibitor", "outcome": "Disability (follow up: 2 years; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22)", "importance": "IMPORTANT", "related_paper_list": ["456cb129"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting no effect."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"JAKi (Tofa)": "373", "MTX monotherapy": "186"}, "Annotation": {"data": "1. JAKi include TOFA.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.2 lower (0.31 lower to 0.09 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "bbb009a1", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "JAK Inhibitor", "outcome": "Serious adverse events (follow up: 2 years)", "importance": "IMPORTANT", "related_paper_list": ["456cb129"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"JAKi (Tofa)": "40/373 (10.7%)", "MTX monotherapy": "22/186 (11.8%)"}, "Annotation": {"data": "1. JAKi include TOFA.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.91 (0.56 to 1.48)", "Absolute Effect (95% CI)": "11 fewer per 1,000 (from 52 fewer to 57 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "adf69a1e", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "JAK Inhibitor", "outcome": "Withdrawal due to adverse events (follow up: 2 years)", "importance": "IMPORTANT", "related_paper_list": ["456cb129"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"JAKi (Tofa)": "40/373 (10.7%)", "MTX monotherapy": "25/186 (13.4%)"}, "Annotation": {"data": "1. JAKi include TOFA.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.80 (0.50 to 1.27)", "Absolute Effect (95% CI)": "27 fewer per 1,000 (from 67 fewer to 36 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "979d5da5", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "JAK Inhibitor", "outcome": "Death (follow up: 2 years)", "importance": "IMPORTANT", "related_paper_list": ["456cb129"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Very low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"JAKi (Tofa)": "3/373 (0.8%)", "MTX monotherapy": "0/186 (0.0%)"}, "Annotation": {"data": "1. JAKi include TOFA.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 3.50 (0.18 to 67.41)", "Absolute Effect (95% CI)": "0 fewer per 1,000 (from 0 fewer to 0 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "06f3ff99", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "JAK Inhibitor", "outcome": "Malignancy (follow up: 2 years)", "importance": "IMPORTANT", "related_paper_list": ["456cb129"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting no effect."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"JAKi (Tofa)": "2/373 (0.5%)", "MTX monotherapy": "1/186 (0.5%)"}, "Annotation": {"data": "1. JAKi include TOFA.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.00 (0.09 to 10.93)", "Absolute Effect (95% CI)": "0 fewer per 1,000 (from 5 fewer to 53 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "9ae722e3", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "JAK Inhibitor", "outcome": "Malignancy (from SRs on harms)", "related_paper_list": ["1fbf0f4e"], "assessment_results": {"GRADE": {"result_interpretation": "The systematic review RefID=1220, 2017 (RCTs=3) comparing tofacitinib 5mg vs placebo + csDMARD among RA showed that for cancer, the result was Peto OR=2.39 (0.50, 11.50)", "Study design": "Systematic Review"}}, "PICO_IDX": "5b", "Database": "2021 ACR RA"}
{"outcome_uid": "6f3e2b8b", "clinical_question": "Should patients with RA on MTX + boDMARD or tsDMARD who are at target continue the boDMARD or tsDMARD at the same dose or lower the dose or increase the interval between doses of the boDMARD or tsDMARD (MTX continued at same dose)?", "population": "Patients with RA on MTX + boDMARD or tsDMARD who are at target", "intervention": "Continue the same dose of the boDMARD or tsDMARD", "comparator": "lower the dose of the boDMARD or tsDMARD", "outcome": "Disease activity (follow up: range 6 months to 12 months; assessed with: DAS28-ESR (Lower values – > benefit) (MCID -1.17)", "importance": "CRITICAL", "related_paper_list": ["d783a7f7", "d2d2cd6c"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": "We did not downgrade due to risk of bias. The one study that contributed 76% of the weight is at low risk of bias; the other study suffers from lack of blinding of participants and personnel and lack of blinding of outcome assessment for non-radiographic outcomes."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"Continue the same dose of the boDMARD or tsDMARD": "250", "Lower the dose of the boDMARD or tsDMARD": "248"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.06 lower (0.24 lower to 0.12 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "62", "Database": "2021 ACR RA"}
{"outcome_uid": "34be8ab9", "clinical_question": "Should patients with RA on MTX + boDMARD or tsDMARD who are at target continue the boDMARD or tsDMARD at the same dose or lower the dose or increase the interval between doses of the boDMARD or tsDMARD (MTX continued at same dose)?", "population": "Patients with RA on MTX + boDMARD or tsDMARD who are at target", "intervention": "Continue the same dose of the boDMARD or tsDMARD", "comparator": "lower the dose of the boDMARD or tsDMARD", "outcome": "Flare (follow up: range 6 months to 12 months)", "importance": "CRITICAL", "related_paper_list": ["d2d2cd6c", "60bbc82c", "a4d3750d"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment in one study and lack of blinding of participants and personnel in both studies."}, "Inconsistency": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious inconsistency. Unexplained heterogeneity I2=65%"}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Continue the same dose of the boDMARD or tsDMARD": "105", "Lower the dose of the boDMARD or tsDMARD": "105(35.2%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "HR 0.68 (0.39 to 1.19)", "Absolute Effect (95% CI)": "97 fewer per 1,000 (from 196 fewer to 51 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "62", "Database": "2021 ACR RA"}
{"outcome_uid": "9eb38c7e", "clinical_question": "Should patients with RA on MTX + boDMARD or tsDMARD who are at target continue the boDMARD or tsDMARD at the same dose or lower the dose or increase the interval between doses of the boDMARD or tsDMARD (MTX continued at same dose)?", "population": "Patients with RA on MTX + boDMARD or tsDMARD who are at target", "intervention": "Continue the same dose of the boDMARD or tsDMARD", "comparator": "lower the dose of the boDMARD or tsDMARD", "outcome": "Radiographic progression (follow up: range 6 months to 12 months; assessed with: Larsen/Sharp (Lower values – > benefit) (values > 0.2 are considered clinically important)", "importance": "IMPORTANT", "related_paper_list": ["d783a7f7", "d2d2cd6c"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": "I2=43%"}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "CI includes both values suggesting harm and values suggesting no effect. According to the Cochrane's handbook, Cohen suggested that SMD=0.2 be considered a 'small' effect size, 0.5 represents a 'medium' effect size and 0.8 a 'large' effect size. This means that if two groups' means do not differ by 0.2 standard deviations or more, the difference is trivial, even if it is statistically significant."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"Continue the same dose of the boDMARD or tsDMARD": "234", "Lower the dose of the boDMARD or tsDMARD": "231"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "SMD 0.13 higher (0.06 lower to 0.31 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "62", "Database": "2021 ACR RA"}
{"outcome_uid": "66fffd10", "clinical_question": "Should patients with RA on MTX + boDMARD or tsDMARD who are at target continue the boDMARD or tsDMARD at the same dose or lower the dose or increase the interval between doses of the boDMARD or tsDMARD (MTX continued at same dose)?", "population": "Patients with RA on MTX + boDMARD or tsDMARD who are at target", "intervention": "Continue the same dose of the boDMARD or tsDMARD", "comparator": "lower the dose of the boDMARD or tsDMARD", "outcome": "Fatigue (follow up: range 6 months to 12 months; assessed with: FACIT-F (Higher values – > benefit) (MCID 15.9)", "importance": "IMPORTANT", "related_paper_list": ["d783a7f7", "d2d2cd6c"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"Continue the same dose of the boDMARD or tsDMARD": "250", "Lower the dose of the boDMARD or tsDMARD": "248"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.79 lower (2.01 lower to 0.44 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "62", "Database": "2021 ACR RA"}
{"outcome_uid": "5d89fc41", "clinical_question": "Should patients with RA on MTX + boDMARD or tsDMARD who are at target continue the boDMARD or tsDMARD at the same dose or lower the dose or increase the interval between doses of the boDMARD or tsDMARD (MTX continued at same dose)?", "population": "Patients with RA on MTX + boDMARD or tsDMARD who are at target", "intervention": "Continue the same dose of the boDMARD or tsDMARD", "comparator": "lower the dose of the boDMARD or tsDMARD", "outcome": "Pain (follow up: range 6 months to 12 months; assessed with: VAS pain (0-100) (Lower values – > benefit) (MCID -11.9)", "importance": "IMPORTANT", "related_paper_list": ["d783a7f7", "d2d2cd6c"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"Continue the same dose of the boDMARD or tsDMARD": "250", "Lower the dose of the boDMARD or tsDMARD": "248"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 2.92 lower (6.34 lower to 0.5 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "62", "Database": "2021 ACR RA"}
{"outcome_uid": "e1e23b8b", "clinical_question": "Should patients with RA on MTX + boDMARD or tsDMARD who are at target continue the boDMARD or tsDMARD at the same dose or lower the dose or increase the interval between doses of the boDMARD or tsDMARD (MTX continued at same dose)?", "population": "Patients with RA on MTX + boDMARD or tsDMARD who are at target", "intervention": "Continue the same dose of the boDMARD or tsDMARD", "comparator": "lower the dose of the boDMARD or tsDMARD", "outcome": "Disability (follow up: range 6 months to 12 months; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22)", "importance": "IMPORTANT", "related_paper_list": ["d783a7f7", "d2d2cd6c"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"Continue the same dose of the boDMARD or tsDMARD": "251", "Lower the dose of the boDMARD or tsDMARD": "248"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.09 lower (0.19 lower to 0)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "62", "Database": "2021 ACR RA"}
{"outcome_uid": "b6821407", "clinical_question": "Should patients with RA on MTX + boDMARD or tsDMARD who are at target continue the boDMARD or tsDMARD at the same dose or lower the dose or increase the interval between doses of the boDMARD or tsDMARD (MTX continued at same dose)?", "population": "Patients with RA on MTX + boDMARD or tsDMARD who are at target", "intervention": "Continue the same dose of the boDMARD or tsDMARD", "comparator": "lower the dose of the boDMARD or tsDMARD", "outcome": "Quality of Life (follow up: range 6 months to 12 months; assessed with: EQ-5D (Higher values – > benefit) (MCID 0.1)", "importance": "IMPORTANT", "related_paper_list": ["d783a7f7", "d2d2cd6c"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"Continue the same dose of the boDMARD or tsDMARD": "251", "Lower the dose of the boDMARD or tsDMARD": "248"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0 (0.03 lower to 0.04 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "62", "Database": "2021 ACR RA"}
{"outcome_uid": "89880c9a", "clinical_question": "Should patients with RA on MTX + boDMARD or tsDMARD who are at target continue the boDMARD or tsDMARD at the same dose or lower the dose or increase the interval between doses of the boDMARD or tsDMARD (MTX continued at same dose)?", "population": "Patients with RA on MTX + boDMARD or tsDMARD who are at target", "intervention": "Continue the same dose of the boDMARD or tsDMARD", "comparator": "lower the dose of the boDMARD or tsDMARD", "outcome": "Withdrawal due to adverse events (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["d783a7f7"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "CI includes both values suggesting harm and values suggesting no effect. According to the Cochrane's handbook, Cohen suggested that SMD=0.2 be considered a 'small' effect size, 0.5 represents a 'medium' effect size and 0.8 a 'large' effect size. This means that if two groups' means do not differ by 0.2 standard deviations or more, the difference is trivial, even if it is statistically significant.\nVery small number of events"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Continue the same dose of the boDMARD or tsDMARD": "7/202 (3.5%)", "Lower the dose of the boDMARD or tsDMARD": "4/202 (2.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.75 (0.52 to 5.89)", "Absolute Effect (95% CI)": "15 more per 1,000 (from 10 fewer to 97 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "62", "Database": "2021 ACR RA"}
{"outcome_uid": "76c9d9bb", "clinical_question": "Should patients with RA on MTX + boDMARD or tsDMARD who are at target continue the boDMARD or tsDMARD at the same dose or lower the dose or increase the interval between doses of the boDMARD or tsDMARD (MTX continued at same dose)?", "population": "Patients with RA on MTX + boDMARD or tsDMARD who are at target", "intervention": "Continue the same dose of the boDMARD or tsDMARD", "comparator": "lower the dose of the boDMARD or tsDMARD", "outcome": "Serious adverse events (follow up: range 6 months to 12 months)", "importance": "IMPORTANT", "related_paper_list": ["d783a7f7", "d2d2cd6c"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": "I2=47%"}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Very small number of events\nCI includes both values suggesting benefit and values suggesting harm"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Continue the same dose of the boDMARD or tsDMARD": "12/221 (5.4%)", "Lower the dose of the boDMARD or tsDMARD": "10/230 (4.3%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.28 (0.56 to 2.91)", "Absolute Effect (95% CI)": "12 more per 1,000 (from 19 fewer to 83 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "62", "Database": "2021 ACR RA"}
{"outcome_uid": "360a8cc9", "clinical_question": "Should patients with RA on MTX + boDMARD or tsDMARD who are at target continue the boDMARD or tsDMARD at the same dose or lower the dose or increase the interval between doses of the boDMARD or tsDMARD (MTX continued at same dose)?", "population": "Patients with RA on MTX + boDMARD or tsDMARD who are at target", "intervention": "Continue the same dose of the boDMARD or tsDMARD", "comparator": "lower the dose of the boDMARD or tsDMARD", "outcome": "Cardiovascular disease (follow up: 6 months)", "importance": "IMPORTANT", "related_paper_list": ["d2d2cd6c"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded for risk of bias as the one included study did not blind participants, providers, or outcome assessors"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Very small number of events\nCI includes both values suggesting benefit and values suggesting harm"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Continue the same dose of the boDMARD or tsDMARD": "3/19 (15.8%)", "Lower the dose of the boDMARD or tsDMARD": "4/28 (14.3%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.11 (0.28 to 4.39)", "Absolute Effect (95% CI)": "16 more per 1,000 (from 103 fewer to 484 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "62", "Database": "2021 ACR RA"}
{"outcome_uid": "91aa1e42", "clinical_question": "Should patients with RA on MTX + boDMARD or tsDMARD who are at target continue the boDMARD or tsDMARD at the same dose or lower the dose or increase the interval between doses of the boDMARD or tsDMARD (MTX continued at same dose)?", "population": "Patients with RA on MTX + boDMARD or tsDMARD who are at target", "intervention": "Continue the same dose of the boDMARD or tsDMARD", "comparator": "lower the dose of the boDMARD or tsDMARD", "outcome": "Malignancy (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["d783a7f7"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Very small number of events\nCI includes both values suggesting benefit and values suggesting harm"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Continue the same dose of the boDMARD or tsDMARD": "2/202 (1.0%)", "Lower the dose of the boDMARD or tsDMARD": "4/202 (2.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.50 (0.09 to 2.70)", "Absolute Effect (95% CI)": "10 fewer per 1,000 (from 18 fewer to 34 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "62", "Database": "2021 ACR RA"}
{"outcome_uid": "ef69f0d0", "clinical_question": "Should patients with RA on MTX + boDMARD or tsDMARD who are at target continue the boDMARD or tsDMARD at the same dose or lower the dose or increase the interval between doses of the boDMARD or tsDMARD (MTX continued at same dose)?", "population": "Patients with RA on MTX + boDMARD or tsDMARD who are at target", "intervention": "Continue the same dose of the boDMARD or tsDMARD", "comparator": "lower the dose of the boDMARD or tsDMARD", "outcome": "Death (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["d783a7f7"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Very small number of events"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Continue the same dose of the boDMARD or tsDMARD": "2/202 (1.0%)", "Lower the dose of the boDMARD or tsDMARD": "0/202 (0.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 5.00 (0.24 to 103.50)", "Absolute Effect (95% CI)": "0 fewer per 1,000 (from 0 fewer to 0 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "62", "Database": "2021 ACR RA"}
{"outcome_uid": "2a38443d", "clinical_question": "Should patients with RA on MTX + boDMARD or tsDMARD who are at target continue the boDMARD or tsDMARD at the same dose or lower the dose or increase the interval between doses of the boDMARD or tsDMARD (MTX continued at same dose)?", "population": "Patients with RA on MTX + boDMARD or tsDMARD who are at target", "intervention": "Continue the same dose of the boDMARD or tsDMARD", "comparator": "increase the interval between the doses of the boDMARD or tsDMARD", "outcome": "Disease activity (follow up: 3 months; assessed with: DAS28-ESR (Lower values – > benefit) (MCID -1.17)", "importance": "CRITICAL", "related_paper_list": ["3ca3e366"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding of participants and personnel."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"Continue the same dose of the boDMARD or tsDMARD": "73", "Increase the interval between the doses of the boDMARD or tsDMARD": "64"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.2 lower (0.56 lower to 0.16 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "62", "Database": "2021 ACR RA"}
{"outcome_uid": "ca0f630b", "clinical_question": "Should patients with RA on MTX + boDMARD or tsDMARD who are at target continue the boDMARD or tsDMARD at the same dose or lower the dose or increase the interval between doses of the boDMARD or tsDMARD (MTX continued at same dose)?", "population": "Patients with RA on MTX + boDMARD or tsDMARD who are at target", "intervention": "Continue the same dose of the boDMARD or tsDMARD", "comparator": "increase the interval between the doses of the boDMARD or tsDMARD", "outcome": "Flare (follow up: 18 months)", "importance": "CRITICAL", "related_paper_list": ["3ca3e366", "47043953"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding of participants and personnel in both studies and lack of blinding of non-radiographic outcome assessors in one study."}, "Inconsistency": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious inconsistency. I2=75%."}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Continue the same dose of the boDMARD or tsDMARD": "50/132 (37.9%)", "Increase the interval between the doses of the boDMARD or tsDMARD": "137/185 (74.1%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.48 (0.38 to 0.62)", "Absolute Effect (95% CI)": "385 fewer per 1,000 (from 459 fewer to 281 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "62", "Database": "2021 ACR RA"}
{"outcome_uid": "882b0910", "clinical_question": "Should patients with RA on MTX + boDMARD or tsDMARD who are at target continue the boDMARD or tsDMARD at the same dose or lower the dose or increase the interval between doses of the boDMARD or tsDMARD (MTX continued at same dose)?", "population": "Patients with RA on MTX + boDMARD or tsDMARD who are at target", "intervention": "Continue the same dose of the boDMARD or tsDMARD", "comparator": "increase the interval between the doses of the boDMARD or tsDMARD", "outcome": "Disability (follow up: 3 months; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22)", "importance": "IMPORTANT", "related_paper_list": ["3ca3e366"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding of participants and personnel."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting no effect."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Continue the same dose of the boDMARD or tsDMARD": "73", "Increase the interval between the doses of the boDMARD or tsDMARD": "64"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.09 lower (0.41 lower to 0.23 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "62", "Database": "2021 ACR RA"}
{"outcome_uid": "3ac9773e", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor + MTX", "outcome": "Disease activity (follow up: range 6 months to 1 year; assessed with: ACR 20)", "importance": "CRITICAL", "related_paper_list": ["aa711738", "834e46fa"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": "Concern about risk of bias associated with lack of allocation concealment and incomplete outcome data in one study is taken into account when rating down for imprecision."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit. According to the Cochrane's handbook, Cohen suggested that SMD=0.2 be considered a 'small' effect size, 0.5 represents a 'medium' effect size and 0.8 a 'large' effect size. This means that if two groups' means do not differ by 0.2 standard deviations or more, the difference is trivial, even if it is statistically significant."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"TNFi + MTX": "521/742 (70.2%)", "MTX monotherapy": "188/298 (63.1%)"}, "Annotation": {"data": "1. TNFis include etanercept (ETN), certolizumab (CZP) and adalimumab (ADA).\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.14 (1.03 to 1.26)", "Absolute Effect (95% CI)": "88 more per 1,000 (from 19 more to 164 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "4b8c77ce", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor + MTX", "outcome": "Disease activity (follow up: 6 months; assessed with: ACR 50)", "importance": "CRITICAL", "related_paper_list": ["aa711738", "834e46fa"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": "Concern about risk of bias associated with lack of allocation concealment and incomplete outcome data in one study is taken into account when rating down for imprecision."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit. According to the Cochrane's handbook, Cohen suggested that SMD=0.2 be considered a 'small' effect size, 0.5 represents a 'medium' effect size and 0.8 a 'large' effect size. This means that if two groups' means do not differ by 0.2 standard deviations or more, the difference is trivial, even if it is statistically significant."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"TNFi + MTX": "426/742 (57.4%)", "MTX monotherapy": "148/298 (49.7%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.17 (1.02 to 1.33)", "Absolute Effect (95% CI)": "84 more per 1,000 (from 10 more to 164 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "41371a37", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor + MTX", "outcome": "Disease activity (follow up: range 6 months to 12 months; assessed with: ACR 70)", "importance": "CRITICAL", "related_paper_list": ["aa711738", "834e46fa"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": "Concern about risk of bias associated with lack of allocation concealment and incomplete outcome data in one study is taken into account when rating down for inconsistency."}, "Inconsistency": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious inconsistency. Unexplained heterogeneity I2=51%."}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"TNFi + MTX": "378/742 (50.9%)", "MTX monotherapy": "108/298 (36.2%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.36 (1.15 to 1.61)", "Absolute Effect (95% CI)": "130 more per 1,000 (from 54 more to 221 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "4754315d", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor + MTX", "outcome": "Disease activity (follow up: range 6 months to 12 months; assessed with: DAS28 or DAS44 (Lower values -> benefit) (values>0.2 are considered clinically important)", "importance": "CRITICAL", "related_paper_list": ["834e46fa", "d354991c"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment in 2 studies."}, "Inconsistency": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious inconsistency. Unexplained heterogeneity I2=78%."}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit. According to the Cochrane's handbook, Cohen suggested that SMD=0.2 be considered a 'small' effect size, 0.5 represents a 'medium' effect size and 0.8 a 'large' effect size. This means that if two groups' means do not differ by 0.2 standard deviations or more, the difference is trivial, even if it is statistically significant."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"TNFi + MTX": "0", "MTX monotherapy": "0"}, "Annotation": {"data": "1. TNFis include etanercept (ETN), certolizumab (CZP) and adalimumab (ADA).\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "SMD 0.21 lower (0.37 lower to 0.05 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "f92893b0", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor + MTX", "outcome": "Remission (follow up: range 6 months to 12 months; assessed with: DAS28<2.6)", "importance": "CRITICAL", "related_paper_list": ["aa711738", "834e46fa", "d354991c"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment in 2 studies."}, "Inconsistency": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious inconsistency. Unexplained heterogeneity I2=58%."}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"TNFi + MTX": "359/797 (45.0%)", "MTX monotherapy": "116/353 (32.9%)"}, "Annotation": {"data": "1. TNFis include etanercept (ETN), certolizumab (CZP) and adalimumab (ADA).\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.49 (1.25 to 1.77)", "Absolute Effect (95% CI)": "161 more per 1,000 (from 82 more to 253 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "e3789d44", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor + MTX", "outcome": "Radiographic progression (follow up: 1 year; assessed with: mTSS (Lower values – > benefit) (MCID 4.6)", "importance": "IMPORTANT", "related_paper_list": ["d354991c"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"TNFi + MTX": "0", "MTX monotherapy": "0"}, "Annotation": {"data": "1. TNFis include etanercept (ETN), certolizumab (CZP) and adalimumab (ADA).\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0 (0.64 lower to 0.64 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "c4d70f94", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor + MTX", "outcome": "Fatigue (follow up: 1 year; assessed with: VAS fatigue (Lower values – > benefit) (MCID -1.12 to -0.82))", "importance": "IMPORTANT", "related_paper_list": ["d354991c"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": "Concern about risk of bias associated with lack of allocation concealment taken into account when rating down for imprecision."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"TNFi + MTX": "55", "MTX monotherapy": "55"}, "Annotation": {"data": "1. TNFis include etanercept (ETN), certolizumab (CZP) and adalimumab (ADA).\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 5.2 lower (17.17 lower to 6.77 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "e40be137", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor + MTX", "outcome": "Pain (follow up: 1 year; assessed with: VAS pain (Lower values – > benefit) (MCID -11.9)", "importance": "IMPORTANT", "related_paper_list": ["d354991c"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": "Concern about risk of bias associated with lack of allocation concealment taken into account when rating down for imprecision."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit. According to the Cochrane's handbook, Cohen suggested that SMD=0.2 be considered a 'small' effect size, 0.5 represents a 'medium' effect size and 0.8 a 'large' effect size. This means that if two groups' means do not differ by 0.2 standard deviations or more, the difference is trivial, even if it is statistically significant."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"TNFi + MTX": "55", "MTX monotherapy": "55"}, "Annotation": {"data": "1. TNFis include etanercept (ETN), certolizumab (CZP) and adalimumab (ADA).\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 18.4 lower (30.88 lower to 5.92 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "f060c05d", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor + MTX", "outcome": "Disability (follow up: range 6 months to 12 months; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22)", "importance": "IMPORTANT", "related_paper_list": ["aa711738", "834e46fa", "d354991c"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment in 2 studies."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit. According to the Cochrane's handbook, Cohen suggested that SMD=0.2 be considered a 'small' effect size, 0.5 represents a 'medium' effect size and 0.8 a 'large' effect size. This means that if two groups' means do not differ by 0.2 standard deviations or more, the difference is trivial, even if it is statistically significant."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"TNFi + MTX": "0", "MTX monotherapy": "0"}, "Annotation": {"data": "1. TNFis include etanercept (ETN), certolizumab (CZP) and adalimumab (ADA).\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.18 lower (0.25 lower to 0.1 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "a5f7c018", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor + MTX", "outcome": "Quality of Life (follow up: range 6 months to 12 months; assessed with: SF-36 PCS (Higher values – > benefit) (MCID 4.4)", "importance": "IMPORTANT", "related_paper_list": ["834e46fa", "d354991c"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment in 2 studies."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit. According to the Cochrane's handbook, Cohen suggested that SMD=0.2 be considered a 'small' effect size, 0.5 represents a 'medium' effect size and 0.8 a 'large' effect size. This means that if two groups' means do not differ by 0.2 standard deviations or more, the difference is trivial, even if it is statistically significant."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"TNFi + MTX": "0", "MTX monotherapy": "0"}, "Annotation": {"data": "1. TNFis include etanercept (ETN), certolizumab (CZP) and adalimumab (ADA).\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 3.21 higher (0.63 higher to 5.79 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "5ad53f57", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor + MTX", "outcome": "Quality of Life (follow up: range 6 months to 12 months; assessed with: SF-36 MCS (Higher values – > benefit) (MCID 3.1)", "importance": "IMPORTANT", "related_paper_list": ["834e46fa", "d354991c"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment in 2 studies."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"TNFi + MTX": "0", "MTX monotherapy": "0"}, "Annotation": {"data": "1. TNFis include etanercept (ETN), certolizumab (CZP) and adalimumab (ADA).\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.54 lower (2.98 lower to 1.89 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "ccbc29f3", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor + MTX", "outcome": "Withdrawal due to lack of efficacy (follow up: range 6 months to 12 months)", "importance": "IMPORTANT", "related_paper_list": ["aa711738", "834e46fa", "d354991c"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment in 2 studies."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"TNFi + MTX": "21/802 (2.6%)", "MTX monotherapy": "24/359 (6.7%)"}, "Annotation": {"data": "1. TNFis include etanercept (ETN), certolizumab (CZP) and adalimumab (ADA).\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.38 (0.21 to 0.69)", "Absolute Effect (95% CI)": "41 fewer per 1,000 (from 53 fewer to 21 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "2f1f6aff", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor + MTX", "outcome": "Withdrawal due to adverse events (follow up: range 6 months to 12 months)", "importance": "IMPORTANT", "related_paper_list": ["aa711738", "834e46fa", "d354991c"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment in 2 studies."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"TNFi + MTX": "61/801 (7.6%)", "MTX monotherapy": "24/357 (6.7%)"}, "Annotation": {"data": "1. TNFis include etanercept (ETN), certolizumab (CZP) and adalimumab (ADA).\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.94 (0.60 to 1.49)", "Absolute Effect (95% CI)": "4 fewer per 1,000 (from 27 fewer to 33 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "33249efd", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor + MTX", "outcome": "Serious adverse events (follow up: range 6 months to 12 months)", "importance": "IMPORTANT", "related_paper_list": ["aa711738", "834e46fa", "d354991c"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": "Concern about risk of bias associated with lack of allocation concealment in two studies taken into account when rating down for inconsistency and imprecision."}, "Inconsistency": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious inconsistency. Unexplained heterogeneity I2=72%."}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"TNFi + MTX": "91/801 (11.4%)", "MTX monotherapy": "45/357 (12.6%)"}, "Annotation": {"data": "1. TNFis include etanercept (ETN), certolizumab (CZP) and adalimumab (ADA).\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.00 (0.71 to 1.43)", "Absolute Effect (95% CI)": "0 fewer per 1,000 (from 37 fewer to 54 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "9ac37672", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor + MTX", "outcome": "Death (follow up: range 6 months to 12 months)", "importance": "IMPORTANT", "related_paper_list": ["aa711738", "834e46fa"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and incomplete outcome data in one study."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"TNFi + MTX": "2/746 (0.3%)", "MTX monotherapy": "1/302 (0.3%)"}, "Annotation": {"data": "1. TNFis include etanercept (ETN), certolizumab (CZP) and adalimumab (ADA).\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.66 (0.06 to 7.23)", "Absolute Effect (95% CI)": "1 fewer per 1,000 (from 3 fewer to 21 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "2aaca0e3", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor + MTX", "outcome": "Malignancy (from SRs on harms)", "related_paper_list": ["45b0286b"], "assessment_results": {"GRADE": {"result_interpretation": "The Systematic Review RefID=4638, 2012 (RCTs=3, n=1842) comparing certolizumab + MTX vs placebo + MTX among RA showed that for cancer, the result was RR=2.8 (0.36-21.6) at 1 year and RR=1.3 (0.24-7.3) at all time points. ", "Study design": "Systematic Review"}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "21155bd2", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept + MTX", "outcome": "Disease activity (follow up: 1 year; assessed with: ACR 70)", "importance": "CRITICAL", "related_paper_list": ["e4903996"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and lack of blinding of non-radiographic outcome assessors."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"ABA+MTX": "109/256 (42.6%)", "MTX monotherapy": "69/253 (27.3%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.56 (1.22 to 2.00)", "Absolute Effect (95% CI)": "153 more per 1,000 (from 60 more to 273 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "eefda449", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept + MTX", "outcome": "Disease activity (follow up: 1 year; assessed with: DAS28 CRP (Lower values – > benefit) (MCID -1.02))", "importance": "CRITICAL", "related_paper_list": ["e4903996"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and lack of blinding of non-radiographic outcome assessors."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"ABA+MTX": "256", "MTX monotherapy": "253"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.73 lower (0.98 lower to 0.48 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "be0d9216", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept + MTX", "outcome": "Remission (follow up: 1 year; assessed with: DAS28-ESR remission <2.6)", "importance": "CRITICAL", "related_paper_list": ["e4903996", "2a7a858b"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and lack of blinding of non-radiographic outcome assessors."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"ABA+MTX": "176/371 (47.4%)", "MTX monotherapy": "109/368 (29.6%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.60 (1.33 to 1.93)", "Absolute Effect (95% CI)": "178 more per 1,000 (from 98 more to 275 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "86346b5d", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept + MTX", "outcome": "Radiographic progression (follow up: 1 year; assessed with: mTSS (Lower values – > benefit) (MCID 4.6))", "importance": "IMPORTANT", "related_paper_list": ["e4903996"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and lack of blinding of non-radiographic outcome assessors."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"ABA+MTX": "0", "MTX monotherapy": "0"}, "Annotation": {"data": "1. The study AGREE found that the RR of developing no radiographic progression (change in mTSS ≤0) was 1.6 (95%CI 0.99 to 1.36), absolute risk increase 84 more per 1000 (95%CI 5 fewer to 190 more).\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.43 lower (0.91 lower to 0.05 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "4e7beb24", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept + MTX", "outcome": "Disability (follow up: 1 year; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22))", "importance": "IMPORTANT", "related_paper_list": ["e4903996"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and lack of blinding of non-radiographic outcome assessors."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"ABA+MTX": "256", "MTX monotherapy": "253"}, "Annotation": {"data": "1. The studies AGREE and AVERT found that the RR of improvement in HAQ-DI (≥0.3 change from baseline) was 1.25 (95%CI 1.12 to 1.39), absolute risk increase 141 more per 1000 (95%CI 668 more to 220 more).\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.2 lower (0.31 lower to 0.09 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "c8fb7321", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept + MTX", "outcome": "Quality of Life (follow up: 1 year; assessed with: SF-36 PCS (Higher values – > benefit) (MCID 4.4))", "importance": "IMPORTANT", "related_paper_list": ["e4903996"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and lack of blinding of non-radiographic outcome assessors."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"ABA+MTX": "256", "MTX monotherapy": "253"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 2.5 higher (0.77 higher to 4.23 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "b6a09845", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept + MTX", "outcome": "Quality of Life (follow up: 1 year; assessed with: SF-36 MCS (Higher values – > benefit) (MCID 3.1))", "importance": "IMPORTANT", "related_paper_list": ["e4903996"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and lack of blinding of non-radiographic outcome assessors."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"ABA+MTX": "256", "MTX monotherapy": "253"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 1.81 lower (3.58 lower to 0.04 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "bf9ffcdf", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept + MTX", "outcome": "Withdrawal due to lack of efficacy (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["2a7a858b"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"ABA+MTX": "5/115 (4.3%)", "MTX monotherapy": "11/115 (9.6%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.45 (0.16 to 1.27)", "Absolute Effect (95% CI)": "53 fewer per 1,000 (from 80 fewer to 26 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "4ab02aef", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept + MTX", "outcome": "Withdrawal due to adverse events (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["e4903996", "2a7a858b"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and lack of blinding of non-radiographic outcome assessors."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by two levels due to serious imprecision. Confidence interval includes both values suggesting harm and values suggesting benefit. Low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"ABA+MTX": "13/375 (3.5%)", "MTX monotherapy": "16/369 (4.3%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.80 (0.39 to 1.64)", "Absolute Effect (95% CI)": "9 fewer per 1,000 (from 26 fewer to 28 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "10cdb697", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept + MTX", "outcome": "Serious adverse events (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["e4903996"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and lack of blinding of non-radiographic outcome assessors."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting harm and values suggesting benefit."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"ABA+MTX": "20/256 (7.8%)", "MTX monotherapy": "20/253 (7.9%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.99 (0.55 to 1.79)", "Absolute Effect (95% CI)": "1 fewer per 1,000 (from 36 fewer to 62 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "d3bcb4c1", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept + MTX", "outcome": "Malignancy (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["e4903996", "2a7a858b"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and lack of blinding of non-radiographic outcome assessors."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"ABA+MTX": "1/371 (0.3%)", "MTX monotherapy": "2/368 (0.5%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.60 (0.08 to 4.48)", "Absolute Effect (95% CI)": "2 fewer per 1,000 (from 5 fewer to 19 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "be9f9f3b", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept + MTX", "outcome": "Death (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["e4903996", "2a7a858b"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and lack of blinding of non-radiographic outcome assessors."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by two levels due to serious imprecision. Confidence interval includes both values suggesting harm and values suggesting benefit. Low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"ABA+MTX": "2/371 (0.5%)", "MTX monotherapy": "4/368 (1.1%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.49 (0.09 to 2.67)", "Absolute Effect (95% CI)": "6 fewer per 1,000 (from 10 fewer to 18 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "bb9c36c1", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept + MTX", "outcome": "Malignancy (from SRs on harms)", "related_paper_list": ["45b0286b"], "assessment_results": {"GRADE": {"result_interpretation": "The Systematic Review RefID=4638, 2012 (RCTs=3, n=2435) comparing Abatacept + csDMARD vs Placebo + csDMARD among RA showed that for Cancer, the result was RR=0.65 (0.25-1.7) at 1 year. ", "Study design": "Systematic Review"}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "5b7a5754", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Rituximab + MTX", "outcome": "Disease activity (follow up: 2 years; assessed with: ACR 20)", "importance": "CRITICAL", "related_paper_list": ["2f031aec"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"RTX+MTX": "185/250 (74.0%)", "MTX monotherapy": "137/249 (55.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.34 (1.18 to 1.54)", "Absolute Effect (95% CI)": "187 more per 1,000 (from 99 more to 297 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "55d0f851", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Rituximab + MTX", "outcome": "Disease activity (follow up: 2 years; assessed with: ACR 50)", "importance": "CRITICAL", "related_paper_list": ["2f031aec"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"RTX+MTX": "155/250 (62.0%)", "MTX monotherapy": "102/249 (41.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.51 (1.27 to 1.81)", "Absolute Effect (95% CI)": "209 more per 1,000 (from 111 more to 332 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "068fbc4c", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Rituximab + MTX", "outcome": "Disease activity (follow up: 2 years; assessed with: ACR 70)", "importance": "CRITICAL", "related_paper_list": ["2f031aec"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"RTX+MTX": "115/250 (46.0%)", "MTX monotherapy": "67/249 (26.9%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.71 (1.34 to 2.18)", "Absolute Effect (95% CI)": "191 more per 1,000 (from 91 more to 318 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "b0f0760a", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Rituximab + MTX", "outcome": "Disease activity (follow up: 2 years; assessed with: DAS28 ESR (Lower values – > benefit) (MCID -1.17)", "importance": "CRITICAL", "related_paper_list": ["2f031aec"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"RTX+MTX": "250", "MTX monotherapy": "249"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 1.19 lower (1.5 lower to 0.88 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "1f1da61a", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Rituximab + MTX", "outcome": "Remission (follow up: 2 years; assessed with: DAS28-ESR remission <2.6)", "importance": "CRITICAL", "related_paper_list": ["2f031aec"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"RTX+MTX": "80/250 (32.0%)", "MTX monotherapy": "32/249 (12.9%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 2.49 (1.72 to 3.61)", "Absolute Effect (95% CI)": "191 more per 1,000 (from 93 more to 335 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "9210976b", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Rituximab + MTX", "outcome": "Radiographic progression (follow up: 2 years; assessed with: mTSS (Lower values – > benefit) (MCID 4.6)", "importance": "IMPORTANT", "related_paper_list": ["2f031aec"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"RTX+MTX": "244", "MTX monotherapy": "233"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 1.54 lower (2.3 lower to 0.78 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "5cfac317", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Rituximab + MTX", "outcome": "Pain (follow up: 1 year; assessed with: VAS pain (Lower values – > benefit) (MCID -11.9)", "importance": "IMPORTANT", "related_paper_list": ["2f031aec"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"RTX+MTX": "0", "MTX monotherapy": "0"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 12.2 lower (16.15 lower to 8.25 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "7f92025d", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Rituximab + MTX", "outcome": "Fatigue (follow up: 1 year; assessed with: FACIT-F (Higher values – > benefit) (MCID 15.9)", "importance": "IMPORTANT", "related_paper_list": ["2f031aec"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"RTX+MTX": "0", "MTX monotherapy": "0"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 3.45 higher (1.77 higher to 5.13 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "77f07bbd", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Rituximab + MTX", "outcome": "Disability (follow up: 2 years; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22)", "importance": "IMPORTANT", "related_paper_list": ["2f031aec"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"RTX+MTX": "250", "MTX monotherapy": "249"}, "Annotation": {"data": "1. The study IMAGE found that the RR of improvement in HAQ-DI (≥0.22 change from baseline) was 1.12 (95%CI 1.03 to 1.21), absolute risk increase 93 more per 1000 (95%CI 23 more to 162 more).\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.25 lower (0.4 lower to 0.1 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "c978e3c2", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Rituximab + MTX", "outcome": "Quality of Life (follow up: 1 year; assessed with: SF-36 PCS (Higher values – > benefit) (MCID 4.4)", "importance": "IMPORTANT", "related_paper_list": ["2f031aec"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"RTX+MTX": "0", "MTX monotherapy": "0"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 3.53 higher (2.04 higher to 5.02 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "5d3448fa", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Rituximab + MTX", "outcome": "Quality of Life (follow up: 1 year; assessed with: SF-36 MCS (Higher values – > benefit) (MCID 3.1)", "importance": "IMPORTANT", "related_paper_list": ["2f031aec"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"RTX+MTX": "0", "MTX monotherapy": "0"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.81 higher (1.03 lower to 2.66 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "5d4c9951", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Rituximab + MTX", "outcome": "Withdrawal due to adverse events (follow up: 2 years)", "importance": "IMPORTANT", "related_paper_list": ["2f031aec"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"RTX+MTX": "7/250 (2.8%)", "MTX monotherapy": "17/249 (6.8%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.41 (0.17 to 0.97)", "Absolute Effect (95% CI)": "40 fewer per 1,000 (from 57 fewer to 2 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "ed7b40f0", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Rituximab + MTX", "outcome": "Serious adverse events (follow up: 2 years)", "importance": "IMPORTANT", "related_paper_list": ["2f031aec"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"RTX+MTX": "33/250 (13.2%)", "MTX monotherapy": "42/249 (16.9%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.78 (0.51 to 1.19)", "Absolute Effect (95% CI)": "37 fewer per 1,000 (from 83 fewer to 32 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "7a9930bd", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Rituximab + MTX", "outcome": "Malignancy (follow up: 2 years)", "importance": "IMPORTANT", "related_paper_list": ["2f031aec"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"RTX+MTX": "3/250 (1.2%)", "MTX monotherapy": "7/249 (2.8%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.43 (0.11 to 1.63)", "Absolute Effect (95% CI)": "16 fewer per 1,000 (from 25 fewer to 18 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "437e487c", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Rituximab + MTX", "outcome": "Death (follow up: 2 years)", "importance": "IMPORTANT", "related_paper_list": ["2f031aec"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"RTX+MTX": "1/250 (0.4%)", "MTX monotherapy": "3/249 (1.2%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.33 (0.03 to 3.17)", "Absolute Effect (95% CI)": "8 fewer per 1,000 (from 12 fewer to 26 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "e2daafa6", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Rituximab + MTX", "outcome": "Malignancy (from SRs on harms)", "related_paper_list": ["45b0286b"], "assessment_results": {"GRADE": {"result_interpretation": "The Systematic Review RefID=4638, 2012 (RCTs=3, n=2435) comparing Abatacept + csDMARD vs Placebo + csDMARD among RA showed that for Cancer, the result was RR=0.65 (0.25-1.7) at 1 year. ", "Study design": "Systematic Review"}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "2b9c6eae", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor + MTX", "outcome": "Disease activity (follow up: 1 year; assessed with: ACR 20)", "importance": "CRITICAL", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Rated down by one level for lack of allocation concealment"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"TCZ+MTX": "374/578 (64.7%)", "MTX monotherapy": "164/287 (57.1%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.13 (1.01 to 1.27)", "Absolute Effect (95% CI)": "74 more per 1,000 (from 6 more to 154 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "bbbc516d", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor + MTX", "outcome": "Disease activity (follow up: 1 year; assessed with: ACR 50)", "importance": "CRITICAL", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Rated down by one level for lack of allocation concealment"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"TCZ+MTX": "314/578 (54.3%)", "MTX monotherapy": "117/287 (40.8%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.33 (1.14 to 1.56)", "Absolute Effect (95% CI)": "135 more per 1,000 (from 57 more to 228 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "ada8736b", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor + MTX", "outcome": "Disease activity (follow up: 1 year; assessed with: ACR 70)", "importance": "CRITICAL", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Rated down by one level for lack of allocation concealment"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"TCZ+MTX": "234/578 (40.5%)", "MTX monotherapy": "84/287 (29.3%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.38 (1.13 to 1.70)", "Absolute Effect (95% CI)": "111 more per 1,000 (from 38 more to 205 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "becc1017", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor + MTX", "outcome": "Disease activity (follow up: 1 year; assessed with: DAS28-ESR (Lower values – > benefit) (MCID -1.17))", "importance": "CRITICAL", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Rated down by one level for lack of allocation concealment"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"TCZ+MTX": "578", "MTX monotherapy": "287"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.83 lower (1.09 lower to 0.57 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "92c7d60d", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor + MTX", "outcome": "Remission (follow up: 1 year; assessed with: DAS28-ESR remission <2.6)", "importance": "CRITICAL", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Rated down by one level for lack of allocation concealment"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"TCZ+MTX": "240/578 (41.5%)", "MTX monotherapy": "56/287 (19.5%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 2.13 (1.65 to 2.74)", "Absolute Effect (95% CI)": "220 more per 1,000 (from 127 more to 340 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "e21c301d", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor + MTX", "outcome": "Radiographic progression (follow up: 1 year; assessed with: mTSS (Lower values – > benefit) (MCID 4.6))", "importance": "IMPORTANT", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Rated down by one level for lack of allocation concealment"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"TCZ+MTX": "540", "MTX monotherapy": "267"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.89 lower (1.45 lower to 0.33 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "34ea1289", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor + MTX", "outcome": "Disability (follow up: 1 year; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22))", "importance": "IMPORTANT", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Rated down by one level for lack of allocation concealment"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"TCZ+MTX": "0", "MTX monotherapy": "0"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.14 lower (0.22 lower to 0.06 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "174741d3", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor + MTX", "outcome": "Quality of Life (follow up: 1 year; assessed with: SF-36 PCS (Higher values – > benefit) (MCID 4.4))", "importance": "IMPORTANT", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Rated down by one level for lack of allocation concealment"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"TCZ+MTX": "0", "MTX monotherapy": "0"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 1.99 higher (0.41 higher to 3.57 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "c32a6542", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor + MTX", "outcome": "Quality of Life (follow up: 1 year; assessed with: SF-36 MCS (Higher values – > benefit) (MCID 3.1))", "importance": "IMPORTANT", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Rated down by one level for lack of allocation concealment"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "SERIOUS", "rationales": "Rated down by one level for imprecision as the CI includes both values suggesting no effect and values suggesting harm"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"TCZ+MTX": "0", "MTX monotherapy": "0"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 1.25 higher (1.58 lower to 4.08 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "775dc934", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor + MTX", "outcome": "Withdrawal due to adverse events (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Rated down by one level for lack of allocation concealment"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"TCZ+MTX": "94/579 (16.2%)", "MTX monotherapy": "21/282 (7.4%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 2.18 (1.39 to 3.42)", "Absolute Effect (95% CI)": "88 more per 1,000 (from 29 more to 180 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "2630e361", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor + MTX", "outcome": "Serious adverse events (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Rated down by one level for lack of allocation concealment"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "SERIOUS", "rationales": "Rated down by one level for imprecision as the CI includes both values suggesting no effect and values suggesting harm"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"TCZ+MTX": "60/579 (10.4%)", "MTX monotherapy": "24/282 (8.5%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.22 (0.78 to 1.91)", "Absolute Effect (95% CI)": "19 more per 1,000 (from 19 fewer to 77 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "0231d62a", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor + MTX", "outcome": "Malignancy (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Rated down by one level for lack of allocation concealment"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "SERIOUS", "rationales": "Rated down by one level for imprecision as the CI includes both values suggesting no effect and values suggesting harm"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"TCZ+MTX": "5/579 (0.9%)", "MTX monotherapy": "3/282 (1.1%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.81 (0.20 to 3.37)", "Absolute Effect (95% CI)": "2 fewer per 1,000 (from 9 fewer to 25 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "85f7287f", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor + MTX", "outcome": "Myocardial infarction (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Rated down by one level for lack of allocation concealment"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Rated down by two levels for imprecision as the CI includes both values suggesting benefit and values suggesting harm"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"TCZ+MTX": "4/579 (0.7%)", "MTX monotherapy": "0/282 (0.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 4.39 (0.24 to 81.28)", "Absolute Effect (95% CI)": "7 fewer per 1,000 (from 480 fewer to 160 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "2aeec28e", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor + MTX", "outcome": "Death (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Rated down by one level for lack of allocation concealment"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD exposed population."}, "Imprecision": {"result": "SERIOUS", "rationales": "Rated down by one level for imprecision as the CI includes both values suggesting no effect and values suggesting harm"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"TCZ+MTX": "6/579 (1.0%)", "MTX monotherapy": "2/282 (0.7%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.46 (0.30 to 7.19)", "Absolute Effect (95% CI)": "3 more per 1,000 (from 5 fewer to 44 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "9d6879db", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor + MTX", "outcome": "Serious adverse events (from SRs on harms)", "related_paper_list": ["286647a1"], "assessment_results": {"GRADE": {"result_interpretation": "The Systematic Review RefID=5712, 2011 (RCTs=4, n=2701) comparing Tocilizumab + MTX vs Placebo + MTX among MTX naïve RA showed that for Serious adverse events, the result was OR=0.78 (0.45, 1.33) ", "Study design": "Systematic Review"}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "748e8672", "clinical_question": " Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor + MTX", "outcome": "Malignancy (from SRs on harms)", "related_paper_list": ["286647a1"], "assessment_results": {"GRADE": {"result_interpretation": "The Systematic Review RefID=4638, 2012 (RCTs=1, n=1190) comparing Tocilizumab + MTX vs Placebo + MTX among RA showed that for Cancer, the result was RR=4.4 (0.56-34.8) at 1 year and RR=0.41 (0.14-1.2) at 6 months (RCT=4, n=2950) ", "Study design": "Systematic Review"}}, "PICO_IDX": "6a", "Database": "2021 ACR RA"}
{"outcome_uid": "78d8a0b8", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor + MTX", "outcome": "Disease activity (follow up: range 6 months to 2 years; assessed with: ACR 20)", "importance": "CRITICAL", "related_paper_list": ["fbec7a1c", "07165ed3", "7ef8f3ac", "7321b644", "54351bf3", "72824791", "ccd87125", "2140c6ee", "cbcb86ec"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"TNFi+MTX": "1414/2051 (68.9%)", "MTX monotherapy": "1134/2094 (54.2%)"}, "Annotation": {"data": "1. TNFis includes Etanercept, Adalimumab, Certolizumab, Golimumab and Infliximab.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.25 (1.19 to 1.31)", "Absolute Effect (95% CI)": "135 more per 1,000 (from 103 more to 168 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "e6b6d583", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor + MTX", "outcome": "Disease activity (follow up: 1 year; assessed with: ACR 50)", "importance": "CRITICAL", "related_paper_list": ["7321b644", "54351bf3", "72824791", "2140c6ee", "cbcb86ec"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"TNFi+MTX": "559/974 (57.4%)", "MTX monotherapy": "363/881 (41.2%)"}, "Annotation": {"data": "1. TNFis includes Etanercept, Adalimumab, Certolizumab, Golimumab and Infliximab.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.42 (1.29 to 1.56)", "Absolute Effect (95% CI)": "173 more per 1,000 (from 119 more to 231 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "ce479e4f", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor + MTX", "outcome": "Disease activity (follow up: range 6 months to 2 years; assessed with: ACR 70)", "importance": "CRITICAL", "related_paper_list": ["fbec7a1c", "07165ed3", "7ef8f3ac", "7321b644", "54351bf3", "72824791", "ccd87125", "2140c6ee", "cbcb86ec"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": "I2=17%"}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"TNFi+MTX": "733/2051 (35.7%)", "MTX monotherapy": "401/2094 (19.1%)"}, "Annotation": {"data": "1. TNFis includes Etanercept, Adalimumab, Certolizumab, Golimumab and Infliximab.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.74 (1.55 to 1.96)", "Absolute Effect (95% CI)": "142 more per 1,000 (from 105 more to 184 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "0f903a27", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor + MTX", "outcome": "Disease activity (follow up: range 6 months to 1 year; assessed with: DAS28-ESR/CRP)", "importance": "CRITICAL", "related_paper_list": ["07165ed3", "7321b644", "72824791", "ccd87125", "cbcb86ec"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": "According to the Cochrane's handbook, Cohen suggested that SMD=0.2 be considered a 'small' effect size, 0.5 represents a 'medium' effect size and 0.8 a 'large' effect size. This means that if two groups' means do not differ by 0.2 standard deviations or more, the difference is trivial, even if it is statistically significant."}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"TNFi+MTX": "1133", "MTX monotherapy": "1200"}, "Annotation": {"data": "1. TNFis includes Etanercept, Adalimumab, Certolizumab, Golimumab and Infliximab.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "SMD 0.39 lower (0.47 lower to 0.31 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "a90be394", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor + MTX", "outcome": "Remission (follow up: range 6 months to 2 years; assessed with: DAS28-ESR remission <2.6)", "importance": "CRITICAL", "related_paper_list": ["fbec7a1c", "07165ed3", "7ef8f3ac", "7321b644", "54351bf3", "2140c6ee", "cbcb86ec"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"TNFi+MTX": "662/1743 (38.0%)", "MTX monotherapy": "353/1667 (21.2%)"}, "Annotation": {"data": "1. TNFis includes Etanercept, Adalimumab, Certolizumab, Golimumab and Infliximab.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.80 (1.62 to 2.01)", "Absolute Effect (95% CI)": "169 more per 1,000 (from 131 more to 214 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "880893eb", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor + MTX", "outcome": "Radiographic progression (follow up: range 6 months to 1 year; assessed with: mTSS)", "importance": "IMPORTANT", "related_paper_list": ["fbec7a1c", "54351bf3", "cbcb86ec"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious inconsistency. I2=90%."}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"TNFi+MTX": "782", "MTX monotherapy": "702"}, "Annotation": {"data": "1. TNFis includes Etanercept, Adalimumab, Certolizumab, Golimumab and Infliximab.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 1.94 lower (3.61 lower to 0.28 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "3f0cd584", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor + MTX", "outcome": "Fatigue (follow up: range 1 year to 2 years; assessed with: VAS-F or FACIT-F)", "importance": "IMPORTANT", "related_paper_list": ["c45ae481", "b6dac38c"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "SERIOUS", "rationales": "I2=55%"}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Rated down by one level for imprecision, as CI includes both values suggesting benefits and values suggesting no effect. According to the Cochrane's handbook, Cohen suggested that SMD=0.2 be considered a 'small' effect size, 0.5 represents a 'medium' effect size and 0.8 a 'large' effect size. This means that if two groups' means do not differ by 0.2 standard deviations or more, the difference is trivial, even if it is statistically significant."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"TNFi+MTX": "530", "MTX monotherapy": "520"}, "Annotation": {"data": "1. TNFis includes Etanercept, Adalimumab, Certolizumab, Golimumab and Infliximab.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "SMD 0.15 higher (0.03 higher to 0.28 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "dba7e264", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor + MTX", "outcome": "Pain (follow up: range 1 year to 2 years; assessed with: VAS pain (0-100))", "importance": "IMPORTANT", "related_paper_list": ["c45ae481", "b6dac38c"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious inconsistency. I2=85%"}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"TNFi+MTX": "530", "MTX monotherapy": "519"}, "Annotation": {"data": "1. TNFis includes Etanercept, Adalimumab, Certolizumab, Golimumab and Infliximab.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 4.66 lower (6.93 lower to 2.39 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "36d3e6c6", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor + MTX", "outcome": "Disability (follow up: range 6 months to 24 months; assessed with: HAQ-DI)", "importance": "IMPORTANT", "related_paper_list": ["07165ed3", "7321b644", "72824791", "ccd87125", "cbcb86ec"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious inconsistency. I2=92%"}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Rated down by one level for imprecision, as CI includes both values suggesting benefits and values suggesting no effect. According to the Cochrane's handbook, Cohen suggested that SMD=0.2 be considered a 'small' effect size, 0.5 represents a 'medium' effect size and 0.8 a 'large' effect size. This means that if two groups' means do not differ by 0.2 standard deviations or more, the difference is trivial, even if it is statistically significant."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"TNFi+MTX": "1135", "MTX monotherapy": "1119"}, "Annotation": {"data": "1. TNFis includes Etanercept, Adalimumab, Certolizumab, Golimumab and Infliximab.\n2. The studies PREMIER, COMET and ASPIRE found that the RR of improvement in HAQ-DI (≥0.22 change from baseline) at 1-2 years was 1.05 (95%CI 0.87 to 1.28), absolute risk increase 36 more per 1000 (95%CI 94 fewer to 201 more).\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.19 lower (0.25 lower to 0.14 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "9165f76f", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor + MTX", "outcome": "Quality of life (follow up: range 1 year to 2 years; assessed with: SF-36 PCS)", "importance": "IMPORTANT", "related_paper_list": ["cbcb86ec", "c45ae481", "b6dac38c"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "SERIOUS", "rationales": "Downgraded by two levels due to very serious inconsistency. I2=88%"}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"TNFi+MTX": "880", "MTX monotherapy": "792"}, "Annotation": {"data": "1. TNFis includes Etanercept, Adalimumab, Certolizumab, Golimumab and Infliximab.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 1.39 higher (1.42 lower to 4.2 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "84f30189", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor + MTX", "outcome": "Quality of life (follow up: range 1 year to 2 years; assessed with: SF-36 MCS)", "importance": "IMPORTANT", "related_paper_list": ["c45ae481", "b6dac38c"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"TNFi+MTX": "521", "MTX monotherapy": "510"}, "Annotation": {"data": "1. TNFis includes Etanercept, Adalimumab, Certolizumab, Golimumab and Infliximab.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.15 lower (1.35 lower to 1.04 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "9bb728fc", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor + MTX", "outcome": "Withdrawal due to lack of efficacy (follow up: range 1 year to 2 years)", "importance": "IMPORTANT", "related_paper_list": ["07165ed3", "7321b644", "cbcb86ec"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": "I2=42%"}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"TNFi+MTX": "33/716 (4.6%)", "MTX monotherapy": "99/628 (15.8%)"}, "Annotation": {"data": "1. TNFis includes Etanercept, Adalimumab, Certolizumab, Golimumab and Infliximab.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.32 (0.19 to 0.52)", "Absolute Effect (95% CI)": "107 fewer per 1,000 (from 128 fewer to 76 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "7adc5bbc", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor + MTX", "outcome": "Withdrawal due to adverse events (follow up: range 6 months to 2 years)", "importance": "IMPORTANT", "related_paper_list": ["07165ed3", "7ef8f3ac", "7321b644", "2140c6ee", "cbcb86ec"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "HIGH", "No of participants": {"TNFi+MTX": "109/1389 (7.8%)", "MTX monotherapy": "53/1305 (4.1%)"}, "Annotation": {"data": "1. TNFis includes Etanercept, Adalimumab, Certolizumab, Golimumab and Infliximab.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.88 (1.36 to 2.59)", "Absolute Effect (95% CI)": "36 more per 1,000 (from 15 more to 65 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "82163f18", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor + MTX", "outcome": "Serious adverse events (follow up: range 6 months to 2 years)", "importance": "IMPORTANT", "related_paper_list": ["07165ed3", "7ef8f3ac", "7321b644", "54351bf3", "72824791", "2140c6ee", "cbcb86ec"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"TNFi+MTX": "235/1677 (14.0%)", "MTX monotherapy": "188/1580 (11.9%)"}, "Annotation": {"data": "1. TNFis includes Etanercept, Adalimumab, Certolizumab, Golimumab and Infliximab.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.17 (0.99 to 1.40)", "Absolute Effect (95% CI)": "20 more per 1,000 (from 1 fewer to 48 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "e9b48a35", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor + MTX", "outcome": "Cardiovascular disease (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["7321b644", "54351bf3", "cbcb86ec"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"TNFi+MTX": "4/721 (0.6%)", "MTX monotherapy": "6/632 (0.9%)"}, "Annotation": {"data": "1. TNFis includes Etanercept, Adalimumab, Certolizumab, Golimumab and Infliximab.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.62 (0.17 to 2.21)", "Absolute Effect (95% CI)": "4 fewer per 1,000 (from 8 fewer to 11 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "ac069dd3", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor + MTX", "outcome": "Malignancy (follow up: range 1 year to 2 years)", "importance": "IMPORTANT", "related_paper_list": ["7ef8f3ac", "54351bf3"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"TNFi+MTX": "6/542 (1.1%)", "MTX monotherapy": "8/525 (1.5%)"}, "Annotation": {"data": "1. TNFis includes Etanercept, Adalimumab, Certolizumab, Golimumab and Infliximab.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 0.74 (0.25 to 2.14)", "Absolute Effect (95% CI)": "4 fewer per 1,000 (from 11 fewer to 17 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "b588c564", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor + MTX", "outcome": "Death (follow up: range 6 months to 2 years)", "importance": "IMPORTANT", "related_paper_list": ["07165ed3", "7ef8f3ac", "2140c6ee", "cbcb86ec", "6a7646d3"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"TNFi+MTX": "10/1587 (0.6%)", "MTX monotherapy": "4/1493 (0.3%)"}, "Annotation": {"data": "1. TNFis includes Etanercept, Adalimumab, Certolizumab, Golimumab and Infliximab.\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.85 (0.57 to 6.00)", "Absolute Effect (95% CI)": "2 more per 1,000 (from 1 fewer to 13 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "2aaca0e3", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "TNF Inhibitor + MTX", "outcome": "Malignancy (from SRs on harms)", "related_paper_list": ["45b0286b"], "assessment_results": {"GRADE": {"result_interpretation": "The Systematic Review RefID=4638, 2012 (RCTs=6, n=1890) comparing any TNFi + csDMARD vs csDMARD among RA showed that for Cancer, the result was RR=0.85 (0.30-2.4) at 2 years and RR=1.3 (0.77-2.1) at all time points combined (6 months, 1 year, 2 years, 2.5 years, RCT=29, n=11144) ", "Study design": "Systematic Review"}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "21155bd2", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept + MTX", "outcome": "Disease activity (follow up: 1 year; assessed with: ACR 70)", "importance": "CRITICAL", "related_paper_list": ["e4903996"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and lack of blinding of non-radiographic outcome assessors."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"ABA+MTX": "109/256 (42.6%)", "MTX monotherapy": "69/253 (27.3%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.56 (1.22 to 2.00)", "Absolute Effect (95% CI)": "153 more per 1,000 (from 60 more to 273 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "35a89a7b", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept + MTX", "outcome": "Disease activity (follow up: 1 year; assessed with: DAS28 CRP (Lower values – > benefit) (MCID -1.02)", "importance": "CRITICAL", "related_paper_list": ["e4903996"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and lack of blinding of non-radiographic outcome assessors."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"ABA+MTX": "256", "MTX monotherapy": "253"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.73 lower (0.98 lower to 0.48 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "be0d9216", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept + MTX", "outcome": "Remission (follow up: 1 year; assessed with: DAS28-ESR remission <2.6)", "importance": "CRITICAL", "related_paper_list": ["e4903996", "2a7a858b"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and lack of blinding of non-radiographic outcome assessors."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"ABA+MTX": "176/371 (47.4%)", "MTX monotherapy": "109/368 (29.6%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.60 (1.33 to 1.93)", "Absolute Effect (95% CI)": "178 more per 1,000 (from 98 more to 275 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "0f217729", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept + MTX", "outcome": "Radiographic progression (follow up: 1 year; assessed with: mTSS (Lower values – > benefit) (MCID 4.6)", "importance": "IMPORTANT", "related_paper_list": ["e4903996"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and lack of blinding of non-radiographic outcome assessors."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"ABA+MTX": "0", "MTX monotherapy": "0"}, "Annotation": {"data": "1. The study AGREE found that the RR of developing no radiographic progression (change in mTSS ≤0) was 1.6 (95%CI 0.99 to 1.36), absolute risk increase 84 more per 1000 (95%CI 5 fewer to 190 more).\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.43 lower (0.91 lower to 0.05 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "14bf9a60", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept + MTX", "outcome": "Disability (follow up: 1 year; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22)", "importance": "IMPORTANT", "related_paper_list": ["e4903996"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and lack of blinding of non-radiographic outcome assessors."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"ABA+MTX": "256", "MTX monotherapy": "253"}, "Annotation": {"data": "1. The studies AGREE and AVERT found that the RR of improvement in HAQ-DI (≥0.3 change from baseline) was 1.25 (95%CI 1.12 to 1.39), absolute risk increase 141 more per 1000 (95%CI 668 more to 220 more).\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.2 lower (0.31 lower to 0.09 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "9b32715a", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept + MTX", "outcome": "Quality of Life (follow up: 1 year; assessed with: SF-36 PCS (Higher values – > benefit) (MCID 4.4)", "importance": "IMPORTANT", "related_paper_list": ["e4903996"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and lack of blinding of non-radiographic outcome assessors."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"ABA+MTX": "256", "MTX monotherapy": "253"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 2.5 higher (0.77 higher to 4.23 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "dbacab53", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept + MTX", "outcome": "Quality of Life (follow up: 1 year; assessed with: SF-36 MCS (Higher values – > benefit) (MCID 3.1)", "importance": "IMPORTANT", "related_paper_list": ["e4903996"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and lack of blinding of non-radiographic outcome assessors."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"ABA+MTX": "256", "MTX monotherapy": "253"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 1.81 lower (3.58 lower to 0.04 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "bf9ffcdf", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept + MTX", "outcome": "Withdrawal due to lack of efficacy (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["2a7a858b"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"ABA+MTX": "5/115 (4.3%)", "MTX monotherapy": "11/115 (9.6%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.45 (0.16 to 1.27)", "Absolute Effect (95% CI)": "53 fewer per 1,000 (from 80 fewer to 26 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "4ab02aef", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept + MTX", "outcome": "Withdrawal due to adverse events (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["e4903996", "2a7a858b"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and lack of blinding of non-radiographic outcome assessors."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by two levels due to serious imprecision. Confidence interval includes both values suggesting harm and values suggesting benefit. Low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"ABA+MTX": "13/375 (3.5%)", "MTX monotherapy": "16/369 (4.3%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.80 (0.39 to 1.64)", "Absolute Effect (95% CI)": "9 fewer per 1,000 (from 26 fewer to 28 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "10cdb697", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept + MTX", "outcome": "Serious adverse events (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["e4903996"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and lack of blinding of non-radiographic outcome assessors."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting harm and values suggesting benefit."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"ABA+MTX": "20/256 (7.8%)", "MTX monotherapy": "20/253 (7.9%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.99 (0.55 to 1.79)", "Absolute Effect (95% CI)": "1 fewer per 1,000 (from 36 fewer to 62 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "d3bcb4c1", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept + MTX", "outcome": "Malignancy (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["e4903996", "2a7a858b"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and lack of blinding of non-radiographic outcome assessors."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"ABA+MTX": "1/371 (0.3%)", "MTX monotherapy": "2/368 (0.5%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.60 (0.08 to 4.48)", "Absolute Effect (95% CI)": "2 fewer per 1,000 (from 5 fewer to 19 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "be9f9f3b", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept + MTX", "outcome": "Death (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["e4903996", "2a7a858b"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and lack of blinding of non-radiographic outcome assessors."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by two levels due to serious imprecision. Confidence interval includes both values suggesting harm and values suggesting benefit. Low number of events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"ABA+MTX": "2/371 (0.5%)", "MTX monotherapy": "4/368 (1.1%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.49 (0.09 to 2.67)", "Absolute Effect (95% CI)": "6 fewer per 1,000 (from 10 fewer to 18 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "bb9c36c1", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Abatacept + MTX", "outcome": "Malignancy (from SRs on harms)", "related_paper_list": ["45b0286b"], "assessment_results": {"GRADE": {"result_interpretation": "The Systematic Review RefID=4638, 2012 (RCTs=3, n=2435) comparing Abatacept + csDMARD vs Placebo + csDMARD among RA showed that for Cancer, the result was RR=0.65 (0.25-1.7) at 1 year.  ", "Study design": "Systematic Review"}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "5b7a5754", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Rituximab + MTX", "outcome": "Disease activity (follow up: 2 years; assessed with: ACR 20)", "importance": "CRITICAL", "related_paper_list": ["2f031aec"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"RTX+MTX": "185/250 (74.0%)", "MTX monotherapy": "137/249 (55.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.34 (1.18 to 1.54)", "Absolute Effect (95% CI)": "187 more per 1,000 (from 99 more to 297 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "55d0f851", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Rituximab + MTX", "outcome": "Disease activity (follow up: 2 years; assessed with: ACR 50)", "importance": "CRITICAL", "related_paper_list": ["2f031aec"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"RTX+MTX": "155/250 (62.0%) ", "MTX monotherapy": "102/249 (41.0%) "}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.51 (1.27 to 1.81)", "Absolute Effect (95% CI)": "209 more per 1,000 (from 111 more to 332 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "068fbc4c", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Rituximab + MTX", "outcome": "Disease activity (follow up: 2 years; assessed with: ACR 70)", "importance": "CRITICAL", "related_paper_list": ["2f031aec"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"RTX+MTX": "115/250 (46.0%) ", "MTX monotherapy": "67/249 (26.9%)  "}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.71 (1.34 to 2.18)", "Absolute Effect (95% CI)": "191 more per 1,000 (from 91 more to 318 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "aff75cda", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Rituximab + MTX", "outcome": "Disease activity (follow up: 2 years; assessed with: DAS28 ESR (Lower values – > benefit) (MCID -1.17))", "importance": "CRITICAL", "related_paper_list": ["2f031aec"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"RTX+MTX": "250  ", "MTX monotherapy": "249  "}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 1.19 lower (1.5 lower to 0.88 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "1f1da61a", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Rituximab + MTX", "outcome": "Remission (follow up: 2 years; assessed with: DAS28-ESR remission <2.6)", "importance": "CRITICAL", "related_paper_list": ["2f031aec"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"RTX+MTX": "80/250 (32.0%)", "MTX monotherapy": "32/249 (12.9%)  "}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 2.49 (1.72 to 3.61)", "Absolute Effect (95% CI)": "191 more per 1,000 (from 93 more to 335 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "c3a13046", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Rituximab + MTX", "outcome": "Radiographic progression (follow up: 2 years; assessed with: mTSS (Lower values – > benefit) (MCID 4.6))", "importance": "IMPORTANT", "related_paper_list": ["2f031aec"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"RTX+MTX": "244 ", "MTX monotherapy": "233"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 1.54 lower (2.3 lower to 0.78 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "475617e3", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Rituximab + MTX", "outcome": "Pain (follow up: 1 year; assessed with: VAS pain (Lower values – > benefit) (MCID -11.9))", "importance": "IMPORTANT", "related_paper_list": ["9d737999"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"RTX+MTX": "0 ", "MTX monotherapy": "0 "}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 12.2 lower (16.15 lower to 8.25 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "5fef0c9e", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Rituximab + MTX", "outcome": "Fatigue (follow up: 1 year; assessed with: FACIT-F (Higher values – > benefit) (MCID 15.9))", "importance": "IMPORTANT", "related_paper_list": ["9d737999"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"RTX+MTX": "0", "MTX monotherapy": "0"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 3.45 higher (1.77 higher to 5.13 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "7aeb5ff3", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Rituximab + MTX", "outcome": "Disability (follow up: 2 years; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22))", "importance": "IMPORTANT", "related_paper_list": ["2f031aec"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"RTX+MTX": "250 ", "MTX monotherapy": "249"}, "Annotation": {"data": "1. The study IMAGE found that the RR of improvement in HAQ-DI (≥0.22 change from baseline) was 1.12 (95%CI 1.03 to 1.21), absolute risk increase 93 more per 1000 (95%CI 23 more to 162 more).\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.25 lower (0.4 lower to 0.1 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "1a227743", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Rituximab + MTX", "outcome": "Quality of Life (follow up: 1 year; assessed with: SF-36 PCS (Higher values – > benefit) (MCID 4.4))", "importance": "IMPORTANT", "related_paper_list": ["9d737999"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"RTX+MTX": "0", "MTX monotherapy": "0 "}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 3.53 higher (2.04 higher to 5.02 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "ebbe8dc5", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Rituximab + MTX", "outcome": "Quality of Life (follow up: 1 year; assessed with: SF-36 MCS (Higher values – > benefit) (MCID 3.1))", "importance": "IMPORTANT", "related_paper_list": ["9d737999"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"RTX+MTX": "0 ", "MTX monotherapy": "0 "}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.81 higher (1.03 lower to 2.66 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "5d4c9951", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Rituximab + MTX", "outcome": "Withdrawal due to adverse events (follow up: 2 years)", "importance": "IMPORTANT", "related_paper_list": ["2f031aec"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"RTX+MTX": "7/250 (2.8%) ", "MTX monotherapy": "17/249 (6.8%) "}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.41 (0.17 to 0.97)", "Absolute Effect (95% CI)": "40 fewer per 1,000 (from 57 fewer to 2 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "ed7b40f0", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Rituximab + MTX", "outcome": "Serious adverse events (follow up: 2 years)", "importance": "IMPORTANT", "related_paper_list": ["2f031aec"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"RTX+MTX": "33/250 (13.2%) ", "MTX monotherapy": "42/249 (16.9%)  "}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.78 (0.51 to 1.19)", "Absolute Effect (95% CI)": "37 fewer per 1,000 (from 83 fewer to 32 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "7a9930bd", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Rituximab + MTX", "outcome": "Malignancy (follow up: 2 years)", "importance": "IMPORTANT", "related_paper_list": ["2f031aec"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"RTX+MTX": "3/250 (1.2%)  ", "MTX monotherapy": "7/249 (2.8%) "}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.43 (0.11 to 1.63)", "Absolute Effect (95% CI)": "16 fewer per 1,000 (from 25 fewer to 18 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "437e487c", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Rituximab + MTX", "outcome": "Death (follow up: 2 years)", "importance": "IMPORTANT", "related_paper_list": ["2f031aec"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"RTX+MTX": "1/250 (0.4%) ", "MTX monotherapy": "3/249 (1.2%)  "}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.33 (0.03 to 3.17)", "Absolute Effect (95% CI)": "8 fewer per 1,000 (from 12 fewer to 26 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "e2daafa6", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "Rituximab + MTX", "outcome": "Malignancy (from SRs on harms)", "related_paper_list": ["45b0286b"], "assessment_results": {"GRADE": {"result_interpretation": "The Systematic Review RefID=4638, 2012 (RCTs=5, n=2066) comparing Rituximab + csDMARD vs Placebo + MTX among RA and showed that for Cancer, the result was RR=1.5 (0.38-6.1) at 24 weeks and RR=0.65 (0.24-1.7) at 2 years (RCT= 1, n=748) ", "Study design": "Systematic Review"}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "2b9c6eae", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor + MTX", "outcome": "Disease activity (follow up: 1 year; assessed with: ACR 20)", "importance": "CRITICAL", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Rated down by one level for lack of allocation concealment"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"TCZ+MTX": "374/578 (64.7%) ", "MTX monotherapy": "164/287 (57.1%) "}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.13 (1.01 to 1.27)", "Absolute Effect (95% CI)": "74 more per 1,000 (from 6 more to 154 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "bbbc516d", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor + MTX", "outcome": "Disease activity (follow up: 1 year; assessed with: ACR 50)", "importance": "CRITICAL", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Rated down by one level for lack of allocation concealment"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"TCZ+MTX": "314/578 (54.3%) ", "MTX monotherapy": "117/287 (40.8%) "}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.33 (1.14 to 1.56)", "Absolute Effect (95% CI)": "135 more per 1,000 (from 57 more to 228 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "ada8736b", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor + MTX", "outcome": "Disease activity (follow up: 1 year; assessed with: ACR 70)", "importance": "CRITICAL", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Rated down by one level for lack of allocation concealment"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"TCZ+MTX": "234/578 (40.5%)", "MTX monotherapy": "84/287 (29.3%)  "}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.38 (1.13 to 1.70)", "Absolute Effect (95% CI)": "111 more per 1,000 (from 38 more to 205 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "a34e9db8", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor + MTX", "outcome": "Disease activity (follow up: 1 year; assessed with: DAS28-ESR)", "importance": "CRITICAL", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Rated down by one level for lack of allocation concealment"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"TCZ+MTX": "578  ", "MTX monotherapy": "287  "}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.83 lower (1.09 lower to 0.57 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "b9d289d8", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor + MTX", "outcome": "Remission (follow up: 1 year; assessed with: DAS28-ESR <2.6)", "importance": "CRITICAL", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Rated down by one level for lack of allocation concealment"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"TCZ+MTX": "240/578 (41.5%) ", "MTX monotherapy": "56/287 (19.5%) "}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 2.13 (1.65 to 2.74)", "Absolute Effect (95% CI)": "220 more per 1,000 (from 127 more to 340 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "eae16dad", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor + MTX", "outcome": "Radiographic progression (follow up: 1 year; assessed with: mTSS)", "importance": "IMPORTANT", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Rated down by one level for lack of allocation concealment"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"TCZ+MTX": "540", "MTX monotherapy": "267"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.89 lower (1.45 lower to 0.33 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "4e4f794d", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor + MTX", "outcome": "Disability (follow up: 1 year; assessed with: HAQ-DI)", "importance": "IMPORTANT", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Rated down by one level for lack of allocation concealment"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"TCZ+MTX": "0 ", "MTX monotherapy": "0"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.14 lower (0.22 lower to 0.06 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "0cc57526", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor + MTX", "outcome": "Quality of Life (follow up: 1 year; assessed with: SF-36 PCS)", "importance": "IMPORTANT", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Rated down by one level for lack of allocation concealment"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"TCZ+MTX": "0 ", "MTX monotherapy": "0 "}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 1.99 higher (0.41 higher to 3.57 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "ab652f6f", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor + MTX", "outcome": "Quality of Life (follow up: 1 year; assessed with: SF-36 MCS)", "importance": "IMPORTANT", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Rated down by one level for lack of allocation concealment"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Rated down by one level for imprecision as the CI includes both values suggesting no effect and values suggesting harm"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"TCZ+MTX": "0", "MTX monotherapy": "0 "}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 1.25 higher (1.58 lower to 4.08 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "775dc934", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor + MTX", "outcome": "Withdrawal due to adverse events (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Rated down by one level for lack of allocation concealment"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"TCZ+MTX": "94/579 (16.2%) ", "MTX monotherapy": "21/282 (7.4%) "}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 2.18 (1.39 to 3.42)", "Absolute Effect (95% CI)": "88 more per 1,000 (from 29 more to 180 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "2630e361", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor + MTX", "outcome": "Serious adverse events (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Rated down by one level for lack of allocation concealment"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Rated down by one level for imprecision as the CI includes both values suggesting no effect and values suggesting harm"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"TCZ+MTX": "60/579 (10.4%) ", "MTX monotherapy": "24/282 (8.5%) "}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.22 (0.78 to 1.91)", "Absolute Effect (95% CI)": "19 more per 1,000 (from 19 fewer to 77 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "0231d62a", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor + MTX", "outcome": "Malignancy (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Rated down by one level for lack of allocation concealment"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Rated down by one level for imprecision as the CI includes both values suggesting no effect and values suggesting harm"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"TCZ+MTX": "5/579 (0.9%) ", "MTX monotherapy": "3/282 (1.1%) "}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 0.81 (0.20 to 3.37)", "Absolute Effect (95% CI)": "2 fewer per 1,000 (from 9 fewer to 25 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "85f7287f", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor + MTX", "outcome": "Myocardial infarction (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Rated down by one level for lack of allocation concealment"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Rated down by two levels for imprecision as the CI includes both values suggesting benefit and values suggesting harm"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"TCZ+MTX": "4/579 (0.7%)", "MTX monotherapy": "0/282 (0.0%) "}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 4.39 (0.24 to 81.28)", "Absolute Effect (95% CI)": "7 fewer per 1,000 (from 480 fewer to 160 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "2aeec28e", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor + MTX", "outcome": "Death (follow up: 1 year)", "importance": "IMPORTANT", "related_paper_list": ["5fc10a78"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Rated down by one level for lack of allocation concealment"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Rated down by one level for imprecision as the CI includes both values suggesting no effect and values suggesting harm"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"TCZ+MTX": "6/579 (1.0%)  ", "MTX monotherapy": "2/282 (0.7%) "}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.46 (0.30 to 7.19)", "Absolute Effect (95% CI)": "3 more per 1,000 (from 5 fewer to 44 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "748e8672", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "MTX monotherapy", "comparator": "IL-6 Receptor Inhibitor + MTX", "outcome": "Malignancy (from SRs on harms)", "related_paper_list": ["45b0286b"], "assessment_results": {"GRADE": {"result_interpretation": "The Systematic Review RefID=4638, 2012 (RCTs=1, n=1190) comparing Tocilizumab + MTX vs Placebo + MTX among RA showed that for Cancer, the result was RR=4.4 (0.56-34.8) at 1 year and RR=0.41 (0.14-1.2) at 6 months (RCT=4, n=2950) ", "Study design": "Systematic Review"}}, "PICO_IDX": "6b", "Database": "2021 ACR RA"}
{"outcome_uid": "f8037ebf", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity, receive long-term (≥ 3 months) low dose (≤ 10mg per day) GCs and mono- or combination csDMARDs or mono or combination csDMARDs alone?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "Mono or combination csDMARDs with long-term (≥ 3 months) low dose (≤ 10mg per day) GCs", "comparator": "mono or combination csDMARDs alone (i.e. without long-term GCs)", "outcome": "Disease activity (follow up: 2 years; assessed with: DAS28-ESR)", "importance": "CRITICAL", "related_paper_list": ["1b777329"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Patients, personnel, and outcome assessors of non-radiographic outcomes were not blinded. Patients, personnel, and outcome assessors of radiographic outcomes were blinded"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"csDMARDs + long-term low-dose GCs": "116", "csDMARDs monotherapy": "126"}, "Annotation": {"data": "1. csDMARD (51% started with MTX and 32% with SSZ, 8% with antimalarials, 8% with gold) + long-term (>= 3 months) prednisolone (7.5mg/day)\n2. csDMARD (55% started with MTX and 34% with SSZ, 4% with antimalarials, 7% with gold)\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.5 lower (0.84 lower to 0.16 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "8a", "Database": "2021 ACR RA"}
{"outcome_uid": "c7144959", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity, receive long-term (≥ 3 months) low dose (≤ 10mg per day) GCs and mono- or combination csDMARDs or mono or combination csDMARDs alone?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "Mono or combination csDMARDs with long-term (≥ 3 months) low dose (≤ 10mg per day) GCs", "comparator": "mono or combination csDMARDs alone (i.e. without long-term GCs)", "outcome": "Remission (follow up: 2 years; assessed with: DAS28-ESR<2.6)", "importance": "CRITICAL", "related_paper_list": ["1b777329"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Patients, personnel, and outcome assessors of non-radiographic outcomes were not blinded. Patients, personnel, and outcome assessors of radiographic outcomes were blinded"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"csDMARDs + long-term low-dose GCs": "64/116 (55.2%)", "csDMARDs monotherapy": "41/126 (32.5%)"}, "Annotation": {"data": "1. csDMARD (51% started with MTX and 32% with SSZ, 8% with antimalarials, 8% with gold) + long-term (>= 3 months) prednisolone (7.5mg/day)\n2. csDMARD (55% started with MTX and 34% with SSZ, 4% with antimalarials, 7% with gold)\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.70 (1.26 to 2.29)", "Absolute Effect (95% CI)": "228 more per 1,000 (from 85 more to 420 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "8a", "Database": "2021 ACR RA"}
{"outcome_uid": "71751a33", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity, receive long-term (≥ 3 months) low dose (≤ 10mg per day) GCs and mono- or combination csDMARDs or mono or combination csDMARDs alone?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "Mono or combination csDMARDs with long-term (≥ 3 months) low dose (≤ 10mg per day) GCs", "comparator": "mono or combination csDMARDs alone (i.e. without long-term GCs)", "outcome": "Radiographic progression (follow up: 2 years; assessed with: Sharp/van der Heijde score)", "importance": "IMPORTANT", "related_paper_list": ["1b777329"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Patients, personnel, and outcome assessors of non-radiographic outcomes were not blinded. Patients, personnel, and outcome assessors of radiographic outcomes were blinded"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting no effect"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"csDMARDs + long-term low-dose GCs": "108", "csDMARDs monotherapy": "117"}, "Annotation": {"data": "1. csDMARD (51% started with MTX and 32% with SSZ, 8% with antimalarials, 8% with gold) + long-term (>= 3 months) prednisolone (7.5mg/day)\n2. csDMARD (55% started with MTX and 34% with SSZ, 4% with antimalarials, 7% with gold)\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 3.9 lower (7 lower to 0.8 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "8a", "Database": "2021 ACR RA"}
{"outcome_uid": "619f45f3", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity, receive long-term (≥ 3 months) low dose (≤ 10mg per day) GCs and mono- or combination csDMARDs or mono or combination csDMARDs alone?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "Mono or combination csDMARDs with long-term (≥ 3 months) low dose (≤ 10mg per day) GCs", "comparator": "mono or combination csDMARDs alone (i.e. without long-term GCs)", "outcome": "Disability (follow up: 2 years; assessed with: HAQ Swedish version)", "importance": "IMPORTANT", "related_paper_list": ["1b777329"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Patients, personnel, and outcome assessors of non-radiographic outcomes were not blinded. Patients, personnel, and outcome assessors of radiographic outcomes were blinded"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting no effect"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"csDMARDs + long-term low-dose GCs": "116", "csDMARDs monotherapy": "126"}, "Annotation": {"data": "1. csDMARD (51% started with MTX and 32% with SSZ, 8% with antimalarials, 8% with gold) + long-term (>= 3 months) prednisolone (7.5mg/day)\n2. csDMARD (55% started with MTX and 34% with SSZ, 4% with antimalarials, 7% with gold)\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.2 lower (0.34 lower to 0.06 lower)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "8a", "Database": "2021 ACR RA"}
{"outcome_uid": "47ba5bac", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity, receive long-term (≥ 3 months) low dose (≤ 10mg per day) GCs and mono- or combination csDMARDs or mono or combination csDMARDs alone?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "Mono or combination csDMARDs with long-term (≥ 3 months) low dose (≤ 10mg per day) GCs", "comparator": "mono or combination csDMARDs alone (i.e. without long-term GCs)", "outcome": "Withdrawal due to adverse events (follow up: 2 years)", "importance": "IMPORTANT", "related_paper_list": ["1b777329"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Patients, personnel, and outcome assessors of non-radiographic outcomes were not blinded. Patients, personnel, and outcome assessors of radiographic outcomes were blinded"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"csDMARDs + long-term low-dose GCs": "26/116 (22.4%)", "csDMARDs monotherapy": "24/126 (19.0%)"}, "Annotation": {"data": "1. csDMARD (51% started with MTX and 32% with SSZ, 8% with antimalarials, 8% with gold) + long-term (>= 3 months) prednisolone (7.5mg/day)\n2. csDMARD (55% started with MTX and 34% with SSZ, 4% with antimalarials, 7% with gold)\n"}, "Effect": {"Relative Effect (95% CI)": "RR 1.18 (0.72 to 1.93)", "Absolute Effect (95% CI)": "34 more per 1,000 (from 53 fewer to 177 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "8a", "Database": "2021 ACR RA"}
{"outcome_uid": "1c6e268f", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity, receive long-term (≥ 3 months) low dose (≤ 10mg per day) GCs and mono- or combination csDMARDs or mono or combination csDMARDs alone?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "Mono or combination csDMARDs with long-term (≥ 3 months) low dose (≤ 10mg per day) GCs", "comparator": "mono or combination csDMARDs alone (i.e. without long-term GCs)", "outcome": "Death (follow up: 2 years)", "importance": "IMPORTANT", "related_paper_list": ["1b777329"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Patients, personnel, and outcome assessors of non-radiographic outcomes were not blinded. Patients, personnel, and outcome assessors of radiographic outcomes were blinded"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Very low number of events"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"csDMARDs + long-term low-dose GCs": "1/116 (0.9%)", "csDMARDs monotherapy": "0/126 (0.0%)"}, "Annotation": {"data": "1. csDMARD (51% started with MTX and 32% with SSZ, 8% with antimalarials, 8% with gold) + long-term (>= 3 months) prednisolone (7.5mg/day)\n2. csDMARD (55% started with MTX and 34% with SSZ, 4% with antimalarials, 7% with gold)\n"}, "Effect": {"Relative Effect (95% CI)": "RR 3.26 (0.13 to 79.15)", "Absolute Effect (95% CI)": "0 fewer per 1,000 (from 0 fewer to 0 fewer)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "8a", "Database": "2021 ACR RA"}
{"outcome_uid": "1eee3a1a", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity, receive long-term (≥ 3 months) low dose (≤ 10mg per day) GCs and mono- or combination csDMARDs or mono or combination csDMARDs alone?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "Mono or combination csDMARDs with long-term (≥ 3 months) low dose (≤ 10mg per day) GCs", "comparator": "mono or combination csDMARDs alone (i.e. without long-term GCs)", "outcome": "Death (age-adjusted) (follow up: 10 years)", "importance": "IMPORTANT", "related_paper_list": ["1a7c95b6"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Patients, personnel, and outcome assessors of non-radiographic outcomes were not blinded. Patients, personnel, and outcome assessors of radiographic outcomes were blinded"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"csDMARDs + long-term low-dose GCs": "119 participants(-)", "csDMARDs monotherapy": "111 participants(8.1%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "HR 1.60 (0.61 to 4.18)", "Absolute Effect (95% CI)": "45 more per 1,000 (from 31 fewer to 216 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "8a", "Database": "2021 ACR RA"}
{"outcome_uid": "06201c5e", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity, receive long-term (≥ 3 months) low dose (≤ 10mg per day) GCs and mono- or combination csDMARDs or mono or combination csDMARDs alone?", "population": "Patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity", "intervention": "Mono or combination csDMARDs with long-term (≥ 3 months) low dose (≤ 10mg per day) GCs", "comparator": "mono or combination csDMARDs alone (i.e. without long-term GCs)", "outcome": "Composite Cardiovascular events (age-adjusted) (follow up: 10 years)", "importance": "IMPORTANT", "related_paper_list": ["1a7c95b6"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious risk of bias. Patients, personnel, and outcome assessors of non-radiographic outcomes were not blinded. Patients, personnel, and outcome assessors of radiographic outcomes were blinded"}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm"}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"csDMARDs + long-term low-dose GCs": "119 participants(-)", "csDMARDs monotherapy": "111 participants(13.5%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "HR 1.8 (0.9 to 3.6)", "Absolute Effect (95% CI)": "95 more per 1,000 (from 13 fewer to 272 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "8a", "Database": "2021 ACR RA"}
{"outcome_uid": "35c628c4", "clinical_question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity, receive long-term (≥ 3 months) low dose (≤ 10mg per day) GCs and mono- or combination csDMARDs or mono or combination csDMARDs alone?", "population": "Patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity", "intervention": "Mono or combination csDMARDs with long-term (≥ 3 months) low dose (≤ 10mg per day) GCs", "comparator": "mono or combination csDMARDs alone (i.e. without long-term GCs)", "outcome": "Disability (follow up: 2 years; assessed with: HAQ)", "importance": "IMPORTANT", "related_paper_list": ["ac248aa9"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm. Small sample size."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"csDMARDs + long-term low-dose GCs": "77", "csDMARDs monotherapy": "74"}, "Annotation": {"data": "1. csDMARD includes SSZ with long-term (>=3 months) prednisone (7mg/day).\n2. csDMARD monotherapy includes SSZ.\n"}, "Effect": {"Relative Effect (95% CI)": "-", "Absolute Effect (95% CI)": "MD 0.22 higher (0.02 lower to 0.46 higher)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "8b", "Database": "2021 ACR RA"}
{"outcome_uid": "9a3ef06c", "clinical_question": "Should patients with RA initiating MTX receive oral MTX or subcutaneous (SC) MTX?", "population": "Patients with RA initiating MTX", "intervention": "Oral MTX", "comparator": "SC MTX", "outcome": "Disease Activity (follow up: 4 months; assessed with: ACR 20)", "importance": "CRITICAL", "related_paper_list": ["5efdfbb8"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": "The study did not report on whether allocation was concealed."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Downgraded by one level due to serious imprecision. Confidence intervals includes both values suggesting no effect and values suggesting benefit."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"SC MTX": "160/188 (85.1%)", "Oral MTX": "144/187 (77.0%)"}, "Annotation": {}, "Effect": {"Relative Effect (95% CI)": "RR 1.11 (1.00 to 1.22)", "Absolute Effect (95% CI)": "85 more per 1,000 (from 0 fewer to 169 more)", "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"}}}, "PICO_IDX": "9", "Database": "2021 ACR RA"}
